Mucosal immunity in COPD : from mucociliary dysfunction to lymphoid follicles by Seys, Leen
  
 
 
 
Mucosal immunity in COPD 
From mucociliary dysfunction to lymphoid follicles 
 
 
Leen Seys 
 
2016 
 
Promotor: Prof. Dr. Guy Brusselle 
Co-promotor: Prof. Dr. Ken Bracke 
 
 
 
 
Thesis submitted to fulfil the requirements for the degree of 
“Doctor in Health Sciences”  
 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Leen Seys, 2016 
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form 
or by any means, without permission from the author, or when appropriate from the publishers of the publications. 
Financial support: the Concerted Research Action of the Ghent University (BOF/GOA, 01G02714), the Fund for 
Scientific Research in Flanders (FWO Vlaanderen, G.0897.12N) and the Interuniversity Attraction Poles program 
(IUAP, P7/30). 
ISBN: 978-94-6197-462-4 
Department of Respiratory Medicine 
Laboratory for Translational Research in Obstructive Pulmonary Diseases 
Ghent University Hospital 
De Pintelaan 185 
9000 Ghent 
BELGIUM  
  
3  
LIST OF PUBLICATIONS 
 
This manuscript is based on the following publications: 
 
CHAPTER 4 is based on: 
Polverino F*, Seys LJ*, Bracke KR, Owen CA. B Cells in Chronic Obstructive Pulmonary Disease: Moving to 
Center Stage. Am J Physiol Lung Cell Mol Physiol 2016; 311: L687-L695. (* equal contribution) 
IF: 4.721/ Ranking in Respiratory System: 8/58 
 
CHAPTER 7 
Seys LJ, Verhamme FM, Dupont LL, Desauter E, Duerr J, Seyhan Agircan A, Conickx G, Joos GF, Brusselle 
GG, Mall MA, Bracke KR. Airway Surface Dehydration Aggravates Cigarette Smoke-Induced Hallmarks of 
COPD in Mice. PloS one 2015; 10: e0129897. 
IF: 3.057 / Ranking in Multidisciplinary sciences: 11/63 
 
CHAPTER 8 
Lies Lahousse, Leen J.M. Seys, Guy F. Joos, RS-PI, Bruno H. Stricker, Guy G. Brusselle. Epidemiology and 
impact of Chronic Bronchitis in COPD.  
Manuscript in preparation 
 
CHAPTER 9 
Seys LJ, Verhamme FM, Schinwald A, Hammad H, Cunoosamy DM, Bantsimba-Malanda C, Sabirsh A, 
McCall E, Flavell L, Herbst R, Provoost S, Lambrecht BN, Joos GF, Brusselle GG, Bracke KR. Role of B Cell-
Activating Factor in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192: 706-
718.  
IF: 13.118 / Ranking in Respiratory System: 2/58 
 
 
 
 
 
 
 
 
 
 
 
 4  
TABLE OF CONTENTS 
 
ABBREVIATIONS ..................................................................................................................................... 6 
ABSTRACT .............................................................................................................................................. 7 
PART I: Introduction ...................................................................................................................................... 9 
chapter 1: Chronic Obstructive Pulmonary Disease .................................................................................. 9 
1.1 Definition ............................................................................................................................. 10 
1.2  Epidemiology and burden of disease .................................................................................. 11 
1.3 Clinical manifestations of COPD and Diagnosis ................................................................... 12 
1.4  Pathology ............................................................................................................................. 15 
1.5 Pathogenesis ....................................................................................................................... 17 
1.6  Treatment ............................................................................................................................ 23 
chapter 2: Mucociliary clearance in COPD .............................................................................................. 25 
2.1  Mucociliary clearance: introduction .................................................................................... 26 
2.2  Mucociliary clearance in health........................................................................................... 26 
2.3 Mucociliary clearance in COPD ............................................................................................ 30 
2.4  Beta-ENaC transgenic mice: a murine model of airway surface dehydration .................... 34 
chapter 3: The chronic bronchitis phenotype in COPD ........................................................................... 37 
3.1  Definition ............................................................................................................................ 38 
3.2  Epidemiology ...................................................................................................................... 38 
3.3  Clinical manifestations and impact of chronic bronchitis in COPD .................................... 39 
3.4  Treatment ............................................................................................................................ 40 
3.5  Overview of epidemiological studies .................................................................................. 41 
chapter 4: B cells, ectopic lymphoid follicles and B cell-activating factor in COPD ................................ 43 
4.1  B cells, ectopic lymphoid follicles and B cell-activating factor: introduction ...................... 44 
4.2  B cells, ectopic lymphoid follicles and B cell-activating factor in COPD .............................. 49 
4.3  Function of B cells, ectopic lymphoid follicles and B cell-activating factor in COPD ........... 53 
Chapter 5: Translational research in COPD: methods ............................................................................. 55 
5.1  Translational research in COPD ........................................................................................... 56 
5.2  Murine model of COPD ....................................................................................................... 57 
5.3 Human studies ..................................................................................................................... 63 
5.4  The Rotterdam Study .......................................................................................................... 64 
 
  
5  
PART II: Research work ................................................................................................................................ 65 
Chapter 6: Research Objectives .............................................................................................................. 65 
Chapter 7: Airway surface dehydration aggravates cigarette smoke-induced ....................................... 69 
 hallmarks of COPD in mice ................................................................................................... 69 
Chapter 8: Epidemiology and impact of chronic bronchitis in COPD ...................................................... 89 
Chapter 9: Role of B cell-Activating Factor in Chronic Obstructive Pulmonary Disease ....................... 103 
Chapter 10: Discussion and future perspectives ................................................................................... 127 
10.1  Role of mucus dysfunction in COPD .................................................................................. 128 
10.2  B cell rich lymphoid follicles in COPD ................................................................................ 133 
10.3  General conclusion ............................................................................................................ 136 
Chapter 11: Summary / Samenvatting .................................................................................................. 139 
SUMMARY ......................................................................................................................................... 140 
SAMENVATTING ................................................................................................................................ 141 
 
PART III: ADDENDUM ................................................................................................................................ 143 
REFERENCES ...................................................................................................................................... 144 
CURRICULUM VITAE .......................................................................................................................... 164 
DANKWOORD .................................................................................................................................... 168 
 
 
 
 
 
 
 
 
 
 
 
 
 6  
ABBREVIATIONS 
 
ASL  airway surface liquid 
ATP  adinosine triphosphate 
BAFF  B cell-activating factor 
BAFFR  B cell-activating factor receptor 
BAL  Bronchoalveolar lavage 
BCMA  B cell maturation antigen 
BCR  B cell receptor 
CB  chronic bronchitis 
CD  cluster of differentiation 
CF  cystic fibrosis 
CFTR  cystic fibrosis transmembrane conductance regulator 
COPD  chronic obstructive pulmonary disease 
CS  cigarette smoke 
DAMP  damage associated molecular pattern 
DC  dendritic cell 
DI  destructive index 
ENaC  epithelial natrium channel 
FDC  follicular dendritic cell 
FEV1  forced expiratory capacity in one second 
FVC  forced vital capacity 
GOLD  global initiative for obstructive lung diseases 
FRC  fibroblastic reticular cell 
GWAS  genome wide association study 
Ig  immunoglobulin 
IL  interleukin 
ILC  innate lymphoid cells 
Lm  mean linear intercept 
MHC  major histocompatibility complex 
MLN  mediastinal lymph nodes 
MMP  matrix metalloproteinase 
MUC  mucin 
PCL  periciliary layer 
qRT-PCR quantitative real time polymerase chain reaction 
ROI  reactive oxygen intermediate 
SLE  systemic lupus erythematosus 
SLO  secondary lymphoid organ 
SPLUNC short palate and lung and nasal epithelial clone 1 
TACI  transmembrane activator and cyclophilin ligand interactor 
Tfh  T follicular helper cell 
Th  T helper cell 
 
 
 
  
7  
ABSTRACT 
 
Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent disease which is characterized by an 
abnormal inflammation and destruction of lung tissue in response to noxious particles and gases, mainly 
cigarette smoke (CS). The pathogenesis of COPD is still not fully unravelled, which hampers the search for 
therapies that stop the progression of the disease. 
In this thesis, we aimed to investigate 2 aspects of the mucosal immune response to CS: airway surface 
liquid dehydration and the formation of B cell-rich lymphoid follicles.   
First, we studied the effect of airway surface liquid dehydration on CS-induced pathology in mice. 
Dehydration of the airway surface causes mucociliary clearance dysfunction and leads clinically to chronic 
bronchitis. Airway surface liquid dehydration was mimicked in mice which overexpress the β-subunit of 
the Epithelial Natrium Channel (ENaC). We subjected βENaC-Tg mice to CS for 4 and 8 weeks and observed 
that airway surface dehydration aggravates CS-induced inflammation and alveolar destruction. 
Furthermore, following 8 weeks of CS exposure, βENaC-Tg mice already started to develop lymphoid 
aggregations whereas wild-type mice did not. This suggests that dysfunction of mucociliary clearance can 
induce or accelerate the adaptive immune response to CS. 
Next, we investigated the effect of chronic bronchitis on clinically important outcomes in patients with 
COPD in a large population-based cohort. We observed that the presence of chronic bronchitis in patients 
with COPD leads to an increased risk for being a frequent exacerbator and increases the risk of mortality. 
This demonstrates the importance of the symptom chronic bronchitis and consequently, the importance 
of a well-functioning mucociliary clearance system.  
Inadequate mucociliary clearance may contribute to the chronic inflammation and lymphoid follicle 
formation seen in COPD. It has been demonstrated that the number of airways with lymphoid follicles is 
associated with disease severity. In addition, the expression of B cell-Activating Factor (BAFF) in these 
lymphoid follicles in patients with COPD is also correlated with disease severity. Therefore, we aimed to 
investigate the role of BAFF and B cell-rich lymphoid follicles in COPD. We localized BAFF expression in 
lymphoid follicles of patients with COPD and antagonized BAFF in mice which were chronically exposed to 
CS. We demonstrated that BAFF is significantly increased in lungs of patients with COPD and is present 
around both immune and stromal cells within lymphoid follicles. Furthermore, antagonizing BAFF in CS-
exposed mice attenuates pulmonary inflammation and alveolar destruction. 
The results shown in this thesis underline the importance of the mucosal immune response in the 
pathogenesis of COPD.  
 8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
9  
 
 
 
PART I: INTRODUCTION 
 
CHAPTER 1: CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 10  
1.1 DEFINITION 
 
Although Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide 
and a major cause of morbidity, the term ‘COPD’ is not well known by the lay public 1, 2. However, the 
association of shortness of breath – the main symptom of the disease – and cigarette smoking does sound 
familiar to many people. 
The definition of the disease is formulated as follows by the Global initiative for chronic Obstructive Lung 
Disease (GOLD) 3 : 
“Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable disease, 
characterized by persistent airflow limitation that is usually progressive and associated with an 
enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to the overall severity in individual patients.” 
The noxious particles and gases mentioned in the definition originate from cigarette smoking, occupational 
exposure to harmful gases and particulate matter and exposure to in- and outdoor pollution 2, 4, 5. COPD 
develops after cumulative exposures to these injurious substances over decades, but only in susceptible 
individuals 2, 3. It is estimated that at least 20% of all smokers develop COPD 4, 6. Several large-scale studies 
have demonstrated that genetic variation accounts for differences in susceptibility 7-10. Other contributing 
factors are intra-uterine growth retardation and low birth weight, history of pulmonary infections during 
childhood, history of pulmonary tuberculosis, chronic asthma, poor nourishment, poor socio-economic 
status and importantly, aging 5, 11, 12. Some of these additional risk factors may in turn be genetically and 
epigenetically regulated 10, 13. 
In most patients, COPD is progressive, leading to severe disability. The only intervention that slows down 
the progression of the disease, is the removal of initiating factors, for instance smoking cessation. 
However, even after smoking cessation, the disease persists 4. Treatments are mainly focussed on 
symptom relief 2. Currently, there is no cure. Further investigation into the pathogenesis of this 
disabilitating disease will advance the search for better therapies 14, 15. 
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1.2  EPIDEMIOLOGY AND BURDEN OF DISEASE 
 
The global burden of COPD is substantial. The World Health Organisation (WHO) states that COPD is the 
third leading cause of death, responsible for approximately 3.1 million deaths worldwide in 2012 1. In 
Europe, around 2010, COPD was the cause of death of approximately 0.15 million people (Figure 1). In 
addition, an average of 1690 thousand disability-adjusted-life-years and a total economic cost of 141.4 
billion euros per year can be accounted to this disease (Figure 1) 16. 
 
 
 
 
 
 
 
 
 
 
Worldwide, approximately 1 billion people smoke tobacco and 3 billion people are exposed to smoke from 
biomass fuel 5, 17. In addition, numerous people are exposed to air pollution or occupational hazardous 
substances, increasing the number of people at risk even further.  
It is estimated that 9 - 10 % of the global population aged 40 years or older suffers from moderate to very 
severe COPD 15. Afonso and colleagues studied the same age-group in the Netherlands and reported a 
prevalence of 3 % of physician-diagnosed COPD and the incidence of physician-diagnosed COPD was 
2.92/1000 person-years 18. 
Although it is generally assumed that in Western Countries cigarette smoking is the most important cause 
of COPD, the prevalence in never-smokers in the USA is estimated at 6.6%, resulting in a quarter of COPD 
patients being never-smokers 19. This has been corroborated by studies in the UK and Spain 5.  
Figure 1: The burden of COPD. A) Burden of COPD in older adults in Europe around 2010. B) Distribution of 
economic costs per category for  COPD in Europe. #: Global Initiative for Chronic Obstructive Lung Diseases 
stage II-IV. Figure adapted from The European Lung White Book Respiratory Health and Disease  in Europe. 
Published 2013, ISBN 978-1-84984-042-2 16 . 
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1.3 CLINICAL MANIFESTATIONS OF COPD AND DIAGNOSIS 
 
1.3.1 MAIN SYMPTOMS AND DIAGNOSIS 
 
Gradually progressing and persistent breathlessness is the main symptom of COPD. This may be 
accompanied by cough and/or sputum of varying severity 2, 3.  
The diagnosis of COPD is based on anamnesis - in particular exposure to cigarette smoke (CS) and other 
risk factors - and symptoms of dyspnea, cough and sputum and requires spirometry to confirm 2. 
Spirometry is a lung function test which measures, among other values, the forced expiratory volume in 1 
second (FEV1) and the forced vital capacity (FVC). A ratio of FEV1/FVC < 0.70 determines the presence of 
airflow limitation according to GOLD standards, whereas a FEV1/FVC < lower limit of normal is required for 
diagnosing COPD according to the Global Lung function Initiative. If the airflow limitation persists after 
inhalation of a bronchodilator (usually salbutamol), the diagnosis of COPD can be made. Disease severity 
is currently assessed based on the degree to which the FEV1 is different from the predicted value for a 
person of that specific age, height and weight (Table 1). Recently, new guidelines are published which take 
in account airflow limitation as well as symptoms (based on the COPD Assessment Test or the Modified 
Medical Research Council Dyspnea Scale) and exacerbation risk. Based on these 3 criteria patients are 
divided into 4 groups, A to D) 3. Additional tests include measurements of diffusing capacity of the lungs 
and computed tomography (CT) which contribute to the assessment of lung function and severity of 
emphysema.  
 
 
 
 
1.3.2 COPD PHENOTYPES 
 
The heterogeneity in clinical presentation and progression of COPD is substantial. Furthermore, the 
response to therapy is highly variable. This has led to subdividing patients according to similar traits or 
similar response to therapy in so called ‘phenotypes’ 20. Since phenotyping can be a rather confusing term, 
GOLD STAGE COPD FEV1/FVC  FEV1 
GOLD I Mild < 0.70 and ≥ 80 % predicted 
GOLD II Moderate < 0.70 and 50 % ≤ FEV1 < 80% predicted 
GOLD III Severe < 0.70 and 30 % ≤ FEV1 < 50 % predicted 
GOLD IV Very severe < 0.70 and < 30% predicted 
Table 1: COPD classification according to the Global Initiative for Chronic Obstructive Lung diseases (GOLD) 
Adapted from Vestbo J. et al., Am J of Respir Crit Care Med 2013;187(4):347-365 2.  
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Meilan Han and colleagues proposed to define a COPD phenotype as: “a single or combination of disease 
attributes that describe differences between individuals with COPD as they relate to clinically meaningful 
outcomes (symptoms, exacerbations, response to therapy, rate of disease progression, or death)” 21. 
Several phenotypes have been proposed (Table 2), however, only four are validated: α1 anti-trypsin  
deficiency, frequent exacerbators, emphysema and chronic bronchitis 14. 
The monogenic disorder α1 anti-trypsin deficiency is an 
autosomal recessive inherited defect in the SERPINEA1 
gene. The product of this gene is a serine protease 
inhibitor which neutralizes proteases such as neutrophil 
elastase. It affects approximately 1 in 2000-5000 
persons in Europe 16, 22. Pulmonary pathology is 
characterized by severe early-onset emphysema and is 
often accompanied by liver disease 22, 23. 
An exacerbation of COPD is defined as “an event in the 
natural course of the disease characterized by a change 
in the patient’s baseline dyspnea, cough, and/or sputum 
that is beyond normal day-to-day variations, is acute in 
onset, an may warrant a change in regular medication 
in a patient with underlying COPD”. Exacerbations can 
be elicited by respiratory infections and increased 
environmental pollution. Patients with 2 or more 
exacerbations per year have a worse quality of life and 
an accelerated lung function decline 24-26. 
The emphysema phenotype has been known as the ‘pink puffer’ phenotype and is associated with 
significant dyspnea, hyperinflation and weight loss, but with adequate oxygenation 27.  One subgroup,  
patients with severe upper lobe emphysema and low exercise capacity at baseline, are a seperate 
phenotype based on a survival advantage after lung-volume-reduction surgery compared to patients with 
severe emphysema with another craniocaudal distribution or with high exercise capacity at baseline 28.  
The chronic bronchitis phenotype will be thoroughly discussed in Chapter 3. 
Other phenotypes may exist but need to be validated. Importantly, patients can also express more than 
one phenotype 29, 30.  
Proposed COPD phenotypes 
α1-antitrypsin deficiency 
Frequent exacerbators 
Emphysema 
Chronic Bronchitis 
Severe hypoxia 
Disproportionate symptoms 
Persistent systemic inflammation 
Chronic airway bacterial colonisation 
Asthma/COPD overlap syndrome 
Early severe airflow limitation 
Extreme pulmonary hypertension 
COPD in never-smokers 
The 4 patientgroups proposed by GOLD 
Table 2: Proposed COPD phenotypes. 
Based on Celli B. et al. An official American 
Thoracic Society/European Respiratory 
Society statement: research questions in 
COPD. Eur Respir J 2015; 45: 879-905 14. 
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1.3.3 SYSTEMIC MANIFESTATIONS AND CO-MORBIDITIES 
 
Pulmonary symptoms in patients with COPD are often accompanied by systemic effects and 
comorbidities 14, 15, 31, 32. It is hypothesized that systemic effects occur due to ‘spill-over’ of pulmonary 
inflammatory mediators into the systemic circulation. However, other factors such as smoking, aging 
and physical inactivity may also contribute 4, 33. In stable COPD and even more so during 
exacerbations, increased levels of cytokines, chemokines, acute phase proteins and leukocytes are 
measured 33. Alongside systemic inflammation, the compromised gas exchange also has systemic 
consequences. Cachexia and skeletal muscle wasting are common systemic manifestations in 
patients with COPD. Comorbidities include cardiovascular disease, diabetes, depression, normocytic 
anemia and importantly, lung cancer 2, 31, 33. Furthermore, in the Rotterdam Study – a large 
population-based cohort study of subjects aged 45 years or older – COPD was found to be associated 
with sudden cardiac death, carotid artery wall thickening, stroke and frailty 34-37. 
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1.4  PATHOLOGY 
 
The pathological changes underlying the symptoms in patients with COPD are chronic bronchitis, 
obstructive bronchiolitis and emphysema (Figure 2) 7, 38. Vascular remodelling, both in the pulmonary 
compartment and systemically, is also a pathological feature of the disease 39.  
The chronically inflamed large airways (> 4 mm in internal diameter) are subjected to goblet cell metaplasia 
and enlargement of the submucosal glands, resulting in excessive mucus production 38. The structure and 
function of the epithelial cilia that propel the mucus towards the larynx are compromised by CS 40-42. 
Further contributing to impairment of mucociliary clearance, is the detrimental effect of CS on epithelial 
ion channels that regulate the hydration of the mucus layer 40. Finally, infiltration of inflammatory cells in 
the subepithelial area and deposition of connective tissue in the bronchial walls further adds to the 
pathological feature of chronic bronchitis 38, 43. 
The constant supply of noxious gases and particles inflicts inflammation in the small airways (< 2 mm in 
internal diameter) as well. The inflammatory infiltrate is characterized by neutrophils, macrophages, B and 
T lymphocytes 44. Chronic inflammation induces goblet cell metaplasia and mucus plugging 45. The 
resistance in the small airways is further increased by smooth muscle hypertrophy and peribronchiolar 
fibrosis 38. Finally, in severe COPD, lymphoid follicles contribute to an increased resistance by increasing 
the wall thickness 38, 44. The end result is obstructive bronchiolitis and air trapping. 
Products of the inflammatory response to CS, such as proteases, break down lung tissue 43. Subsequently, 
repair and remodelling processes are initiated. The result of this cascade is destruction of terminal and 
respiratory bronchioli, leading to centrilobular lesions and emphysema 46. Loss of terminal bronchioli 
precedes emphysematous damage which is characterized by destruction of alveolar walls leading to 
bullous lesions 46, 47. Emphysema can also be generated through increased apoptosis 48. The outcome is 
loss of elastic recoil and static hyperinflation.  
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Figure 2: COPD pathology: A) Healthy large airway. B) Large airway of a patient with COPD: goblet cell metaplasia 
and submucosal gland hypertrophy, resulting in a thick mucus layer. C) Healthy small airway and alveoli. D) Small 
airway and alveoli of a patient with COPD: a thick mucus layer and infiltration of inflammatory cells in the airway 
lumen, goblet cell metaplasia, lymphoid follicle formation, subepithelial fibrosis and destruction of alveolar walls 
(emphysema). 
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1.5 PATHOGENESIS 
 
Lung inflammation is present in all smokers. However, not all smokers develop COPD. In those who do, the 
inflammatory response is abnormal . The difference in response to tobacco smoke can be contributed to 
genetic variations and early-life lung development 15, 49, 50. 
Since COPD is generally caused by CS in Western Countries, the pathogenesis of CS-induced COPD will be 
described. Importantly, CS is a mixture of thousands of toxic particles and fumes. It is estimated that each 
cigarette puff contains over 2000 xenobiotic compounds and 1014 free radicals 51, 52.  
 
1.5.1 GENETICS 
 
Twin-studies have suggested a strong genetic component in the risk of developing COPD 53 and several 
Genome Wide Association Studies (GWAS) have identified genetic variants associated with lung function 
or risk of developing COPD 8, 9. Hunninghake et al. have demonstrated that the minor allele of a single 
nucleotide polymorphism in the gene encoding for MMP12 reduced the risk of developing COPD, and more 
importantly, showed that the outcome of this genetic variation altered with different environments 54, 55. 
Moreover, genome-wide studies also reveal genetic variations at the base of smoking behavior 56, 57. 
Recently, the UK BiLEVE study demonstrated variability in the underlying genetic framework of both 
smoking behavior and lung health 10. Nevertheless, these variations only account for a small part of the 
phenotypic differences 8, 10. In the last decade, the importance of epigenetic modulation has become 
apparent. Several microRNAs have already been described in association with COPD 10, 13, 58. And evidence 
linking other epigenetic mechanisms (long non-coding RNAs, DNA methylation and histone modifications) 
to the pathogenesis of COPD is rapidly emerging 10, 13, 59. 
 
1.5.2  EARLY-LIFE LUNG DEVELOPMENT  
 
Although the importance of early-life lung development has been emphasised by paediatricians and was 
already implied by Fletcher and Peto in the 1970s 49, 60, only fairly recent this issue has caught a spotlight 
in COPD research. The crucial years to be able to reach the maximal lung function in young adulthood, are 
the first 4 to 6 years of life 61. Even compromised lung development in utero – for instance due to maternal 
smoking during pregnancy - increases the risk for reduced lung function in adulthood 11, 50, 61. Other 
‘childhood disadvantage factors’, such as maternal asthma, paternal asthma, childhood asthma and 
childhood respiratory infections, also contribute to an impaired lung function in adulthood and 
significantly increase the risk of developing COPD 50, 61, 62. The effect of having 2 or more early-life 
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disadvantages is estimated to be as important as heavy smoking for development of COPD 50. Recently, a 
large-scale study in 3 independent cohorts has confirmed that half of the patients with COPD displayed a 
low FEV1 in early adulthood and a subsequent moderate decline instead of the usual trajectory of a rapid 
decline in FEV1 starting from a normal lung capacity (Figure 3) 63.  
 
 
 
 
 
1.5.3  ABNORMAL INFLAMMATORY RESPONSE TO CIGARETTE SMOKE IN COPD 
 
Damage to airway epithelial cells is key in the initiation of pulmonary inflammation (Figure 4) 64, 65. The 
multitude of toxic substances in CS injure the epithelium directly or by inducing oxidative stress and tissue 
hypoxia, leading to cell death and release of damage-associated molecular patterns (DAMPs) 4, 52, 66-68. In 
addition, CS exposure induces the release of DAMPs by macrophages and neutrophils as well 69, 70. In 
broncho-alveolar lavage (BAL) fluid of patients with COPD, there is an increased concentration of DAMPs, 
such as high-mobility group box 1(HMGB1) and extra-cellular ATP, compared to controls 69, 71. DAMPs are 
recognised by pattern recognition receptors on innate immune cells and structural cells 4, 51. In response 
to the release of DAMPs, airway epithelial cells and immune cells secrete an array of cytokines, chemokines 
and growth factors 4, 72. As result, the capillary endothelium is activated to allow leukocyte adhesion and 
migration 73 and leukocytes are attracted to the site of injury 4, 38, 51, 68. 
Figure 3: Adapted Fletcher and Peto Curve. The effect of impaired lung development and genetic susceptibility 
on lung function decline. Adapted from Brusselle GG., N Engl J Med, 2009;361(27):2664-2665 55. 
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In response to the chemoattractant CXCL8, neutrophils infiltrate the airway lumen 68, 74, the bronchial wall 
and submucosal glands 44, 75, 76 and airway smooth muscle bundles 77. The substantial increase in 
neutrophils is associated with airflow limitation and peripheral airway dysfunction in patients with COPD 
75, 78. In accordance, neutrophil-derived products are consistently shown to be elevated in airways of 
patients with COPD compared to controls and correlate with disease severity 79, 80. Neutrophils and their 
derivatives are implicated in several pathogenic mechanisms leading to COPD. First, they release a wide 
range of pro- and anti-inflammatory cytokines, chemokines and growth factors contributing to the 
activation and regulation of the immune response 81. Second, neutrophils produce a variety of proteases. 
Neutrophil elastase, cathapsin-G, proteinase-3 and neutrophil-produced matrix metalloproteases (MMP) 
are important factors in degradation of tissue, propagating the development of emphysema 4, 82, 83. Third, 
neutrophils are a major source of reactive oxygen intermediates (ROI), thus contributing to oxidative stress 
and tissue damage – directly and indirectly by inactivating anti-proteases 81, 84. Fourth, in COPD, the 
phagocytic activity of neutrophils is impaired leading to accumulation of apoptotic cells and secondary 
necrosis with release of danger signals 85. Fifth, neutrophils play a significant role in the overproduction of 
mucins at least in part through its product neutrophil elastase 83. And finally, neutrophils also produce 
neutrophil extracellular traps - fibrillary networks composed from nuclear material and pattern recognition 
molecules, such as pentraxin-3. These neutrophil extracellular traps are intended to work as a mesh to 
capture pathogens 81. However, both pentraxin-3 and neutrophil extracellular traps have been associated 
with COPD 86-88.  
In the pathogenesis of COPD, macrophages play a pivotal role as well. Alveolar macrophages are present 
in homeostatic circumstances, but their numbers increase significantly upon CS exposure both through 
local proliferation and attraction of monocytes from the peripheral blood 89, 90. Interstitial macrophages, a 
second tissue-resident macrophage population, reside in the lung parenchyma and represent less than 
10% of the lung macrophages 90, 91. The inflammatory response is characterised by a 5- to 10-fold increase 
in macrophages in airways, lung parenchyma, BAL and sputum of patients with COPD compared to controls 
4, 38, 44, 75, 83. The severity of COPD is positively correlated with macrophage numbers 75, 92. Furthermore, 
depletion of macrophages in a short-term mouse model of COPD resulted in protection against the 
development of COPD-like pathology, underlining their crucial role in the disease 93. The release of anti- 
and pro-inflammatory cytokines, chemokines and growth factors, ROI and several proteases – including 
MMP2, MMP9, MMP12 and cathepsins K, L and S – by macrophages drives several elements in the 
pathogenesis of COPD 52, 83, 90. Importantly, macrophages are also impaired in their ability to phagocytose 
apoptotic cells, resulting in secondary necrosis and amplification of inflammation 89, 94. Alveolar 
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macrophages exhibit an enormous plasticity to adapt to the ever changing microenvironment in the 
airways and alveoli. Exposure to CS drives the development of both pro-inflammatory (M1) macrophages 
and anti-inflammatory (M2) macrophages 90, 95. However, transcriptional profiling revealed a 
downregulation of M1-associated genes and an induction of M2-associated genes involved in 
immunoregulation and tissue remodelling 96. 
Alongside increased numbers of macrophages and neutrophils, other innate immune cells infiltrate the 
lungs and airways of patients with COPD. Increased numbers of natural killer cells have been associated 
with disease severity 75. Mast cells are significantly increased in airway tissues of patients with COPD, 
especially in patients with centrolobular emphysema 65, 97. Interestingly, innate lymphoid cells type 3 (ILC3) 
and more specifically, the natural cytotoxicity receptor-negative ILC3, tend to be increased in patients with 
COPD 98.  
 
 
Figure 4: COPD pathogenesis. Cigarette smoke damages airway epithelial cells and alveolar macrophages which 
release damage associated molecular patterns (DAMPs). Subsequently, inflammatory cells are attracted to the 
airways and dendritic cells migrate to the draining lymph nodes. In chronic inflammation, constant release of 
proteases by the inflammatory cells causes alveolar wall destruction. In addition, mucus plugging, airway wall 
remodeling and the formation of lymphoid follicles contribute to the small airway obstruction.  
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At the crossroad between innate and adaptive immunity, dendritic cells (DC) play a crucial role in the 
immune response to CS. Following encounter with an immunogenic antigen, these antigen presenting cells 
migrate towards the draining lymph nodes and display antigen in the T cell-rich zone. Langerin+ DCs 
accumulate in small airways of patients with COPD and their increase is associated with disease severity 
99. Furthermore, increased expression of costimulatory molecules on several DC subsets is correlated with 
disease severity as well 100. 
Where innate immunity is essential in the initiation phase of the immune response to CS, the adaptive 
immune system is important in the progression and consolidation phases of the COPD pathogenesis 51. 
Following antigen presentation by DCs, T cells are activated and recruited to the lung through binding of 
the chemoattractant CXCL10 – produced by structural cells in the lung – to its receptor CXCR3 on activated 
T cells 51, 101. Characteristic for airways and lungs of patients with COPD are increased numbers of CD8+ 
cytotoxic T cells which correlate with disease severity 102, 103. Importantly, CD8+ T cells in patients with 
COPD possess enhanced cytotoxicity compared to healthy smokers and non-smokers 104. In contrast to 
CD8+ cells which recognise antigen presented by major histocompatibility class 1 (MHCI) molecules on 
most cells, CD4+ T cells require antigen presented by MHCII on professional antigen-presenting cells. These 
cells are not cytotoxic themselves, but exert their function through release of cytokines which guide the 
responses of other cells. The percentage of airways containing CD4+ T cells significantly increases with 
COPD severity 44. However, this increase does not necessarily result in an increased immunological 
protection since the Th1 response to gram-negative bacteria is impaired in COPD 105. Th17 cells, which are 
important in immunological responses against extracellular pathogens and in auto-immune responses, are 
increased in bronchial mucosa and peripheral blood of patients with COPD 106, 107. Interestingly, recent 
evidence shows that IL-17, which is primarily produced by Th17 cells, seems to be implicated in the 
pathogenesis of COPD 108, 109.  
In the last decade, B cells have gained importance in the pathogenesis of COPD. Although the increase in 
B cells in patients with COPD was already reported in the early nineties, it was not until the landmark paper 
of Hogg et al. that interest in this cell type rekindled 44, 110. Not only isolated B cells are more numerous, B 
cells are the main cell type of tertiary lymphoid follicles and the percentage of airways associated with 
lymphoid follicles is significantly higher in patients with severe COPD compared to non-COPD control 
subjects and patients in the earlier stages of the disease 44. B cells, lymphoid follicles and their importance 
in the pathogenesis of COPD will be further discussed in Chapter 4. 
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1.5.4  MECHANISMS DRIVING THE PATHOGENESIS OF COPD 
 
Central in the pathogenesis of COPD is an excess of oxidants, both from exogenous and endogenous origin, 
which exceeds the amount of anti-oxidants present 84. Endogenous oxidants derive from innate immune 
cells and airway epithelial cells following injury. Markers for oxidative stress have been detected in exhaled 
breath condensate of patients with COPD and increase further during exacerbations 111. Increase in several 
oxidative stress markers is correlated with lung function decline in COPD 84. Oxidative stress contributes 
to many of the pathogenic events in COPD. Neutrophils and macrophages produce large quantities of 
proteases such as neutrophil elastase and MMP12 4, 82. Oxidative stress adds to the imbalance between 
proteases and anti-proteases by inactivating the latter 84, 112.  Furthermore, oxidative stress enhances lung 
inflammation by inducing the release of chemokines which attract more inflammatory cells to the airways 
113. These inflammatory cells induce fibrosis and remodelling of the airway wall and the proteases they 
release, cause tissue destruction. In addition, oxidants generate upregulation of nuclear factor ƙB (NF-ƙB) 
and activating protein 1 (AP-1), thereby inducing inflammation 114. Moreover, oxidants such as reactive 
oxygen species (ROS) lead to activation of the NLRP3 inflammasome, suggesting a role for this 
inflammasome in the pathogenesis of COPD 115. This large signalling complex controls the activation of IL-
1β and IL-18, which are elevated in lungs of patients with COPD 116.  
Although research has elucidated parts of the pathogenesis, there are still important questions to be 
raised. Recently, several exciting new hypotheses are being investigated to discover the missing links in 
the pathogenesis of COPD. For instance, autophagy, either defective or excessive, is observed in patients 
with COPD. Since autophagy, lung inflammation and oxidative stress are all witnessed in normal aging as 
well, it has been hypothesized that the mechanism driving COPD is accelerated aging of the lung 12.  
Furthermore, it is now recognised that interactions between host and microbiome are able to steer 
immune responses in the host. The microbiome in patients with COPD is less diverse and characterised by 
an expansion of the Proteobacteria phylum. In a murine model of COPD, lack of microbiota significantly 
attenuated both inflammation and decline of lung function. Moreover, in patients with COPD, decline in 
microbial diversity is associated with emphysema and remodelling. It is hypothesized that these 
interactions can account for the chronicity in COPD 109, 117. This thought fits perfectly with the concept of 
innate immune training; a concept that can enlighten the self-perpetuating nature of the inflammatory 
response in COPD 118, 119. 
Finally, in advanced COPD, it is speculated that auto-immunity may contribute to the pathogenesis. 
Arguments for and against this hypothesis will be discussed in Chapter 4. 
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1.6  TREATMENT 
 
COPD is treatable but not curable. Smoking cessation is the most effective intervention to slow down 
disease progression. To enhance the success rate of long-term smoking cessation, counselling is often 
supplemented with nicotine replacement products, such as nicotine gum or patches, and varencicline, 
bupropion or nortriptyline. Therapy is primarily based on symptom relief and prevention of exacerbations. 
The degree of airflow limitation, the exacerbation frequency and the symptoms the patients experience 
determine the choice of bronchodilator and whether or not corticosteroids will be prescribed. Patients 
with mild to moderate airflow limitation and maximum 1 exacerbation per year, are treated with inhaled 
bronchodilators (either anticholinergics or β2-agonists). The choice for short-acting versus long-acting 
bronchodilators is based on the degree to which patients suffer from symptoms. Patients with severe or 
very severe airflow limitation and 2 or more exacerbations per year are treated with inhaled 
corticosteroids and long-acting bronchodilators. When these patients suffer from symptoms, roflumilast, 
a phosphodiesterase-4 inhibitor can be added to the treatment 3.  
Aside from the pharmacological treatment, patients are encouraged to be physical active and when 
necessary, to pursue pulmonary rehabilitation. Very severe airflow limitation can warrant for oxygen 
therapy. To prevent exacerbations prophylactic measures, such as influenza vaccination, are advised. 
The treatment of exacerbations depends on the cause of the exacerbation (non-infectious, bacterial or 
viral) 2, 15. 
Currently, many new molecules are tested for safety and efficacy in clinical trials. Most of these new 
molecules induce bronchodilation. Some molecules exert an antagonistic function on muscarinic receptors 
while having an agonistic effect on β2-adrenoceptors. Triple therapy, combining a long-acting 
anticholinergic and a long-acting β2-agonist with a corticosteroid in 1 device, is also currently tested. This 
triple therapy could enhance therapy compliance 120.  
Other candidate-drugs for COPD are new phosphodiesterase inhibitors, mitogen-activated protein (MAP) 
kinase inhibitors, andolast (modulator of calcium-activated potassium channels), ivacaftor (cystic fibrosis 
transmembrane conductance regulator (CFTR) enhancer) and several monoclonal antibodies. Of these 
monoclonal antibodies anti-IL-5 (mepoluzimab), anti-IL-5R (benralizumab), anti-IL-13 (lebrikizumab) and 
anti-IL-8 (ABX-IL8) are currently in phases 2 or 3 of the clinical trials. Others such as anti-IL-6, anti-17(R), 
anti-CD22 and anti-BAFF(R), are promising but are still in the first phases of testing 120-122.  
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PART I: INTRODUCTION 
 
CHAPTER 2: MUCOCILIARY CLEARANCE IN COPD 
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2.1  MUCOCILIARY CLEARANCE: INTRODUCTION 
 
Breathing air inevitably means that air-borne particles, toxins, gases, fumes and infectious agents enter 
the respiratory tract. Therefore, a mucus layer, which lies on top of the airway epithelium, delineates the 
respiratory tract and captures these inhaled noxious substances 123, 124. The airway epithelium is largely 
ciliated and unidirectional beating of these cilia in combination with coughing propels the mucus, loaded 
with trapped particles and gases, towards the pharynx. This process of mucociliary clearance provides an 
essential first line of defence in respiratory immunity 40, 123.  
Dysfunction of the mucociliary clearance system can arise from excess mucus production, abnormal mucus 
hydration or cilia impairment. CS induces all three these defects, resulting in chronic bronchitis in a 
subpopulation of smokers and patients with COPD. In addition, independent of the presence of chronic 
bronchitis, mucus exudates cause obstruction of the small airways in patients with COPD and contribute 
to the narrowing of small airways 44, 47. Moreover, progression of COPD is associated with the degree to 
which the lumen of small airways is filled with mucus exudates 44. Importantly, mucus stasis predisposes 
for bacterial infections in airways 124, 125. 
 
2.2  MUCOCILIARY CLEARANCE IN HEALTH 
 
The airway epithelium fulfils many functions in the mucociliary clearance system. Not only does it provide 
cilia which propel mucus towards the pharynx, it also regulates airway surface liquid hydration, the 
secretion of immunoglobulins and other anti-microbial substances and provides mucins which constitute 
a major component of the mucus layer 40, 124, 126. Furthermore, epithelial cells also provide anti-
inflammatory signals preventing patrolling immune cells in the airway lumen of overreacting in case of an 
encounter with a harmless antigen 89. The airway epithelium harbours ciliated cells, secretory cells, basal 
cells and a variety of less frequent cells, such as neuroendocrine cells. The relative contribution of these 
cell types depends on the airway level 127. In addition to secretory cells in the epithelium, large airways 
contain submucosal glands which secrete mucins, proteoglycans and numerous antimicrobial proteins into 
the airway lumen 40. 
A large proportion of airway epithelial cells is ciliated. The cilia on these airway cells are motile and are 
typically constructed in a 9 + 2 arrangement of microtubules with dynein arms and radial spokes 128. Each 
ciliated epithelial cell generally possesses about 200 cilia at the apical plasma membrane and the cilia beat 
at a frequency of 10 to 15 Hz 124. Mucus is unidirectionally propelled towards the pharynx by a vertical 
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effective stroke of the cilia, while the recovery stroke takes place in the periciliary layer in a horizontal 
plane 126, 128. Ciliary beat frequency is regulated by changes in phosphorylation state of ciliary components 
such as dynein subunits, changes in intracellular pH and Ca2+ 129. 
In healthy lungs, the epithelial cilia are surrounded by an approximately 7 µm high peri-ciliary layer (PCL) 
(Figure 5). This PCL gel-layer is covered by the mucus layer which is more visco-elastic than the PCL and 
variable in height. Together, these two layers constitute the airway surface liquid (ASL), which can be 
regarded as a movable physical barrier 40, 124, 130.  
 
 
 
 
 
In healthy individuals, the mucus layer exists of only 1.5 to 3 % solids, which include mucins, non-mucin 
proteins, anti-microbial substances, lipids, ions and cellular debris 40, 131. Much of the properties of the 
mucus layer are mediated by the large glycoproteins, known as mucins 130. The predominant mucins in the 
mucus layer are MUC5AC and MUC5B, both heavily glycosylated proteins with at least one region of 
amino-acids rich in serine and threonine residues where carbohydrate structures are linked. The rich 
Figure 5: Airway surface liquid and mucins. The periciliary layer (PCL) and the mucus layer together constitute 
the airway surface liquid (ASL). Cell-tethered mucins (MUC1, MUC4, MUC16 and MUC20) attach to the microvilli 
and cilia of the airway epithelial cells and provide the gel structure of the PCL. MUC5B and MUC5AC are secreted 
mucins and form a mucus layer on top of the PCL. Mucus cells in the submucosal glands contribute to the 
production of MUC5B and MUC16. 
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diversity of carbohydrates aids in trapping bacteria by interaction with microbial sugar-binding proteins. 
Furthermore, by oligomerization at the 3’ and 5’ termini, mucins form a polymer network that provides 
structure to the mucus gel 40, 130, 132. Recent research shows that globular proteins are important 
contributors to this framework and mucin-protein interactions are crucial for the biophysical properties of 
mucus 133. Of note, these globular proteins constitute about 60 to 70 % of the solids in the mucus layer 40, 
133.  
Mucins are secreted continuously at a baseline level 40. Submucosal glands release mucins in a circadian 
rhythm, most likely regulated by the vagal nerve 132. In contrast, goblet cells, which are a minority 
population of about 5 % of the epithelial cells in healthy individuals, secrete mucins due to stimulation of 
P2Y2 purinergic receptors by the low amount of ATP that is present in the ASL 40, 131. Before secretion, 
mucins are packed in vesicles in dehydrated condition. Their negative charges are shielded by Ca2+ and H+. 
Upon release, mucins dramatically expand and bind water. Therefore, the mucus layer is able to function 
as a water reservoir for the underlying PCL 124. Interestingly, MUC5B is thought to be predominantly 
secreted from the submucosal glands, whereas goblet cells secrete MUC5AC 130.  
In contrast to former believes, the PCL is not a watery layer but a gel-based structure, composed of several 
different mucins and proteins 134. Cell-tethered mucins attach to the apical membrane and microvilli 
(MUC1), to the cilia (MUC4 and MUC20) or to goblet cells (MUC 16) of the airway epithelium (Figure 5) 135. 
They possess a similar structure as secreted mucins and are heavily glycosylated as well, which causes 
them to extend far from the cell surface with the carbohydrates branching out from the axis. This 
conformation resembles that of a bottle brush 136. This characteristic look of tethered mucins leads to 
shielding of extra-cellular receptors and hence protection against adhesion of microbial organisms 137. The 
cell-tethered mucins and large mucopolysaccharides create a mesh with selective barrier functions 135, 138. 
This relatively new concept has elegantly been described as a ‘gel-on-brush’ structure and explains why 
secreted mucins do not enter the PCL 138.  
For efficient mucociliary clearance, the ASL must be adequately hydrated 124. The ‘gel-on-brush’ model 
explains that the highly concentrated PCL, with an osmotic pressure higher than that of the mucus layer, 
can withdraw water from the mucus layer up to the point where the concentration of the latter becomes 
so high that the osmotic pressure exceeds that of the PCL. At that point the PCL collapses and mucus stasis 
is established 138.  
ASL hydration basically means a balance between cation absorption and anion secretion. For a large part, 
water follows passively via the paracellular pathway. Cl- secretion is mediated by CFTR (Cystic Fibrosis 
Transmembrane conductance Regulator) and Na+ absorption by ENaC (Epithelial Natrium Channel). In 
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mice, Ca2+ activated Cl- channels (CaCC) additionally secrete Cl- into the lumen 124. Importantly, in addition 
to Cl-, HCO3- is secreted in smaller concentrations by CFTR and has a buffering effect on ASL pH 139. CFTR is 
a member of the adenine nucleotide-binding cassette transporter subfamily and works as an cAMP-
dependent anion channel. ENaC is a heterotrimer with a α-, β- and γ-subunit. The α- and γ- subunit need 
to be proteolytically cleaved for activation. Volume sensors, such as nucleotides (ATP, UTP and UDP), 
adenosine and short palate lung and nasal epithelial clone 1 (SPLUNC1), regulate ASL hydration. 
Nucleotides and adenosine do so by interacting with purinergic receptors, initiating Cl- secretion 124, 125. 
SPLUNC1 binds directly to ENaC, causing internalisation of this Na+ channel and thus, its inactivation 140, 
141. Interestingly, cilia, beating in the mucus layer, sense alterations in mechanical strain which reflect 
alterations in hydration state of the mucus layer and subsequently regulate ATP release 142. Regulation of 
the ion channels also depends on whether or not they are co-expressed. CFTR seems to have a suppressing 
effect on the activation of ENaC. However, the interactions between both ion channels are not well 
understood 124, 143. 
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2.3 MUCOCILIARY CLEARANCE IN COPD 
 
2.3.1  CILIARY BEATING IN COPD 
 
CS impairs ciliogenesis, leads to shortened cilia, reduces ciliary beat frequency and increases the number 
of ciliary microtubule abnormalities 124. Cilia length was measured in endobronchial biopsies from healthy 
smokers and non-smokers and a significant 15% reduction in cilia length was detected in healthy smokers 
41. It was recently determined that CS induces upregulation of histone deacetylase 6 activity which results 
in removal of ciliary proteins and subsequent ciliary shortening 144. Furthermore, chronic CS exposure of 
wild-type mice resulted in loss of ciliated cells and decreased ciliary beat frequency mediated by activation 
of protein kinase C 145. All these effects on ciliary function will have repercussions on the efficiency of 
mucociliary clearance, although coughing provides a back-up mechanism for mucus clearance 146. 
 
2.3.2  MUCUS PRODUCTION AND SECRETION IN COPD 
 
The chronic bronchitis phenotype in COPD is characterized by excess production of mucus and is 
associated with current smoking 147. In addition, small airway obstruction due to mucus plugging is present 
in patients with severe COPD, irrespective of the presence of chronic bronchitis, and correlates to disease 
severity 38, 44. Both glandular hyperplasia and goblet cell hyperplasia/metaplasia contribute to this 
overabundance of mucins 38, 40. In smokers with airflow obstruction, goblet cell numbers and size in the 
large airways correlate with disease severity 148. The transition of ciliated cells into goblet cells, is most 
likely regulated via EGFR (epidermal growth factor receptor) and IL-13. EGFR activation inhibits apoptosis 
and IL-13 mediates activation of ERK1/2 and STAT6, which promotes the transdifferentiation to goblet 
cells 149. A transdifferentiation of Clara cells into goblet cells may also occur 131, 149. In patients with COPD 
and in current smokers, EGFR and MUC5AC expression is increased 150, 151. Takeyama et al. showed, both 
in vitro and in vivo, that CS induces activation of EGFR and subsequent upregulation of Muc5AC and goblet 
cell numbers  152. Upregulation of MUC5AC expression can be mediated by many stimuli, among which CS 
components, microbial agents, neutrophil elastase, MMP9, oxidants and several cytokines 40, 131, 153, 154. 
Signalling through one of at least 5 different pathways that have been implicated in the upregulation of 
Muc5AC, leads to rapid production of the protein within 2 hours 130, 132. The regulation of MUC5B is less 
understood. Mucin secretion is regulated separately from mucin production and is in goblet cells 
predominantly mediated via ATP binding to P2Y2 receptors 155. Mucin release from submucosal glands is 
neurologically regulated 40. 
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Mucus hypersecretion is driven by an enormous increase in MUC5AC, whereas the relative contribution 
of MUC5B is unclear 40, 156. Interestingly, MUC5B is thought to be necessary for airway defence. It forms 
non-covalent heterotypic complexes with many anti-microbial agents, among which secretory IgA (sIgA) 
and amylase 130, 156. Of note, glycosylation of the secretory component of sIgA is necessary for retention in 
bronchial mucus 130.  
Mucin hypersecretion leads to a substantial increase in the percentage of solids within the mucus layer, 
causing a relative dehydration 125. While the mucus layer comprises a maximum of 3% solids in healthy 
individuals, in smokers, the percentage of solids can increase up to 10 % 40, 157. Anderson et al. observed 
that the osmotic pressure of the mucus layer causes compression of the PCL when the percentage of solids 
is higher than 3 %. Furthermore, the percentage of solids is inversely correlated with mucus clearance in 
patients with chronic bronchitis. Both mucus clearance and the percentage of solids in sputum are 
negatively associated with airflow limitation in patients with chronic bronchitis 158. 
Developing pre-clinical animal models of chronic bronchitis is difficult since the definition of chronic 
bronchitis is a clinical one. Furthermore, there is substantial variation between species with regard to the 
occurrence and localisation of both submucosal glands and goblet cells. In response to CS, mice do not 
readily develop goblet cell metaplasia. In rats, goblet cell metaplasia following CS exposure is restricted to 
the proximal airways. In contrast, guinea pigs do develop goblet cell metaplasia in the small airways as 
well. However, using guinea pigs involves a number of disadvantages such as a greater cost, and a lack of 
tools (antibodies and gene sequences) to study these animals. Aside from CS, other inducing agents have 
been used to evoke chronic bronchitis in animals. The most frequently used agents are sulphur dioxide, 
lipopolysaccharide and proteases. The downside of these agents is that the relevance to mechanisms that 
occur with CS exposure is unclear. Finally, goblet cell metaplasia can be induced in genetically engineered 
mice, for instance by overexpression of Th2 cytokines. However, this approach induces other elements 
(such as eosinophilia) which do not comply with COPD pathogenesis.   
 
2.3.3  AIRWAY SURFACE LIQUID HYDRATION STATE IN COPD 
 
Aside from the effects of mucin hypersecretion and increase in percentage of solids in the mucus layer of 
patients with COPD, ASL is also compromised by direct and indirect effects of CS on the ion channels 
responsible for hydration 123.  
The prototype disease of airway surface dehydration and subsequent mucociliary clearance dysfunction is  
cystic fibrosis (CF). This disease is caused by mutations of the Cftr gene and is recessive inheritable. Patients 
suffer from severe neutrophilic airway inflammation and mucus stasis from birth onwards and their life 
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expectancy is reduced due to recurrent bacterial pulmonary infections.  The function of the CFTR protein 
is often completely diminished and as a result there is no active Cl- and HCO3- secretion to the airway lumen 
through the CFTR channel. Mucus stasis predisposes for bacterial colonization and neutrophilic 
inflammation. The proteases which are released from the inflammatory cells further alter the function of 
ion channels and aggravate the airway surface dehydration. Lack of HCO3- leads to an acidic pH which 
inhibits effective bacterial killing 159, 160.  
Although both COPD and CF result in obstructive lung disease in which airway surface dehydration 
contributes to the pathogenesis, there are several difference between both diseases. In contrast to CF, 
cigarette smoking induces an acquired dysfunction of the CFTR channel and the function can be restored 
after smoking cessation. The dysfunction is generally not complete; the CFTR channel remains active for 
some part 159, 160. 
In cigarette smokers with and without COPD, the CFTR function is suppressed in both upper and lower 
airways 161, 162. Moreover, loss of CFTR function correlates with the presence of chronic bronchitis and 
dyspnea 162. In chronic smokers, CFTR function is decreased by 55 to 70 %. This acquired dysfunction is 
thought to be due to internalisation of CFTR in a Ca2+-dependent way (Figure 6) 124, 157. Protein misfolding 
of CFTR due to CS has been suggested as a potential cause for this internalisation 124. The function of CFTR 
is also systemically impaired in cigarette smokers and acrolein has been identified as an agent conveying 
the deleterious effects of CS on CFTR 163. Furthermore, oxidative stress and heavy metals, both present in 
lungs of patients with COPD, reduce the activity of CFTR 124, 164. Pharmacological intervention with 
ivacaftor, a CFTR potentiator, or roflumilast, a phosphodiesterase inhibitor, improved activation of CFTR 
and thereby airway surface 
dehydration 165, 166. Interestingly, CFTR 
dysfunction results in loss of HCO3- 
secretion and acidification of ASL, 
leading to impaired bacterial killing and 
increased infection risk 139. 
Figure 6: CFTR and ENaC. In healthy airways, 
the presence of CFTR inhibits the function of 
ENaC. Following cigarette smoke exposure, 
CFTR is internalized, resulting in loss of Cl- 
and HCO3- secretion and activation of ENaC. 
Adapted from Ghosh et al. Cell Mol Life Sci. 
2015; 72: 3637-3652 121. 
 
  
33  
The role of ENaC dysfunction in COPD is less clear. Downs et al. showed that ROS and H2O2, both oxidants 
present in CS, activate ENaC in alveolar epithelial cells 167, 168. It was also reported that hypoxia inhibits 
ENaC activation 169. In lung tissue of COPD patients, Zhao et al. observed that the expression of α- and β-
ENaC was increased and inversely correlated with lung function. They also showed that CFTR expression 
was decreased and this also correlated with lung function 170. Since CFTR has a suppressive effect on ENaC 
activity, it can be argued that loss of CFTR might result in activation of ENaC. Furthermore, proteases such 
as neutrophil elastase and MMP9 are abundantly present in airways of patients with COPD and are potent 
activators of ENaC by performing the necessary cleaving of the α- and γ-subunit 124, 125, 160. Nevertheless, 
these speculations need scientific proof. Of note, regardless of the importance of ENaC hyperactivation in 
the pathogenesis of COPD, pharmacological targeting of ENaC seems a promising approach for improving 
airway surface dehydration 171, 172. 
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2.4  BETA-ENAC TRANSGENIC MICE: A MURINE MODEL OF AIRWAY SURFACE DEHYDRATION 
 
Research into the role of airway surface dehydration in the pathogenesis of COPD is a challenging quest. 
In health, airways of mice harbor only few goblet cells and exposure to CS does not substantially influence 
this feature. Furthermore, mice only possess submucosal glands near the first few tracheal rings in contrast 
to humans which possess submucosal glands in all the large airways (> 2 mm) 173. As a result of these 
characteristics of mice, mimicking airway surface dehydration through increased mucus secretion is not 
evident. In addition, cftr-/- mice do not exhibit a lung phenotype 174, 175. Recently, Shah et al. demonstrated 
that this absence of phenotype in mice is caused by a lack of H+/K+ adenosine triphosphatase (ATP12A), 
which causes secretion of H+ into the lumen. In humans and pigs with CFTR dysfunction, this H+ secretion 
acidifies the ASL, resulting in impairment of host defenses and increase in airway bacteria 139. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: βENaC-transgenic mice. In wild-type mice, CFTR (cystic fibrosis transmembrane conductance 
regulator) regulates the function of ENaC (epithelial natrium channel), balancing Na+ absorption and CL- 
secretion. Normal hydration of the airway surface liquid results in a periciliary layer (PCL) of approximately 7 
µm which allows the cilia to beat optimally. In βENaC-transgenic mice, overexpression of βENaC leads to Na+ 
hyperabsorption and a subsequent imbalance between Na+ absorption and Cl- secretion. The result is 
dehydration of the airway surface liquid, compression of the PCL and impaired mucociliary clearance.  
Adapted with permission from Mall MA et al., Nat Med, 2004;10:487-493 173. 
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To obtain airway surface dehydration, Mall and colleagues created transgenic mice that overexpress the 
β-subunit of ENaC (Scnn1b) in an airway specific way by coupling to a clara cell specific promotor (CCSP). 
This overexpression is responsible for hyperabsorption of Na+ and subsequent dehydration of the ASL 
(Figure 7). In contrast to cftr-/- mice, βENaC-transgenic (βENaC-Tg) mice display a lung phenotype 
resembling cystic fibrosis with reduced mucus transport, airway mucus obstruction and pulmonary death 
176. The severity of the induced lung disease is demonstrated by the high neonatal death due to mucus 
plugging and subsequent asphyxia. Surviving mice develop remarkable goblet cell metaplasia and airway 
inflammation, followed by substantial emphysema at early age, features resembling COPD 177. By 
backcrossing to a C57BL/6 wild-type background, Johannesson et al. created βENaC-Tg mice with 
significantly less mucus plugging and neonatal mortality, resulting in a phenotype more relevant for COPD 
research 178.  
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PART I: INTRODUCTION 
 
CHAPTER 3: THE CHRONIC BRONCHITIS PHENOTYPE IN COPD 
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3.1  DEFINITION 
 
Chronic bronchitis (CB) is a disease entity on its own and is most commonly described as: 147 
“chronic cough and sputum production for at least 3 months per year for two consecutive years”. 
Chronic bronchitis, affecting 3.4 – 22.0 % of the general population, has long been linked to tobacco 
smoking 179. Other risk factors include exposure to environmental tobacco smoke, mineral dust and high 
exposure to noxious gases and fumes. In CB patients without COPD, male gender involves an increased 
risk for developing CB 180.  
The chronic bronchitis phenotype of COPD describes patients with COPD and concomitant CB, with or 
without emphysema. In this population of subjects with both COPD and CB, Dijkstra, et al. did not find an 
association with occupational exposures to gases, fumes or mineral dust; nor with male gender 180. In 
contrast, the COPDGene study did report an association between the presence of chronic cough and 
phlegm and occupational exposure to dust and fumes 181. Furthermore, COPD patients with chronic cough 
and phlegm are more likely to suffer from allergic upper airway symptoms 182. The underlying pathological 
features of chronic bronchitis in COPD have been briefly discussed in Chapter 1. 
3.2  EPIDEMIOLOGY 
 
The prevalence of CB in patients with COPD ranges from 7.4 % up to 74 % 147, 183. This wide dispersion 
results from the use of different CB definitions and differences in the studied populations, such as 
ethnicity, sex and disease severity 147. Ethnicity may play a role in the prevalence of CB in COPD patients, 
with a higher prevalence in Caucasian patients with COPD. Gender differences have been an issue of 
debate. All three possible outcomes (no difference in prevalence between men and women, more 
prevalent in men and more prevalent in women) have been reported repeatedly 180, 181, 184. It must be taken 
into account that cultural issues can influence this outcome, underlining the importance of geographical 
background of studies 179. Furthermore, the highest prevalence of CB was found in a cohort of COPD 
patients with predominantly severe COPD, recruited from university hospitals in France, whereas the 
lowest prevalence was described in a population-based cohort in South-America with subjects with 
predominantly mild-to-moderate COPD 179, 183. This notion emphasises the difficulties in appointing a clear-
cut prevalence percentage to this phenotype in patients with COPD.  
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3.3  CLINICAL MANIFESTATIONS AND IMPACT OF CHRONIC BRONCHITIS IN COPD 
 
Linking clinical features to a COPD phenotype encloses several difficulties. First, the natural course of the 
disease or treatment of the disease may change the phenotype of patients over time. Second, patients can 
have more than one phenotype. And finally, patients can suffer from several diseases 14. However, making 
an abstraction of these difficulties, the CB phenotype in COPD has been associated with several clinical 
outcomes. 
In the COPDGene study, COPD patients with CB exhibited worse respiratory symptoms. These symptoms 
included wheezing and awakening by cough or dyspnea 185. The ECLIPSE study, the PLATINO study and a 
population-based study in China all reported that COPD patients with CB had on average worse airflow 
limitation than those without CB 32, 183, 186. Moreover, in the Copenhagen City Heart Study, an excess decline 
in FEV1 of 22.8 ml/year was detected in men with COPD and CB compared to male COPD patients without 
CB. There was no significant excess decline in FEV1 in women with both COPD and CB. In this cohort, 
chronic mucus hypersecretion was also associated with hospitalization due to COPD 187.  
The presence of chronic productive cough significantly affects health-related quality of life of patients with 
COPD 147. This was illustrated in the COPDGene and ECLIPSE studies by worse St. George’s Respiratory 
Questionnaire disease-specific quality of life scores and in the PLATINO study by more limitations due to 
physical health 32, 183, 185. 
An important clinical outcome in COPD is the exacerbation rate, which has a significant impact on the 
progression of the disease 188. In the GOLD executive summary, an exacerbation is described as “an acute 
event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-
day variations and leads to a change in medication” 2. Reports regarding the association between the 
chronic bronchitis phenotype in COPD and COPD exacerbations render inconsistent data. In the ECLIPSE 
study, COPD patients with CB did not have a significantly increased risk for exacerbations 189. Additionally, 
in the PLATINO study, the number of exacerbations in the previous year did not differ significantly between 
COPD patients with and without CB, although the percentage of subjects with both COPD and CB which 
reported at least one exacerbation, was significantly higher than in COPD subjects without CB 183. In 
contrast, in the COPDGene study, patients with both COPD and CB reported significantly more 
exacerbations than COPD patients without CB. Moreover, COPD patients with CB experienced more severe 
exacerbations in the previous year compared to those without CB 185. Results of other patient-based 
studies support the association between the presence of CB and COPD exacerbations 25, 30. Interestingly, 
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even a productive cough which has not been present for two consecutive years, is associated with 
increased exacerbation risk and increased mortality risk 190. 
Whether or not COPD patients with CB have an increased mortality is under discussion as well. Data from 
the Copenhagen City Heart study show that the presence of chronic mucus hypersecretion entails a 
relative risk (RR) of death from COPD with pulmonary infection of 3.5 (95 % confidence interval (CI) 1.8-
7.1). However this study did not indicate that COPD patients with CB have an increased mortality risk in 
absence of pulmonary infection 191. In a study incorporating two rural Finnish cohorts, Pelkonen et al. 
determined that the presence of CB increased the hazard ratio for all-cause mortality in addition to 
mortality due to respiratory and cardiovascular diseases 192. However, in the NHANES study, only a trend 
towards increased all-cause mortality risk was registered (RR: 1.2 (95 % CI: 0.97-1.4) 193. These conflicting 
data suggest the need for further epidemiological research.  
 
3.4  TREATMENT 
 
Smoking cessation is the most important intervention and can improve cough and mucociliary function. 
Mucus clearance can be improved by chest physiotherapy. Pharmaceuticals improving symptoms of 
chronic bronchitis include short-acting β-adrenergic receptor agonists, methylxanthines, glucocorticoids 
and antioxidants 147, 182. A meta-analysis reviewing the effect of mucoactive drugs, revealed that the use 
of N-acetylcysteine or carbocysteine reduced the number of exacerbations 194. Furthermore, the use of 
low dose macrolides reduced the number of exacerbations as well; however, there is no additional benefit 
for COPD patients with CB 182. 
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3.5  OVERVIEW OF EPIDEMIOLOGICAL STUDIES REGARDING THE CHRONIC BRONCHITIS PHENOTYPE IN COPD 
Study (ref) Subjects Follow-
up 
Prevalence 
in COPD 
Main observations regarding COPD patients with 
CB 
Copenhagen City 
Heart Study 
187, 191 
Population-based 
Longitudinal 
14223 
subjects 
10 years ND  Association with FEV1 decline 
 Association with hospitalization due to 
COPD 
 Association with COPD-related mortality 
with pulmonary infection 
 No association with COPD-related 
mortality without pulmonary infection 
ECLIPSE Study 32, 
189, 195 
Patient-based 
Longitudinal  
 
2138 
patients 
GOLD II-IV 
3 years 34.66 % 
at baseline 
 Lower mean FEV1 at baseline but not a 
more rapid decline 
 Association with lower health-related 
quality of life 
 No association with number of 
exacerbations 
Population-based  
Study in Finland 
192 
Longitudinal 
1711 men 
40-59 years 
40 years 10.37 % 
at baseline 
 Cumulative incidence of COPD + CB = 19% 
 Association with lower FEV0.75  
 Association with all-cause mortality 
 Association with mortality by respiratory 
and cardiovascular diseases 
COPDGene Study 
185 
Patient-based 
Cross-sectional  
 
1061 
patients 
GOLD II-IV 
 27.33 %  Association with respiratory symptoms 
 Association with lower health-related 
quality of life (SGRQ and mMRC) 
 Association with number of exacerbations 
in the previous year (including severe 
exacerbations) 
PLATINO Study 
183 
Population-based 
Cross-sectional 
 
5314 
subjects 
(759 with 
COPD) 
 7.4 %  Association with lower FEV1  
 Association with respiratory symptoms 
 Association with lower quality of life 
(short form-12 physical score, limitation 
due to physical health)  
 No significant association with number of 
exacerbations 
Patient-based 
study in Spain 
196 
Cross-sectional 
331 patients  
GOLD I-IV 
 44.7 %  No association with exacerbations 
 Association with arterial hypertension, 
dyslipidemia, sleep apnea syndrome and 
diabetes 
Population-based 
Study in China 
186 
Cross-sectional 
20245 
subjects  
(1668 with 
COPD) 
 29.98 %  Association with current smoking and 
male gender 
 Association with FEV1/FVC (%) and 
dyspnoea severity (mMRC) 
Patient-based 
study in France 30 
Cross-sectional 
433 patients 
GOLD I-IV 
(> 50% III-IV) 
 
 74.1%  Association with frequent exacerbations, 
(moderate and severe exacerbations) 
 Number of exacerbations in the previous 
year = independent factor linked to CB 
Patient-based 
study in Sweden 
29 
Cross-sectional 
373 patients 
GOLD stage 
III-IV 
 36.97 %  Association with current smoking 
 Association with frequent exacerbations 
 Association with musculoskeletal 
symptoms  
ND: not determined  
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PART I: INTRODUCTION 
 
CHAPTER 4: B CELLS, ECTOPIC LYMPHOID FOLLICLES AND B CELL-ACTIVATING FACTOR IN COPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: 
Polverino F*, Seys LJ*, Bracke KR, Owen CA. B Cells in Chronic Obstructive Pulmonary Disease: Moving to 
Center Stage. Am J Physiol Lung Cell Mol Physiol 2016; 311: L687-L695 197. (* equal contribution) 
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4.1  B CELLS, ECTOPIC LYMPHOID FOLLICLES AND B CELL-ACTIVATING FACTOR: INTRODUCTION 
 
4.1.1 B CELL DEVELOPMENT 
 
B cells develop from common lymphoid progenitor cells through a highly controlled process. The early 
developmental stages take place in specialized niches in bone marrow (Figure 8) 198. The differentiation 
from pro-B cells into immature B cells depends on rearrangement of immunoglobulin heavy-chain genes, 
followed by rearrangement of light-chain loci. Strongly self-reactive immature B cells follow the path of 
either receptor editing or clonal deletion 199. Weakly or non-self-reactive B cells develop into transitional 
B cell stages and further into mature B cells; a process that is predominantly completed in the spleen. At 
this point B cells have become either marginal zone B cells or follicular B cells, depending on the strength 
of the B cell receptor (BCR) signal and the presence of B cell-activating factor (BAFF) 199, 200. Marginal zone 
B cells are located in the marginal sinus of the spleen, have the capacity to self-renew and are primarily 
responsive to blood-borne pathogens 200. Follicular B cells – the fate chosen by the majority of B cells – 
recirculate through the bloodstream. 
When passing through lymph nodes, a chemotactic gradient of CXC-chemokine ligand 13 (CXCL13), which 
binds to collagen IV in the basal lamina of the high endothelial venules and the surrounding reticular 
network, entice B cells to migrate through the endothelial wall into B cell follicles 201-203. This process is 
mediated by the interaction of CXCL13 with its receptor CXCR5, which is expressed by B cells and T follicular 
helper (Tfh) cells. In lymph nodes, an encounter with cognate antigen is mainly facilitated through antigen 
presentation by follicular dendritic cells (FDC), macrophages and dendritic cells (DC) 201. Subsequent to 
antigen-recognition, B cells can differentiate into extrafollicular plasma cells, germinal center cells or early 
memory cells, depending largely on the strength of the BCR antigen recognition. High affinity will induce 
the formation of plasma cells which then produce high affinity immunoglobulins (Ig). In case of low to 
moderate affinity of the BCR for the antigen, B cells will enter the germinal center reaction, which is 
defined by affinity maturation, somatic hypermutation and class switch recombination. Mutated BCRs 
with high affinity are positively selected via interaction with FDC and become either long-lived memory 
cells or plasma cells 200, 204, 205.  
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Figure 8: B cell development. B cell development begins in the bone marrow from common lymphoid progenitor 
cells (1). Via a pro-B cell (2) and pre-B cell stage (3), B cells develop into an immature B cell which possesses a 
mature B cell receptor (BCR) (4). Maturation proceeds via two transitional stage (5) and is completed in the spleen 
(6). At this point a fate decision is made whether B cells become marginal zone B cells or follicular B cells. The 
decision is dependent on the strength of the BCR signal, the presence of BAFF, Notch2 and NF-κB activation. 
Marginal zone B cells reside in the marginal sinus in the spleen, whereas follicular B cells recirculate and enter 
follicles in secondary lymphoid organs in search of their cognate antigen. When antigen is encountered and co-
stimulatory signals are provided by T cells at the B cell/T cell border, B cells can enter the germinal center (GC) to 
increase the affinity of their BCR for the antigen. In the dark zone of the germinal center, B cells undergo somatic 
hypermutation (SHM) and proliferation. Next, B cells enter the light zone of the germinal center. Follicular 
dendritic cells (FDC) present antigen and the affinity of the mutated BCRs for the antigen is tested. Low affinity 
results in apoptosis. B cells with high affinity compete for T follicular helper cell (Tfh cell) help. Finally, B cells can 
either re-enter the dark zone for further affinity maturation, become a memory B cell or plasma cell.  
Adapted from Heesters et al. Nat rev Immunol, 2014; 14: 495-504 200. 
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4.1.2  ECTOPIC LYMPHOID FOLLICLE FORMATION IN LUNG 
 
In health, mucosal immunity in the lung does not seem to incorporate organized lymphoid tissue. The 
presence of organized bronchus-associated lymphoid tissue (BALT) in healthy adults is debatable 206, 207. 
The formation of BALT requires a specialized epithelium above the organized lymphoid follicles and this 
lymphoepithelium has only rarely been observed 208. In contrast, ectopic lymphoid follicles which show 
varying degrees of organization, have been described in healthy controls 110, 209, 210. This organization 
includes the presence of B- and T cell areas, follicular dendritic cells, high endothelial venules, germinal 
center formation and efferent lymphatic vessels 208, 211. Fully organized, these lymphoid follicles are often 
called inducible BALT (iBALT) or tertiary lymphoid organs (TLO), indicating their similarity with secondary 
lymphoid organs such as lymph nodes 206, 211.  
The process responsible for the formation of ectopic lymphoid follicles is called lymphoid neogenesis. It is 
initiated by repeated or chronic inflammation in non-lymphoid organs 206, 212. Much like lymph node 
organogenesis, the basic ingredients of lymphoid neogenesis are stromal cells, haematopoietic cells, 
homeostatic chemokines and their receptors, adhesion molecules and cytokines (Figure 9) 206, 213. 
 
 
 
 
Figure 9: Lymphoid neogenesis. Lymphoid follicle formation begins with the expression of lymphotoxin α1β2 (LT 
α1β2) by inducing cells, such as B cells, and the expression of lymphotoxin β receptor (LTβR) by stromal cells, 
such as fibroblasts. Interaction of LTα1β2 with LTβR leads to the release of homeostatic chemokines which 
attract dendritic cells, T cells and B cells.  
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Briefly, in lymph node organogenesis, lymphoid tissue inducer cells express lymphotoxin α1β2 (LTα1β2) 
which interacts with the LTβ-receptor (LTβR) on lymphoid tissue organizer cells. This induces the 
expression of adhesion molecules and homeostatic chemokines, resulting in accumulation and 
organization of lymphocytes and dendritic cells into lymph nodes. In this process, CC-chemokine ligand 
(CCL)19, CCL21, CXC-chemokine ligand (CXCL)12 and CXCL13 attract DC, T and B cells via the receptors 
CCR7 and CXCR5 213-215. The cells and molecules involved in this process are not necessarily identical for 
lymphoid neogenesis and several murine models of COPD have been used to investigate both the 
similarities and the discrepancies between both (see 4.2.3 Lymphoid neogenesis in murine models of 
COPD) 206, 216.  
 
4.1.3  B CELL-ACTIVATING FACTOR  
 
The tightly controlled process of B cell development does not only rely on BCR editing but requires the 
presence of several survival factors as well. One of these factors is B cell-activating factor from the tumor 
necrosis factor (TNF) family, also known as BAFF, which was discovered in 1999. BAFF is a type II 
transmembrane homotrimer protein and signals through three receptors: BAFF-receptor (BAFFR), 
transmembrane activator and cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA). 
BAFF itself is produced by stromal cells, innate immune cells, activated T cells and B cells, whereas the 
receptors are predominantly located on lymphocyte subsets (Figure 10). A proliferation-inducing ligand 
(APRIL), a family member of BAFF, also interacts with TACI and BCMA 217-219. B cell homeostasis requires 
processed soluble BAFF through proteolytic cleavage; however, membrane-bound BAFF is active as well 
220. 
BAFF functions primarily as a necessary survival and maturation factor for B cells through interaction with 
BAFFR 218, 221. Both BAFF-/- and BAFFR-/- mice exhibit a limited number of peripheral B cells past transitional 
stage 1 217, 221, 222. Pro- and pre-B cells in the bone marrow do not seem to rely on BAFF signaling. BAFF 
interaction with BAFFR induces activation of the non-canonical NF-ƙB pathway via de-repression of NF-ƙB 
inducing kinase (NIK), resulting in upregulation of anti-apoptotic proteins. In contrast, BAFF signaling 
through TACI activates the classical NF-ƙB pathway and negatively regulates the B cell pool 221, 223. 
Furthermore, TACI is necessary for T cell-independent responses and class-switch recombination 224. BAFF 
signaling through BCMA activates classical NF-ƙB as well and results in promotion of long-lived plasma cell 
maintenance in bone marrow 218, 221.  
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Systemic BAFF production is thought to be relatively constant and Gorelik et al. demonstrated that radio-
resistant non-hematopoietic cells are capable of sustaining B cell homeostasis 225, 226. For instance, in 
secondary lymphoid organs, fibroblastic reticular cells are responsible for the production of BAFF that is 
necessary for B cell homeostasis and organization of follicles 227. However, within germinal centers, T 
follicular helper (Tfh) cell-derived BAFF is indispensable for efficient selection of high affinity B cell clones 
228. BAFF derived from other immune cells is also thought to be most important during inflammation 229. 
Alongside the non-redundant role in B cell homeostasis, other immune cells are affected by BAFF as well. 
BAFF promotes T helper type 1 (Th1)-mediated and inhibits Th2-mediated responses and promotes the 
development of Th17 cells 229, 230. In addition, BAFF induces survival of monocytes and differentiation of 
monocytes into macrophage-like cells 231. Furthermore, DC activation and maturation is stimulated by 
BAFF 232.  
Soon after its discovery, BAFF has been implicated in several auto-immune diseases. Belimumab, a 
monoclonal antibody against BAFF, is already approved for use in patients with systemic lupus 
erythematosus (SLE). Aside from SLE, rheumotoid arthritis, multiple sclerosis and primary Sjögren 
syndrome have repeatedly been associated with excessive levels of BAFF as well 233. In addition, abnormal 
BAFF levels have also been detected in other diseases such as graft-versus-host disease, common variable 
immunodeficiency, several infections, allergy and hematological and lymphoid cancers 224. 
 
 
 
 
 
 
 
 
 
Figure 10: B cell-activating factor (BAFF) and its receptors. BAFF is produced by innate immune cells, stromal 
cells, activated T cells and B cells. BAFF interacts with the highest affinity to BAFF-receptor (BAFFR) which is 
located on B cells and T cell subsets. BAFF also interacts with Transmembrane Activator and Cyclophilin ligand 
Interactor (TACI). BAFF binds with the least affinity to B cell maturation antigen (BCMA) situated on plasma cells. 
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4.2  B CELLS, ECTOPIC LYMPHOID FOLLICLES AND B CELL-ACTIVATING FACTOR IN COPD 
 
4.2.1 ISOLATED B CELLS IN THE LUNGS IN COPD 
 
Under homeostatic conditions, a limited number of B cells forms an integrated part of the mucosal 
immunity in lungs. Memory B cells, locally generated during infection, remain in the lung in peri-bronchial 
infiltrates and can rapidly differentiate into plasma cells when activated 234-236. Upon reinfection, these 
tissue-resident memory B cells produce not only more immunoglobulins but also cross-reactive 
immunoglobulins important in response to viral escape 237, 238. Brandsma and colleagues observed a 
significant increase in memory B cells in lungs of patients with COPD compared to non-COPD controls, but 
no significant difference was noticed in total CD20+ B cells between both groups 239. In contrast, Bosken 
et al. and Hogg et al. did detect a significant raise in total B cell numbers in peri-bronchiolar regions and 
additionally, a correlation between the accumulated volume of B cells and COPD severity 44, 110. The 
number of B cells was also significantly expanded in central airways of patients with COPD and this 
correlated with disease severity as well 240. Alongside CD20+ B cells, plasma cells are located in 
subepithelial and periglandular regions of the airways and produce predominantly polymeric IgA, a crucial 
component of the mucociliary clearance system of the airways 207, 241. Smokers with chronic bronchitis and 
airflow obstruction tend to harbor increased numbers of plasma cells in these peri-bronchial regions. 
Moreover, the majority of the peri-glandular plasma cells produce IL-4 and/or IL-5, suggesting a role in 
mucus hypersecretion 241.  
4.2.2  ECTOPIC LYMPHOID FOLLICLES IN COPD 
 
In COPD, B cells are the dominant cell type in ectopic lymphoid follicles and these follicles are located in 
peri-bronchiolar and peri-vascular regions and in lung parenchyma 44, 210, 242, 243. The landmark paper of 
Hogg et al. demonstrated an association between disease severity and the percentage of small airways 
containing lymphoid follicles 44. Several other studies have since corroborated an increase in number and 
even size of lymphoid follicles in patients with severe COPD compared to never-smokers and smokers 
without airflow limitation 219, 244, 245. Lymphoid follicles in patients with COPD seem to possess some 
characteristic features. In order to organize lymphoid follicles, lymphocytes need to be recruited to the 
lung. In patients with COPD, there is an increased expression of CXCL13 which attracts B cells 246. In 
addition, lymphocytes within lymphoid follicles express CXCR3 and the percentage of CXCR3+ cells 
correlates inversely with the degree of airflow limitation. Furthermore, an increase in expression of CXCL9, 
CXCL10 and CXCL11 – ligands of CXCR3 – was measured in macrophages, DC and airway epithelium in the 
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vicinity of the lymphoid follicles, suggesting a role for CXCR3 in lymphocyte recruitment and/or retention 
in lymphoid follicles in patients with COPD 244. Recently, Roos et al. measured an elevated level of IL-17A 
in peripheral lung tissue of patients with COPD compared to non-COPD controls. They found that IL-17A 
contributes to the formation of lymphoid follicles in end-stage COPD by inducing CXCL12 expression 108.  
Few differences are reported in cellular composition of lymphoid follicles in patients with and without 
COPD. Plumb et al. observed an increased number of regulatory T cells (Tregs) in lymphoid follicles in 
patients with COPD compared to control subjects. No differences were detected in Treg count in 
subepithelial areas and unorganized clusters of lymphocytes, indicating that this augmented Treg count is 
specific for lymphoid follicles. A possible function of these Tregs in the lymphoid follicles in COPD is 
mediation of B cell-activity; however, their exact role must yet be elucidated 245, 247. Lymphoid follicles of 
patients with COPD also harbor an increased number of CD57+ cells. The function of these cells within the 
follicles needs to be unraveled as well 210. Although cellular composition does not substantially alter, two 
types of lymphoid follicles are described based on the density of apoptotic B cells and BAFF-producing B 
cells. Compared to mild to moderate COPD, lymphoid follicles in severe COPD harbor less apoptotic B cells 
and more BAFF-producing B cells 219. 
Although crucial to determine whether these lymphoid follicles are beneficial or harmful in the 
pathogenesis of COPD, the inducing antigens are still unknown. However, some advances have been made 
that can help to narrow down the possible suspects. First, using 3D-reconstruction, Mori et al. found that 
the vast majority of lymphoid follicles are in contact with alveolar epithelium and that this epithelium 
changes towards a columnar type in severe COPD. At the interface between lymphoid follicles and changed 
alveolar epithelium, they observed an accumulation CD207+ DC, which are responsible for antigen-
capturing in the alveoli 243. Furthermore, lymphoid follicles are in contact with a vast network of lymphatic 
vessels 243. In patients with severe COPD, an increased number of lymphatic vessels are detected in the 
alveolar parenchyma when compared to never-smokers 248. Van der Strate et al. described that in patients 
with emphysema, B cells in lymphoid follicles engage in an oligoclonal, antigen-specific proliferation and 
the authors did not detect viral nor bacterial nucleic acids 242. This oligoclonality was recently corroborated 
by Baraldo et al. who reported this feature in COPD patients with and without α1-antitrypsin deficiency 
249. Finally, a network analysis of lung transcriptomics recently showed a distinct B cell signature and 
lymphoid follicle formation in COPD patients with emphysema but not in those with obstructive 
bronchiolitis 250.  
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4.2.3  LYMPHOID NEOGENESIS IN MURINE MODELS OF COPD 
 
To unravel the inducing factors and cellular and molecular requirements of lymphoid follicle formation in 
COPD, murine models of the disease are of great use. Hundreds of genetically manipulated strains are 
available in which a single gene is either over-expressed or knocked-out, making it possible to study the 
specific role of these genes and their proteins 251, 252.  
Exposing wild-type mice chronically (i.e. 3 to 6 months) to CS leads to lymphoid follicle formation in the 
lungs. The number and size of the follicles increase as the duration of the exposure increases 242. As in 
patients with COPD, these follicles are situated in peri-bronchial, peri-vascular and parenchymal areas. 
Using this model, Demoor et al. showed that LTα – although essential in the formation of secondary 
lymphoid organs - is not necessary for the development of lymphoid follicles in the lung. However, 
deficiency in LTα resulted in very low IgA levels in bronchoalveolar lavage (BAL) fluid, suggesting a lack of 
germinal center formation and isotype-switching in absence of LTα. In addition, this paper indicated that 
stimulation of LTβR in lung fibroblasts resulted in enhanced mRNA expression of CXCL13 and CCL19, 
supporting the presumption that fibroblasts take on the role of organizer cells in the formation of ectopic 
follicles 253-255.  
Other studies showed that deletion of CCR5 or CCR6 attenuated the formation of CS-induced follicles, 
whereas CS-exposure of CCR7-/- mice unexpectedly demonstrated that CCR7 was not required for this 
process, again in contrast to lymph node organogenesis 256-258. On the other hand, neutralization of CXCL13 
by administering a monoclonal anti-CXCL13 antibody to CS-exposed wild-type mice, almost completely 
abolished formation of organized follicles without substantially affecting the presence of unorganized 
lymphoid aggregates. As a result, airway inflammation and emphysematous destruction of lung 
parenchyma were significantly attenuated 246. Finally, a recent study using the CS-induced COPD model, 
demonstrated a crucial role of interleukin (IL)-17 in CS-induced lymphoid follicle formation. Deletion of IL-
17 led to unorganized lymphoid clusters of B cells as opposed to highly organized lymphoid follicles in wild-
type mice. This was accompanied by a reduction in the number of CXCL12+ cells, but did not have an 
influence on CXCL13 expression 108.  
Patients with COPD are more vulnerable to respiratory infections and are often chronically colonized by 
pathogens, hence murine models using pathogens or pathogen-derived products are highly relevant to 
study lymphoid follicle formation in COPD 15, 206. Using both intra-nasal instillation with lipopolysaccharide 
(LPS) and influenza infection, Rangel-Moreno et al. showed that lymphoid follicles can be induced in lungs 
 52  
in absence of ILC3-type lymphoid tissue inducer cells. Furthermore, they demonstrated a crucial role for 
IL-17 in the initiation of lymphoid follicle formation 259. Fleige et al. also concluded that IL-17 is important 
in the development of lymphoid follicles by stimulating stromal cells to produce CXCL12. Additionally, they 
showed that the induction of lymphoid follicles is pathogen-dependent 260. 
Recently, in a murine model using LPS/elastase treatment, it was illustrated that chronic inflammation 
results in an altered microbiota in the lungs. Moreover, this paper showed that microbiota enhance 
inflammation and induce the production of IL-17A by T cells. Neutralizing IL-17A reduced lung compliance, 
airway inflammation and lymphoid follicle formation 109. Finally, although lymphocytes constitute the 
majority of lymphoid follicles, two different infection models have demonstrated the indispensable role of 
DC in maintenance of lymphoid follicles 261, 262.  
 
4.2.4  B CELL-ACTIVATING FACTOR IN COPD 
 
In 2010, Polverino and colleagues reported that BAFF expression was increased in alveolar macrophages 
and lymphoid follicles of patients with COPD compared to non-COPD controls. Moreover, the number of 
BAFF-positive macrophages correlated inversely to airflow limitation in patients with COPD 263. Recently, 
this group added that the number of BAFF-positive B cells in blood and in BAL was also significantly higher 
in patients with COPD compared to control subjects. Furthermore, they observed more lymphoid follicles 
containing a high percentage BAFF-positive B cells in patients with severe COPD compared to patients with 
mild/moderate COPD 219. BAFF mRNA expression is significantly higher in bronchial epithelium of patients 
with COPD versus non-COPD subjects as well. In addition, co-culture of healthy B cells with airway 
epithelium from patients with COPD induced upregulation of TACI in B cells. Conversely, airway epithelium 
from healthy controls did not cause this effect in B 
cells 264. Evidence of a role for BAFF in COPD was also 
illustrated in the recent network analysis of lung 
transcriptomics of patients with COPD, which revealed 
that BAFF protein was specifically upregulated in lung 
tissue of patients with emphysema but not in patients 
with obstructive bronchiolitis 250.  
Figure 11: Confocal microscopy image of a BAFF-staining 
of a lymphoid follicle (COPD patient GOLD stage III).     
Blue: DAPI. Red: BAFF. 
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4.3  FUNCTION OF B CELLS, ECTOPIC LYMPHOID FOLLICLES AND B CELL-ACTIVATING FACTOR IN COPD 
 
The respiratory system is in constant contact with the outside world and utilizes mucociliary clearance as 
a first line defense 40. An important component in this system is secretory IgA (sIgA), produced by local 
plasma cells in the subepithelial areas of airways 265. Moyron-Quiroz et al. demonstrated that ectopic 
lymphoid follicles are capable of mounting a primary immune response against influenza in mice who lack 
secondary lymphoid organs (SLO), thus driving local Ig production 266. Moreover, lymphoid follicles in the 
lung were shown to be a niche for maintenance of memory cells. This was demonstrated by an effective 
secondary immune response to influenza in absence of SLOs 267. In lungs of patients with COPD, there is 
an increase in plasma cell number and along with disease severity, lymphoid follicles develop 44, 241. As 
expected, an elevated IgA synthesis is detected in lungs of COPD patients compared to non-COPD subjects 
264. Interestingly, this does not translate in an increased mucosal IgA immunity due to downregulation of 
the receptor responsible for translocation of polymeric immunoglobulins to the airway lumen (pIgR) 268. 
Downregulation of pIgR and decrease of sIgA in BAL both correlate with disease severity 268, 269. 
The role of lymphoid follicles and B cells in COPD is not yet unraveled. It is possible that lymphoid follicles 
arise from pulmonary infections and that they are essential to generate high affinity antibodies against 
pathogens. COPD patients with CB are more vulnerable for chronic pulmonary infections. As such, 
lymphoid follicles might develop as a consequence of CB. On the other hand they might produce antibodies 
against self-antigens or CS-derived neo-antigens as well. The oligoclonal nature of B cell proliferation in 
lymphoid follicles in COPD has repeatedly been observed 242, 249. Moreover, several reports have described 
the presence of auto-antibodies in patients with COPD 270-272. Interestingly, in a murine model of COPD, 
the presence of microbiota significantly increased the amount of auto-antibodies 109. These studies suggest 
that lymphoid follicles might well be important in the persistence and progression of inflammation in 
COPD. In this light it is proposed that the enhanced BAFF production by B cells creates a self-perpetuating 
loop ensuring survival of B cells and expansion of lymphoid follicles 219.  
Aside from their essential role in humoral immunity, B cells are important regulators of T cell mediated 
immunity (Figure 12) 273, 274. They do so by presenting antigen to T cells and are in this capacity especially 
useful when the amount of antigen is limited 204, 274. Furthermore, upon stimulation by TLR-ligands or 
interaction with T cells, B cells produce cytokines that modulate the immune response as well 275. 
Alongside modulation of the T cell response, polarization of macrophages is influenced by cytokine-
producing B cells 276, 277. In vitro stimulation with CS extract resulted in release of IL-10 by B cells and this 
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IL-10 stimulated macrophages to produce MMP12 276. Reports of the importance of B cell-derived 
cytokines in the pathogenesis of COPD are scarce, therefore requiring further investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: B cell function. Aside from antibody production, B cells produce a wide range of cytokines which 
regulate the immune response. Regulation of immune response includes dendritic cell and T cell regulation 
and lymphoid follicle formation. Furthermore, B cells are important professional antigen-presenting cells. 
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5.1  TRANSLATIONAL RESEARCH IN COPD 
 
Translating research from bench-to-bedside to expedite the search for new therapies is the ultimate goal 
of translational research (Figure 13). Using genetically manipulated mouse models, it is possible to 
research the importance of a single gene or molecule in vivo. In wild-type mice, administration of 
antibodies against a specific molecule can reveal specific functions of that molecule in a disease model. In 
our translational laboratory, a model has been optimized in which mice are exposed to CS to provoke the 
development of CS-induced hallmarks of COPD 278. Results obtained in this murine model are confirmed 
by ex vivo studies on human lung samples.  
Alongside the traditional from bench-to-bedside translation, a third research approach is used to study 
COPD: population-based research. Here, we use data from a large, prospective cohort study, the 
Rotterdam Study, to investigate the contribution of symptoms or co-morbidities to clinically important 
outcomes in subjects with COPD. Furthermore, the impact of having COPD on the vulnerability to other 
diseases is also studied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Translational research: the intersection of laboratory research with clinical research (from bench-to-
bedside) and the intersection with population-based research.  
  
57  
5.2  MURINE MODEL OF COPD 
 
5.2.1  PROTOCOL 
 
In order to elicit the hallmarks of COPD, mice are exposed to CS 4 times a day, with 30 minute smoke-free 
intervals and for 5 days a week. To administer the CS, mice are placed in a plexiglass chamber which is 
connected to a smoking apparatus and are subjected to the mainstream smoke of 5 simultaneously lit 
cigarettes. The plexiglass chamber is supplied with pressured air to obtain a smoke/air ratio of 1/6.  
In this dissertation, exposure periods of 4, 8 and 24 weeks were used. Chronic CS exposure of 24 weeks 
allows investigation of lymphoid follicles and structural changes such as emphysema and airway wall 
remodeling 278, 279. In experiments with shorter CS exposure terms, the main goal is to study inflammation.  
Experiment endpoints are performed 24 hours after the last CS exposure. Mice are weighed and sacrificed 
with an overdose of pentobarbital. Next, bronchoalveolar lavage (BAL) is performed and blood and lung 
tissue are collected. All in vivo manipulations were approved by the local Ethics Committee for animal 
experimentation of the Faculty of Medicine and Health Sciences. 
 
5.2.2 ADVANTAGES AND LIMITATIONS OF THE CS-INDUCED MURINE MODEL OF COPD 
 
A major advantage of CS-exposed mice as a model for COPD, is the use of the same etiologic agent as in 
the human disease. This adds to the relevance of this model compared to animal models which elicit COPD-
like symptoms by instillation of 1 agent, for instance elastase and lipopolysaccharide. Furthermore, the 
use of mice has several advantages compared to other animals, in particular the relative low cost, the 
existence of hundreds of genetically modified strains and the availability of a substantial number of 
antibodies and gene sequences. As in patients with COPD, CS induces a neutrophilic inflammation in the 
airways of mice. Macrophages and CD8+ T cells are also increased in BAL and lung tissue of CS-exposed 
mice. As in humans, chronic CS exposure induces emphysematous lesions in lung parenchyma and 
remodeling of small airways in mice.  
The most important limitations are the differences in anatomy (less bronchial generations, lack of 
respiratory bronchioli, submucosal glands are only present near the proximal tracheal rings and few to no 
goblet cells are present in the lower airways) and the lack of chronic bronchitis symptoms in response to 
CS. In addition, even after chronic CS exposure (6-8 months or longer), mice do not develop a disease 
resembling severe or very severe COPD. Finally, CS-exposed mice do not experience acute exacerbations 
which are a very important aspect of the human disease. 
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5.2.3 INFLAMMATION 
 
By performing BAL, intra-luminal and alveolar 
inflammatory cells can be isolated.  BAL cells are 
processed, resulting in cytospins and cells labelled for 
flow cytometric analyses. Cytospins are cytocentrifuged 
preparations which are stained with May-Grünwald-
Giemsa staining (Figure 14). At least 400 cells are counted 
to obtain a differential cell count.  
 
 
 
 
 
 
 
 
By flow cytometric analyses of BAL cells, the percentage of macrophages, neutrophils, dendritic cells, B-
lymphocytes and CD4+ and CD8+ T-lymphocytes is assessed. BAL supernatans is used for protein 
measurements by ELISA or Cytometric Bead Array. 
Pulmonary inflammation is assessed by multiple methods. First, a single cell suspension is made of one 
lobe of the right lung. This single cell suspension is labelled to determine inflammatory cell percentages 
by flow cytometry (Figure 15). Second, a lobe of the right lung is suspended in RNA later and stored at -
80°C to be processed for quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Third, the left lung 
is embedded in paraffin and subsequently fixed in formalin. Sections of the left lung are used for 
immunohistochemical stainings of several proteins. Additionally, mediastinal lymph nodes are processed 
to obtain single cell suspensions and are subsequently labeled for flow cytometric analyses.  
 
 
 
 
 
 
Figure 14: Cytospins.  
A) Cytospin of cells isolated via bronchoalveolar lavage (BAL) 
of an air-exposed mouse. B) Cytospin of BAL cells of a CS-
exposed mouse. 
1 = macrophage, 2 = neutrophil, 3 = lymphocyte 
 
 
1 
2 
3 
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Figure 15: Gating strategy for the characterisation of inflammatory cells (lung tissue). A) Selection of single 
cells. B) FVD = Fixable Viability Dye; cells negative for this dye are alive. C) Selection of CD45+ cells (leukocytes). 
D) Eosinophils are characterised as SiglecF-positive and CD11c-negative. The rest fraction is further analysed. E) 
Dendritic cells are defined as CD45+, SiglecF-, MHCII+ and CD11c+. The MHCII- and CD11c- fraction is further 
analysed. F) Selection of the CD11b-positive cells. G) Neutrophils are characterized as CD45+, SiglecF-, MHCII-
CD11c-, CD11b+, Ly6c ± and Ly6G+. Monocytes are CD45+, SiglecF-, MHCII-, CD11c-, CD11b+, Ly6G- and Ly6C+. 
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5.2.3  LYMPHOID FOLLICLE FORMATION 
 
 
Localization and quantification of lymphoid 
follicles is based on immunohistochemical 
staining of CD3 (T cell marker)/B220 (B cell 
marker) on sections of the formalin-fixed, 
paraffin-embedded left lung (Figure 16) 253. 
All lymphoid infiltrates in the proximity of 
airways and in the parenchyma are counted. 
Dense accumulations of at least 50 cells are 
defined as lymphoid follicles, whereas 
accumulations of less than 50 cells are 
defined as lymphoid aggregates. The 
number of infiltrates in the proximity of 
airways is normalized for the number of 
airways per lung section. Counts of infiltrates in the parenchyma are normalized for the area of lung 
parenchyma. All measurements are performed in a blinded fashion. 
 
5.2.4  GOBLET CELL METAPLASIA 
 
 
Goblet cell metaplasia is assessed by staining sections with Periodic acid-Shiff (PAS) (Figure 17). The 
number of goblet cells are counted with Axiovision software (Zeiss) and are expressed as the number of 
cells per millimeter basal membrane. Both major mucins in the airways, Muc5ac and Muc5b, have also 
been stained immunohistochemically on airways and trachea respectively (Figure 17). The gene expression 
of Muc5ac and Muc5b is quantified by qRT-PCR. All measurements are performed in a blinded fashion. 
 
Figure 16: Immunohistochemical staining of lymphoid 
follicles. CD3 (brown): T cell marker, B220 (blue): B cell 
marker. 
Figure 17: Goblet cell metaplasia and mucin production. A) Periodic acid-Schiff staining of a murine bronchus. B) 
Muc5AC immunohistochemical staining of a murine bronchus. C) Muc5B immunohistochemical staining of a 
murine trachea (positive staining in submucosal glands). 
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5.2.5  EMPHYSEMA 
 
Airspace enlargement is determined on haematoxylin and eosin stained sections of the left lung by 
measuring the mean linear intercept (Lm) (Figure 18) 280. Using a Zeiss microscope, photomicrographs of 
the lung parenchyma are captured. Only images without artefacts, compression, blood vessels and airways 
are assessed. To measure the Lm, a 100 x 100 µm grid is placed upon the photomicrographs of the 
parenchyma. Each intercept of alveolar wall with a line of the grid is counted and the total length of each 
line of the grid is divided by the total number of intercepts on that line. This results in an average distance 
between two alveolar walls, i.e. the Lm. 
 
 
 
In addition, using the same photomicrographs, destruction of alveolar tissue is measured by the 
Destructive Index (DI) (Figure 19) 281. For measurement of the DI a grid with 42 points is placed over the 
lung sections. For each point of the grid it is determined whether the structure underneath the point is 
normal (N) or destroyed (D). The DI is calculated as follows: DI = D/(D+N) x 100. All measurements are 
performed in a blinded fashion. 
 
 
 
 
 
 
 
 
 
 
Figure 18: Mean linear intercept (Lm). 
Using Image J software, a grid is placed 
over photomicrographs. Each 
intersection of an alveolar wall with a 
grid line is counted. The length of the 
grid lines divided by the number of 
intersections is the mean distance 
between alveolar walls. 
Figure 19: Destructive Index (DI). 
Using Image J software, a grid of 42 
points is placed over the 
photomicrographs. N = normal, D = 
destroyed. DI = D/(D+N) x 100 
 
 
D 
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5.2.6  AIRWAY WALL REMODELING 
 
Airway wall remodeling is assessed by 
measuring the deposition of collagen and 
fibronectin. Collagen is stained with Sirius Red, 
whereas fibronectin is stained 
immunohistochemically with anti-fibronectin 
antibody 282. By using the Axiovision software, 
the area between the basal membrane and the 
adventitial perimeter that stains positive for 
collagen or fibronectin is calculated and 
normalized for the length of the basal 
membrane (Figure 20). All airways with a basal 
membrane length less than 2000 µm and cut in 
reasonable cross sections are included in the 
analyses. All measurements are performed in a 
blinded fashion. 
5.2.7  LUNG FUNCTION MEASUREMENTS 
 
Lung function measurements are assessed using the Flexivent System (SCIREQ, Montreal, Canada). For 
baseline lung function measurements the ‘snapshot’ perturbation, the forced oxcillation (Quick Prime 3) 
perturbation and pressure-volume loops are performed, so that static and dynamic compliance, 
resistance, elastance,  total lung capacity and hysteresis are determined. Lung function measurements are 
performed on anaesthetized and tracheostomised mice, which received a neuromuscular blocker 
(pancuronium bromide (1mg/kg).  
 
 
 
 
 
 
 
 
 
Figure 20: Airway wall remodeling. 
Quantification of collagen deposition (Sirius Red 
stain). The area positive for collagen is indicated 
in green in the small insert.  
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5.3 HUMAN STUDIES 
 
 
Ex vivo studies are performed on human lung tissue from patients undergoing lung resection surgery at 
the Ghent University Hospital. Diagnosis of COPD and severity assessment is made based on pre-operative 
spirometry according to the GOLD classification 2. All participants provide a written informed consent 
according to protocols approved by the medical ethical committee of the Ghent University Hospital. 
Exclusion criteria for participation are treatment with neo-adjuvant chemotherapy, tuberculosis, recent 
COPD exacerbations and recent pulmonary infections. All participants are interviewed on their smoking 
habits and medication use. Ex-smokers are defined as having quit for at least one year.  
Lung tissue is collected by a pathologist at maximum distance from the pulmonary lesions and without 
signs of retro-obstructive pneumonia or tumor invasion. Small pieces of the resection samples are 
submersed in RNA-later and stored at -80°C until RNA extraction and subsequent qRT-PCR analyses. In 
addition, tissue blocks from the resection samples are snap-frozen in liquid nitrogen and stored at -80°C. 
This tissue is used for protein detection by ELISA. A final set of tissue blocks are fixed in paraformaldehyde 
and embedded in paraffin. Sections of these blocks are used for immunohistochemical staining (Figure 
21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Protocol for the collection 
of human lung tissue. Lung tissue 
from resection surgery is collected by 
a pathologist. This tissue is used for 
immunohistochemical analyses of 
proteins, qRT-PCR analyses of mRNA 
expression and protein 
measurement via ELISA. Adapted 
from F. Verhamme. 
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5.4  THE ROTTERDAM STUDY 
 
 
In order to investigate the impact of chronic bronchitis on clinically important outcomes in subjects with 
COPD, we analyzed data from the Rotterdam Study (Figure 22). This is a large, prospective, population-
based study, situated in the city of Rotterdam, the Netherlands. The study started in 1990 when all 
residents from the district of Ommoord, aged 55 or older, were invited to participate (first cohort). In 2000 
and in 2006, residents who had become 55 and 45 years respectively, were invited to join the study 
(second and third cohort). Follow-up examinations occur approximately every 4 to 5 years. Data is 
collected from home interviews and a set of physical examinations performed is a designated research 
building. In addition, medical and pharmacy records are linked to the study 283.  
  
Figure 22: The Rotterdam Study. The green blocks represent examination cycles of the first cohort which enrolled 
in 1989-1993. The second cohort was asked to participate in 2000 and the examination cycles of this cohort is 
represented by yellow blocks. A third cohort was enrolled in 2006 and they have been invited for an examination 
twice, represented by the two purple blocks. Adapted from Hofman et al. Eur J Epidemiol. 2015;30(8)661-708 278. 
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RESEARCH OBJECTIVES 
Worldwide, COPD affects more than 200 million people, imposing a huge burden of disease. Noxious 
particles and gases entering the airways cause the characteristic airway inflammation, mucus 
hypersecretion, airway wall remodelling and emphysema in susceptible individuals. The pathogenesis of 
COPD is multifaceted and not fully understood. Bearing in mind that there is currently no cure for COPD, 
an improved comprehension of the pathogenesis could aid in the search for new therapeutic targets. In 
this research we have applied a translational approach combining functional studies in murine models 
with ex vivo studies on human lung resection tissue and population-based research embedded in the 
Rotterdam Study.  
 
We aimed to investigate the role of mucociliary dysfunction in COPD in two separate studies. Mucociliary 
impairment arises primarily from dehydration of the airway surface, originating either from excess 
production of mucins and non-mucin proteins, dysfunction of ion channels or both.  
First, the role of airway surface dehydration in the pathogenesis of COPD has not been determined in 
vivo. Therefore, we studied the effect of airway surface dehydration on the hallmarks of COPD in βENaC-
Tg mice, a mouse model for airway surface dehydration, and exposed these mice and their wild-type 
littermates to air or CS. 
Research question 1:  Does airway surface dehydration aggravate cigarette smoke-induced 
inflammation and structural changes in a mouse model of COPD?  
Next, airway surface dehydration is associated with chronic bronchitis and increases the risk for airway 
infections. In addition, airway infections are a major cause of COPD exacerbations. Therefore, we 
wondered whether subjects with COPD and concomitant chronic bronchitis exhibit an increased risk for 
exacerbations and mortality, two clinically relevant outcomes. Since literature renders inconsistent reports 
on this subject, we aimed to investigate the exacerbation and mortality risk in COPD subjects with and 
without chronic bronchitis in a large prospective population-based cohort, the Rotterdam Study. 
Research question 2: Does the presence of chronic bronchitis affect the exacerbation and mortality 
risk in subjects with COPD? 
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We also used a translational approach to continue our research on the role of B cell-rich lymphoid follicles 
in COPD, by investigating the role of B cell activating factor (BAFF) in the pathogenesis of COPD. In COPD, 
an increased number of B cells and airways with lymphoid follicles are associated with disease severity. In 
addition, the level of BAFF in these lymphoid follicles is associated with disease severity as well. We 
hypothesised that the presence of BAFF and B cells contributes to the pathological hallmarks of COPD. For 
this research, we investigated the functional role of BAFF in a mouse model of CS-induced pathology. 
Furthermore, we aimed to investigate the expression of BAFF in patients with COPD compared to control 
patients and the localisation of BAFF within lymphoid follicles in patients with COPD. 
Research question 3: Does antagonizing B cell activating factor attenuate the hallmarks of cigarette 
smoke-induced pulmonary disease in a murine model of COPD?  
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CHAPTER 7: AIRWAY SURFACE DEHYDRATION AGGRAVATES CIGARETTE SMOKE-INDUCED   
                       HALLMARKS OF COPD IN MICE 
 
 
 
 
 
 
 
 
 
 
 
 
Imbalance of ion secretion and absorption contributes to airway surface dehydration which leads to 
mucociliary dysfunction. Research shows that airway surface dehydration is present in smokers with and 
without COPD. However, the role of airway surface dehydration in the pathogenesis of COPD has not been 
studied in vivo.  
 
 
 
 
 
 
Seys LJ, Verhamme FM, Dupont LL, Desauter E, Duerr J, Seyhan Agircan A, Conickx G, Joos GF, Brusselle 
GG, Mall MA, Bracke KR. Airway Surface Dehydration Aggravates Cigarette Smoke-Induced Hallmarks of 
COPD in Mice. PloS one 2015; 10: e0129897 284. 
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ABSTRACT 
Introduction: Airway surface dehydration, caused by an imbalance between secretion and absorption of 
ions and fluid across the epithelium and/or increased epithelial mucin secretion, impairs mucociliary 
clearance. Recent evidence suggests that this mechanism may be implicated in chronic obstructive 
pulmonary disease (COPD). However, the role of airway surface dehydration in the pathogenesis of 
cigarette smoke (CS)-induced COPD remains unknown. 
Objective: We aimed to investigate in vivo the effect of airway surface dehydration on several CS-induced 
hallmarks of COPD in mice with airway-specific overexpression of the β-subunit of the epithelial Na+ 
channel (βENaC).  
Methods: βENaC-Tg mice and wild-type (WT) littermates were exposed to air or CS for 4 or 8 weeks. 
Pathological hallmarks of COPD, including goblet cell metaplasia, mucin expression, pulmonary 
inflammation, lymphoid follicles, emphysema and airway wall remodelling were determined and lung 
function was measured. 
Results: Airway surface dehydration in βENaC-Tg mice aggravated CS-induced airway inflammation, mucin 
expression and destruction of alveolar walls and accelerated the formation of pulmonary lymphoid 
follicles. Moreover, lung function measurements demonstrated an increased compliance and total lung 
capacity and a lower resistance and hysteresis in βENaC-Tg mice, compared to WT mice. CS exposure 
further altered lung function measurements.  
Conclusions: We conclude that airway surface dehydration is a risk factor that aggravates CS-induced 
hallmarks of COPD. 
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INTRODUCTION 
 
Efficient mucociliary clearance is an essential innate defence mechanism of the lung 40, 125, 126, 146. Although 
ciliary activity and mucus secretion play an important role in airway mucus clearance, evidence from 
biophysical studies indicates that the hydration state of the airway surface is the key determinant 138, 285. 
While airway surface dehydration is a well-established disease mechanism in cystic fibrosis 176, 285, recent 
research suggests that this abnormality may also play a role in chronic obstructive pulmonary disease 
(COPD) 157, 160, 161, 166. Pathologically, COPD is mainly caused by cigarette smoking and characterized by 
mucus obstruction of the small airways 44, chronic pulmonary inflammation, obstructive bronchiolitis and 
emphysema 38, 286.  
Several studies demonstrated that cigarette smoke (CS) has detrimental effects on the hydration of airway 
surfaces. First, it was shown that CS affects ion channels in the apical membrane of airway epithelial cells, 
thereby disturbing the balance between Na+ absorption and Cl- secretion and leading to airway surface 
dehydration. Most notably, CS induces an acquired deficiency of the cystic fibrosis transmembrane 
conductance regulator (CFTR), a crucial cAMP-dependent Cl- channel that is mutated in cystic fibrosis 157, 
161, 166. In chronic smokers, CFTR function is reduced to ~ 45% of normal and mucus is hyperconcentrated 
in vivo 157, 161. This acquired CFTR dysfunction contributes to inadequate mucociliary transport 166 and is 
associated with chronic bronchitis and dyspnoea in smokers with and without COPD 162. Furthermore, 
exposure to CS extract enhances the activity of the epithelial Na+ channel (ENaC) in alveolar type I and type 
II cells 167, suggesting that CS exposure results in a hyposecretory/hyperabsorptive ion transport 
phenotype. Along these lines, recent studies on the protein levels of CFTR and ENaC in lung tissue of COPD 
patients demonstrated that CFTR levels were positively correlated with lung function, whereas levels of α- 
and βENaC showed a negative correlation with lung function 287. In mice, an imbalance between Na+ 
absorption and Cl- secretion, has been achieved in βENaC transgenic (βENaC-Tg) mice. In these mice, 
airway-specific overexpression of βENaC causes constitutive airway surface dehydration and spontaneous 
chronic obstructive lung disease characterized by airway mucus obstruction, neutrophilic inflammation 
and development of emphysema early in life 176, 177. 
A second mechanism by which CS can contribute to airway surface dehydration, is the CS-induced mucin 
hypersecretion 38, 40, 160. The two major secreted mucins in airways, MUC5AC and MUC5B, are both 
increased in patients with COPD 130, 288, 289. These mucin macromolecules are secreted in a dry form and 
thus increase the concentration of the mucus gel layer if the availability of airway surface fluid is limited. 
In their gel-on-brush model, Button et al. recently showed that an increased concentration of mucins 
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causes an increase in the osmotic pressure of the mucus gel layer and, above a certain threshold, this 
causes a compression of the subjacent periciliary layer, leading to a collapse of the cilia and mucostasis 138.  
Since observational evidence indicates that there is a degree of airway surface dehydration in patients 
with COPD, this study aimed to investigate the in vivo effect of airway surface dehydration on several 
pathological hallmarks of COPD and on lung function. To achieve this goal, we exposed βENaC-Tg mice and 
wild-type (WT) littermates to air or CS for 4 or 8 weeks and determined mucin expression, goblet cell 
metaplasia, pulmonary inflammation, lymphoid follicles, pulmonary emphysema and airway wall 
remodelling, and measured lung function.  
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METHODS 
Details of materials and methods used can be found in the online supplement. 
 
Primary tracheal epithelial cultures 
For each experiment, freshly excised tracheae were collected and pooled from 10 mice per group. 
Epithelial cells were isolated and cultured on membranes (T-Col, Costar, Cambridge, MA) under air-liquid 
interface conditions as described previously 290, and cultures were studied after reaching confluence (14 
days). 
 
Measurement of airway surface liquid height 
Primary tracheal epithelial cultures were washed with PBS, and 20 µl of PBS containing 2 mg/ml 
Rhodamine dextran (10 kDa; Molecular Probes) was added to the lumen to visualize the airway surface 
liquid layer. To avoid evaporation of the ASL, 80 µl of immiscible perfluorocarbon (Fluorinert-77, Sigma-
Aldrich) was added to the airway surface following the addition of the labeling dye. Images of the 
Rhodamine-labeled airway surface liquid were acquired by confocal microscopy (Leica TCS SP8, Leica 
Microsystems, Mannheim, Germany). The height of the airway surface liquid was measured by averaging 
the heights obtained from xz scans of sixteen predetermined positions on the culture as previously 
described 290. Airway surface liquid height was measured 5 min following the addition of the Rhodamine 
dextran and at designated time points over a period of 24 h in primary tracheal epithelial cultures from 
βENaC-Tg mice and WT littermates. 
 
Animals 
Male βENaC-Tg mice, backcrossed onto the C57Bl/6 background 178, were mated with female C57Bl/6Cr1 
wild-type (WT) mice (Charles River). All mice were bred in the animal facility of the Ghent University 
Hospital and housed in filtertop cages in standard conditions under a 12 h light-dark cycle and provided 
with a standard diet (Pavan, Brussels, Belgium) and chlorinated tap water ad libitum. Mice were 
euthanized with an overdose of pentobarbital (Sanofi, Libourne, France). All in vivo manipulations were 
approved by the local Ethics Committee for animal experimentation of the Faculty of Medicine and Health 
Sciences (Ghent University). 
 
Cigarette smoke exposure 
Groups of 8 to 11 βENaC-Tg mice and WT littermates were exposed whole body to cigarette smoke as 
described before (a total of 120 mice was used) 257. In short, mice were exposed 5 days a week to the 
mainstream cigarette smoke of 5 cigarettes (Reference cigarette 3R4F without filter, University of 
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Kentucky, Lexington, KY, USA), 4 times a day with a 30 minute smoke free interval between exposures. A 
standard smoking apparatus was used with the smoking chamber adapted for a group of mice. A smoke/air 
ratio of 1/6 was obtained. Control mice were exposed to room air. CS exposure started at an age of 7-8 
weeks and the exposure period was either 4 or 8 weeks.  
 
βENaC immunohistochemistry 
Lung sections were evaluated for overexpression of the β-subunit of ENaC, using a rabbit polyclonal anti-
βENaC antibody 291. 
. 
Goblet cell analysis and mucin gene expression 
Transversal sections were made from the paraffin-embedded left lung and were stained with Periodic acid-
Schiff (PAS). Goblet cells were counted using Axiovision software (Zeiss) and were expressed as number of 
cells per millimetre basal membrane. Expression of Muc5ac and Muc5b was quantified by quantitative 
real-time polymerase chain reaction (qRT-PCR). 
 
Pulmonary inflammation 
Bronchoalveolar lavage (BAL) fluid was collected via a tracheal cannula. Differential cell counts of the 
lavage fluid were obtained by cytocentrifuged preparations after May-Grünwald-Giemsa staining. Flow 
cytometric analysis was used for quantifying inflammatory cell types in BAL fluid and single cell 
suspensions of lung tissue 257, 292, 293. qRT-PCR was used to evaluate the expression of several chemokines. 
The protein levels of Cxcl1 and Ccl20 in BAL fluid supernatant of mice were determined with an ELISA kit 
(R&D systems). 
 
Lymphoid follicles 
In order to quantify lymphoid follicles, defined as dense accumulations of at least 50 lymphocytes, paraffin-
embedded sections of the left lung were immunohistochemically stained with anti-CD3 (Dako) and anti-
B220 (BD biosciences) 253. The number of follicles was normalized for the total area of parenchyma that 
was scored. 
 
Emphysema 
In order to evaluate pulmonary emphysema, two complementary methods were used, the mean linear 
intercept (Lm) and the destructive index (DI). The Lm is a measurement of alveolar space enlargement 
whereas the DI is a calculation of the percentage of destroyed alveolar walls. Both analyses were 
performed using the Image J software on haematoxylin and eosin (H&E) stained lung sections.  
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Airway wall remodelling 
To evaluate the deposition of fibronectin and collagen, paraffin-embedded sections of the left lung were 
used for immunohistological staining. Fibronectin was stained with mouse anti-fibronectin (Thermo-
Scientific). Collagen was stained chemically with Sirius Red. The amount of collagen and fibronectin in the 
airway wall was quantified using the Axiovision software (Zeiss). 
 
Lung function measurements  
Using the Flexivent System (SCIREQ, Montreal, Canada), baseline lung function was examined invasively in 
tracheostomised anaesthetized mice 294. The jugular vein was used to administer pancuronium bromide 
(1 mg/kg) (Inresa, Freiburg, Germany), which induces a neuromuscular blockade. The mice were ventilated 
with an average breathing frequency of 150 breaths/minute. Once the mice were stable, resistance (R) 
and dynamic compliance (Cdyn) were measured using a ‘snapshot perturbation’ manoeuvre. The forced 
oscillation perturbation (Quick Prime 3) was applied to assess the tissue damping (G). Pressure-volume 
(PV) loops were generated to measure the static compliance (Cstat), total lung capacity (TLC) and hysteresis. 
 
Statistical analyses 
Sigma Stat Software (SPSS 21.0, Chicago, IL, USA) was used to perform non-parametric tests (Kruskall-
Wallis and Mann-Whitney-U). Reported values are expressed as mean ± SEM. P-values < 0.05 were 
considered to be significant. 
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RESULTS 
Overexpression of βENaC and reduced airway surface liquid height in βENaC-Tg mice 
To confirm the overexpression of the β-subunit of ENaC in βENaC-Tg mice, we performed an 
immunohistochemical staining for βENaC on lung tissue sections from WT and βENaC-Tg mice. βENaC-
positive cells were readily detected in conducting airways and alveoli in lungs of WT mice (Fig. 1 A). The 
intensity of the immunoreactive signal was substantially stronger in airways from βENaC-Tg compared to 
WT mice, consistent with a marked increase in βENaC protein in epithelial cells (Fig. 1 A). 
 
 
 
 
 
 
 
 
Figure 1. Overexpression of βENaC and reduced airway surface liquid height in βENaC-Tg mice.  
Immunolocalization of βENaC in airways from WT and βENaC-Tg mice. (A) Representative images of βENaC 
immunostaining of lung sections from WT and βENaC-Tg mice that were exposed to air or CS for 8 weeks. n = 5 per 
group.Dysregulation of steady state airway surface liquid (ASL) height on airway epithelia from βENaC-Tg mice 
under thin film conditions. Representative confocal images (B) and summary of measurements of airway surface 
liquid height (C) at t = 0, 2, 4, 8 and 24h after mucosal addition of 20 µl of PBS containing Rhodamine dextran to 
primary tracheal epithelial cultures from βENaC-Tg mice and WT littermates. Scale bar, 7 µm. n = 4 experiments 
per group.*p<0.001 compared to βENaC-Tg; §p<0.001 for t = 0h compared to all other time points within the same 
genotype; †p<0.05 for t = 24h wild-type compared to t = 2h wild-type; ‡p<0.005 for t = 24h wild-type compared to 
t = 4h and 8h wild-type. 
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To determine the effects of βENaC overexpression on the regulation of airway surface liquid, primary 
tracheal epithelial cell cultures of WT and βENaC-Tg mice grown at an air-liquid-interface were challenged 
with a small volume of liquid added to the luminal compartment. Airway surface liquid height was 
monitored sequentially by confocal microscopy over a period of 24h. Within 2h after the initial volume 
challenge, the airway surface liquid was absorbed to a height of ~4.5 µm in both WT and βENaC-Tg mice 
(Fig. 1 B-C). However, at 24h, airway surface liquid height increased to ~6.3 µm in airway cultures from 
WT mice, whereas it remained significantly reduced in βENaC-Tg mice (Fig. 1 B-C). Consistent with previous 
studies 290, these results demonstrate that βENaC-Tg airway epithelia fail to regulate airway surface liquid 
to normal levels, and that steady state airway surface liquid is reduced in βENaC-Tg compared to WT mice. 
 
Cigarette smoke-induced mucin expression is aggravated in βENaC-Tg mice 
The expression of Muc5ac and Muc5b was quantified in total lung tissue by qRT-PCR. The airway surface 
dehydration in air-exposed βENaC-Tg mice resulted in a higher expression of both Muc5ac and Muc5b, 
compared to WT mice (Fig. 2 A-B). Four weeks of CS exposure significantly increased the expression of 
Muc5ac in βENaC-Tg mice, but not in WT mice (Fig. 2 A). In contrast, CS exposure did not induce a 
significant upregulation of Muc5b expression in lung, neither in βENaC-Tg mice nor in WT mice (Fig. 2 B). 
Similar results were obtained after 8 weeks of CS exposure (Suppl. Fig. S1). 
 
 
 
 
 
 
 
 
 
Goblet cell metaplasia was assessed by quantifying the number of periodic-acid-Schiff positive (PAS+) cells 
in the bronchial epithelium. Air-exposed βENaC-Tg mice had higher numbers of PAS+ cells compared to 
WT mice. However, 4 weeks of CS exposure did not induce an increase in PAS+ cells, neither in WT nor in 
Figure 2. Cigarette smoke-induced mucin expression is increased in βENaC-Tg mice. 
mRNA expression of Muc5ac (A) and Muc5b (B) in total lung tissue upon 4 weeks of air or CS exposure. mRNA 
expression data were normalized for 3 reference genes (Hprt1, Gapdh, Tfrc). n = 6/group 
*p<0.05, **p<0.01, ***p<0.001 
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βENaC-Tg mice (Fig. 3 A-C). In a subgroup of animals (n=3/group), PAS+ mucus content was measured in 
the airway lumen of non-lavaged mice following 4 weeks of air or CS exposure. Similar to goblet cell 
metaplasia, there was more mucus present in the airway lumen of βENaC-Tg mice, compared to WT 
controls independent of CS exposure (Fig. 3 D-F). Quantification of goblet cell metaplasia after 8 weeks of 
CS exposure, resulted in a similar outcome (Suppl. Fig. S1) 
 
 
 
Cigarette smoke-induced pulmonary inflammation is aggravated in βENaC-Tg mice 
Following air exposure, the numbers of inflammatory cells in BAL fluid were significantly increased in 
βENaC-Tg compared to WT mice. Four weeks of CS exposure led to a significant increase in the number of 
total BAL cells, macrophages, neutrophils and lymphocytes, both in WT and βENaC-Tg mice (Fig. 4 A-D). 
Importantly, this increase in innate and adaptive immune cells was significantly higher in βENaC-Tg mice, 
compared to WT mice (Fig. 4 A-D). Additionally, 4 weeks of CS exposure significantly increased the number 
Figure 3. Goblet cell metaplasia and mucus secretion upon air or CS exposure. 
(A) Goblet cell count upon 4 weeks of air or CS exposure. n=8/group. Representative images of goblet cells in 
airways of CS-exposed WT mice (B) and CS-exposed βENaC-Tg mice (C) upon 4 weeks of CS exposure. Arrows 
indicate goblet cells. (D) Quantification of PAS+ mucus content in lumen of airways of non-lavaged mice upon 4 
weeks of air or CS exposure  n=3/group. Representative image of PAS+ mucus content in airways of CS-exposed 
WT mice (E) and CS-exposed βENaC-Tg mice (F). *p<0.05, **p<0.01, ***p<0.001 
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of macrophages in the lungs of βENaC-Tg and WT mice (Fig. 4 E), but had no effect on the number of 
neutrophils, dendritic cells and CD4+ and CD8+ T-lymphocytes (data not shown). Interestingly, the CS-
induced increase in macrophages in lung tissue was aggravated in βENaC-Tg mice, compared to WT 
controls (Fig. 4 E). 
 
 
Similar results were obtained after 8 weeks of CS exposure (Suppl. Fig. S2). Following 8 weeks of CS 
exposure, additional cell types were quantified. While the CS-induced increase in dendritic cells and CD4+ 
T-lymphocytes in BAL did not differ in WT and β-ENaC (Fig. 4 F-H), the increase in CD8+ T-lymphocytes was 
significantly aggravated in CS-exposed βENaC-Tg mice, compared to WT littermates (Fig. 4 H).  
Quantification of inflammatory chemokines revealed higher mRNA expression of Cxcl1 and Ccl20 in lung 
tissue of air-exposed βENaC-Tg mice, compared to WT littermates (Fig. 5 A-D). The CS-induced increase in 
Figure 4. Cigarette smoke-induced pulmonary inflammation is increased in βENaC-Tg mice. 
(A) Total inflammatory cell count in BAL upon 4 weeks of air or CS exposure.  Quantification of macrophages (B), 
neutrophils (C) and lymphocytes (D) in BAL upon 4 weeks of air or CS exposure. n = 7-8/group. (E) Quantification 
of macrophages in total lung after 4 weeks of CS exposure. n = 7-8/group. Quantification of dendritic cells (F), 
CD4+ T-lymphocytes (G) and CD8+ T-lymphocytes (H) in BAL upon 8 weeks of air or CS exposure. n = 8-11/group. 
*p<0.05, **p<0.01, ***p<0.001 
  
 
A B C
<
<
<
< 
D E F
<
<
<
<
<
< 
G H 
0
1 0
2 0
3 0
4 0
5 0
a ir
C S
**
**
***
***
T
o
ta
l 
B
A
L
 c
e
ll
s
 x
 1
0
5
w ild -t y p e  E N a C -T g
0
1 0
2 0
3 0
4 0
5 0
a ir
C S
**
**
***
***
B
A
L
 N
e
u
tr
o
p
h
il
s
 x
 1
0
4
w ild -t y p e  E N a C -T g
0
1
2
3
4
a ir
C S
*
**
*
B
A
L
 L
y
m
p
h
o
c
y
te
s
 x
 1
0
4
w ild -t y p e  E N a C -T g
0
1 0
2 0
3 0 a ir
C S
*** **
*
L
u
n
g
 M
a
c
ro
p
h
a
g
e
s
 x
 1
0
4
w ild -t y p e  E N a C -T g
0
5
1 0
1 5
***
p  =  0 .0 5 1
***
a ir
C S
w ild -t y p e  E N a C -T g
B
A
L
 D
e
n
d
ri
ti
c
 c
e
ll
s
 x
 1
0
4
0 .0
0 .5
1 .0
1 .5 a ir
C S
***
***
**
*
B
A
L
 C
D
8
+
 T
-c
e
ll
s
 x
 1
0
4
w ild -t y p e  E N a C -T g
0
2
4
6
8 a ir
C S
***
***
w ild -t y p e  E N a C -T g
B
A
L
 C
D
4
+
 T
-c
e
ll
s
 X
 1
0
4
0
5
1 0
1 5
2 0
2 5
3 0
3 5
a ir
C S
**
***
***
**
B
A
L
 M
a
c
ro
p
h
a
g
e
s
 x
 1
0
5
w ild -t y p e  E N a C -T g
 80  
pulmonary Ccl20 mRNA expression was aggravated in βENaC-Tg mice, especially upon 8 weeks of CS 
exposure (Fig. 5 A-D). Protein levels of Cxcl1 and Ccl20 in BAL fluid were significantly higher in βENaC-Tg 
mice, compared to WT littermates (Fig. 5 E-H). Moreover, the CS-induced increase in Cxcl1 protein levels 
in BAL was significantly aggravated in βENaC-Tg mice (Fig. 5 E). 
 
 
 
Cigarette smoke-induced formation of lymphoid follicles is accelerated in βENaC-Tg mice  
Eight weeks of CS exposure did not induce lymphoid follicles in WT mice. In contrast, after 8 weeks of CS 
exposure, the formation of lymphoid follicles was already detected in βENaC-Tg mice (Fig. 6). Whereas 
lymphoid follicle formation upon chronic CS exposure (i.e. 6 months) was shown to be associated with 
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Figure 5. mRNA expression and protein levels of chemokines upon air or CS exposure. 
mRNA expression of Cxcl1 in total lung tissue upon 4 weeks (A) and 8 weeks (C) air or CS exposure. mRNA 
expression of Ccl20 in total lung tissue upon 4 weeks (B) and 8 weeks (D) air or CS exposure. mRNA expression 
data were normalized for 3 reference genes (Hprt1, Gapdh, Tfrc). n = 6-8/group. 
Protein levels of Cxcl1 in BAL fluid upon 4 weeks (E) and 8 weeks (G) air or CS exposure. Protein levels of Ccl20 in 
BAL fluid upon 4 weeks (B) and 8 weeks (D) air or CS exposure. Protein levels were measured by ELISA. n = 8-
11/group.  *p<0.05, **p<0.01, ***p<0.001 
  
0
2
4
6
8
C S
A ir
* *
*
w ild -t y p e  E N a C -T g
C
x
c
l1
 m
R
N
A
 e
x
p
re
s
s
io
n
0
2
4
6
C S
A ir
* *
p  =  0 .0 5 2
w ild -t y p e  E N a C -T g
C
c
l2
0
 m
R
N
A
 e
x
p
re
s
s
io
n
0
2 0 0
4 0 0
6 0 0
8 0 0
a ir
C S
*
**
***
***
w ild - ty p e  E N a C -T g
c
x
c
l1
 (
p
g
/m
l)
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
1 2 0 0
a ir
C S
p = 0 .0 5 4
***
***
w ild - ty p e  E N a C -T g
c
c
l2
0
 (
p
g
/m
l)
0
1 0 0
2 0 0
3 0 0
4 0 0 a ir
C S
***
***
***
w ild -t y p e  E N a C -T g
c
x
c
l1
 (
p
g
/m
l)
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0 a ir
C S
***
***
w ild  t y p e  E N a C -T g
c
c
l2
0
 (
p
g
/m
l)
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5 a ir
C S
*** p = 0 .0 5 5
w ild -t y p e  E N a C -T g
m
R
N
A
 e
x
p
re
s
s
io
n
 c
x
c
l1
0
1
2
3
4
5
a ir
C S
**
***
***
w ild -t y p e  E N a C - t g
C
c
l2
0
 m
R
N
A
 e
x
p
re
s
s
io
n
  
81  
elevated expression of Cxcl13 in WT mice, transcript levels of this chemokine were not increased following 
8 weeks of CS-exposure in βENaC-Tg mice (data not shown). 
 
 
 
 
 
 
 
 
 
Cigarette smoke-induced alveolar destruction is aggravated in βENaC-Tg mice 
Emphysema was measured by two complementary methods. The mean linear intercept (Lm), a measure 
for alveolar airspace enlargement, was significantly enlarged in the βENaC-Tg mice compared to WT 
littermates (Fig. 7 A). However, 4 weeks of CS exposure did not further increase the Lm, neither in the 
βENaC-Tg mice nor in the WT controls (Fig. 7 A). Emphysema was also quantified by determining the 
destructive index (DI). This measure quantifies the percentage of destruction of the alveolar walls. The DI 
tended to be higher in air-exposed βENaC-Tg compared to WT mice (Fig. 7 D). Importantly, 4 weeks of CS 
exposure did not result in an increased DI in WT mice, but did induce a significantly increased level of 
destruction in βENaC-Tg mice. (Fig. 7 D). Similar results were obtained after 8 weeks of CS exposure (Suppl. 
Fig. S3). Interestingly, Mmp12 mRNA expression was higher in lungs of βENaC-Tg mice compared to WT 
littermates (Fig. 7 G). 
 
Cigarette smoke does not induce airway wall remodelling in βENaC-Tg mice  
We investigated airway wall remodelling in mice by measuring the amount of fibronectin and collagen 
deposited in the airway walls. Fibronectin and collagen deposition in the airway walls did not differ 
between WT and βENaC-Tg mice and was not affected by 4 or 8 weeks of CS exposure (Suppl. Fig. S4). 
Figure 6. Cigarette smoke-
induced lymphoid follicle 
formation in βENaC-tg, but 
not in WT mice after 8 
weeks of CS exposure. 
(A) Quantification of 
lymphoid follicles 
normalized for the area of 
parenchyma (mm2) upon 8 
weeks of air or CS exposure. 
n = 8-11/group. (B-C) 
Representative images of 
lymphoid follicles found in 
CS-exposed βENaC-Tg mice.  
*p<0.05, **p<0.01, 
***p<0.001 
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Cigarette smoke-induced changes in lung function in WT and βENaC-Tg mice  
We assessed the pulmonary function of WT and βENaC-Tg mice after 4 weeks of exposure to air or CS. Air-
exposed βENaC-Tg mice exhibited a lower total pulmonary resistance, compared to air-exposed WT mice 
(Fig. 8 A). CS exposure did not influence the total pulmonary resistance, neither in WT nor in βENaC-Tg 
mice (Fig. 8 A). However, CS exposure significantly decreased the tissue damping in βENaC-Tg mice, 
whereas CS exposure of WT mice resulted in an increased tissue damping (Fig. 8 B). This parameter is used 
to assess the tissue resistance. In addition, the tissue elasticity was significantly lower in CS-exposed 
βENaC-Tg mice, compared to CS-exposed WT mice (Fig. 8 C). 
A significantly increased static and dynamic compliance was registered in βENaC-Tg mice compared to WT 
mice, consistent with the increase in mean linear intercept measured in βENaC-Tg mice (Fig. 8 A). Whereas 
CS exposure induced a significant decrease of both compliances in WT mice, CS exposure had no significant 
Figure 7. Cigarette smoke-induced  alveolar destruction is increased in βENaC-Tg mice. 
(A) Mean linear intercept (Lm) upon 4 weeks of air or CS exposure. n = 7-8/group. Representative image of WT 
mice: air-exposed (B) and CS-exposed (C). Destructive index (DI) upon 4 weeks of air or CS exposure (D). n = 7-
8/group. Representative image of βENaC-Tg mice: air-exposed (E) and CS-exposed (F). mRNA expression of 
Mmp12 in total lung upon 4 weeks of air- or CS exposure (G). Normalized for 3 reference genes (Hprt1, Gapdh, 
and Tfrc). n = 6/group.  *p<0.05, **p<0.01, ***p<0.001 
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effect on the elevated static and dynamic compliance in the βENaC-Tg mice (Fig. 8 D-E). The total lung 
capacity (TLC) was significantly higher in βENaC-Tg compared to WT mice. CS exposure induced a decrease 
in TLC in WT mice, but did not influence this parameter in βENaC-Tg mice (Fig. 8 F). Analysis of the PV-
loops demonstrated that the hysteresis, i.e. area between inflating and deflating part of the PV-loop, was 
significantly decreased in air-exposed βENaC-Tg mice compared to WT mice (Fig. 9 A-C). Exposing mice to 
CS, decreased the hysteresis both in WT and in βENaC-Tg mice. Of note, hysteresis was significantly lower 
in CS-exposed βENaC-Tg mice compared to CS-exposed WT mice (Fig. 9 C).  
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Figure 8. Effect of CS exposure on lung function in WT and βENaC-Tg mice. 
Lung function was determined in WT and βENaC-Tg mice after exposure to air or CS for 4 weeks. (A) Resistance 
(R) of the entire compartment (airways, tissue and chest wall). (B) Tissue damping (G), related to tissue 
resistance. (C) Tissue elasticity (H). (D) Static compliance (Cstat). (E) Dynamic compliance (Cdyn). (F) Total lung 
capacity (TLC).  *p<0.05, **p<0.01, ***p<0.001 
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Figure 9. Pressure-Volume loops of air- and 
CS-exposed mice. 
(A) Representative PV loops of air-exposed WT 
(black) and βENaC-Tg (red) mice. (B) 
Representative PV loops of CS-exposed WT 
(black) and βENaC-Tg (red) mice. (C) Area of PV 
loop or hysteresis. 
*p<0.05, **p<0.01, ***p<0.001 
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DISCUSSION 
There is increasing evidence of airway surface dehydration in smokers and patients with COPD. This study 
demonstrates that airway surface dehydration in βENaC-Tg mice aggravates CS-induced airway 
inflammation, mucin expression and destruction of alveolar walls and accelerates the formation of 
pulmonary lymphoid follicles. In contrast, CS exposure did not induce airway wall remodelling and had no 
effect on goblet cell metaplasia in βENaC-Tg mice. 
It has been demonstrated that CS suppresses the function of the CFTR channel, with airway surface 
dehydration and decreased mucociliary clearance as consequences 157, 161, 162, 166, 295. Moreover, Dransfield 
et al. showed that a diminished CFTR function correlates with the presence of chronic bronchitis and the 
degree of dyspnoea 162. Since Cftr-deficient mice do not exhibit imbalanced airway ion transport in the 
lower airways and do not display cystic fibrosis-like disease 174-176, 295, 296, we used βENaC-Tg mice, 
backcrossed onto a C57Bl/6 background 178, to test the hypothesis whether the presence of airway surface 
dehydration has an impact on CS-induced pathology and pathophysiology in vivo. βENaC-Tg mice 
overexpress the β-subunit of ENaC through an airway-specific cluB cell secretory protein (CCSP) promotor 
176. The constitutive hyperabsorption of Na+ leads to airway surface dehydration and decreased 
mucociliary clearance 176, 177. 
Besides an imbalance of epithelial ion transport, mucus hypersecretion may contribute to airway surface 
dehydration and mucociliary dysfunction. As Button et al. elegantly showed in their gel-on-brush model, a 
hyperconcentrated mucus gel layer with > 8% solids can create sufficient osmotic pressure to cause a 
collapse of the cilia and mucostasis 138. Clunes et al. found that mucus of chronic cigarette smokers 
contained approximately 10% solids, which makes it likely that osmotic pressure of the hyperconcentrated 
mucus layer contributes to mucociliary dysfunction in smokers 146, 297. The predominant secreted mucins 
in airway mucus are MUC5AC and MUC5B and both are upregulated in COPD 130, 288, 289. Consistent with 
previous studies, we observed higher transcript levels of Muc5ac and Muc5b and a significant higher 
number of goblet cells in βENaC-Tg mice compared to WT mice 177. Although the Muc5b mRNA expression 
tended to be increased after 4 weeks of CS exposure, this increase did not reach significance. In contrast, 
CS induced a significant increase of Muc5ac expression in the βENaC-Tg mice, both after 4 and 8 weeks of 
CS exposure. Since mice do not readily develop goblet cell metaplasia upon CS exposure 173, 298, we did not 
observe an increase in goblet cell metaplasia after CS exposure, neither in WT nor in βENaC-Tg mice. 
However, substantial mucin hypersecretion has been detected without increase in goblet cell numbers. It 
has been suggested that Clara cells produce and secrete Muc5ac without being subjected to metaplastic 
changes, including the formation of PAS positive storage granules 155, 299. Taken together, our results are 
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consistent with the observation that Muc5ac is highly inducible by noxious stimuli 288 and suggest that 
hypersecretion of Muc5ac in response to CS exposure may contribute to mucus hyperconcentration and 
airway surface dehydration.  
Airway surface dehydration produces chronic airway inflammation in BAL in βENaC-Tg mice, with higher 
numbers of macrophages, neutrophils and lymphocytes compared to WT littermates 176-178. Our study 
confirms and extends these findings by showing that BAL of βENaC-Tg mice also exhibits more dendritic 
cells and CD8+ T-lymphocytes. By exposing both WT littermates and βENaC-Tg mice to CS, we 
demonstrated that airway surface dehydration was associated with an aggravated CS-induced 
inflammatory response in βENaC-Tg mice. In BAL, CS exposure induced a significantly higher increase in 
macrophages, neutrophils and CD8+ T-lymphocytes, key players in COPD pathophysiology, in βENaC-Tg 
mice than in WT mice 4, 38, 45, 104. Interestingly, this exaggerated response already occurred after a subacute 
CS exposure, i.e. 4 weeks.  
In lung tissue, the CS-induced inflammatory response was limited to an increase in macrophages. Along 
with this increase in macrophage numbers, we observed an increase in matrix metalloproteinase 12 
(Mmp12), a macrophage-derived protease important in emphysema development in WT and βENaC-Tg 
mice 300, 301. 
Severe COPD is associated with increased numbers of airways containing lymphoid follicles 44. Moreover, 
the presence of lymphoid follicles has also been demonstrated in the lung parenchyma of patients with 
COPD 242. In WT mice, lymphoid follicles are usually detected after 6 months of CS exposure 246. In this 
study, lymphoid follicles were already detected in βENaC-Tg mice after 8 weeks of CS exposure, suggesting 
that airway surface dehydration accelerates the CS-induced formation of lymphoid follicles. Since we did 
neither observe a dominance of B cells in these lymphoid follicles, nor an upregulation in total lung tissue 
of Cxcl13 transcript levels, a chemokine involved in lymphoid follicle formation upon chronic CS exposure 
246, we speculate that we observed early stages of follicle formation. Importantly, we did not find evidence 
of pulmonary infection. 
In COPD patients, emphysema develops after many years of cigarette smoking and it consistently requires 
several months of CS exposure, i.e. 6 months, to evoke emphysema in WT mice. In contrast, βENaC-Tg 
mice develop severe emphysema early in life 177, 300, 302. Similar elements that lead to the onset of 
emphysema, can be found in both βENaC-Tg mice and patients with COPD. First, in COPD, a 
proteinase/antiproteinase imbalance plays a key role in the development of emphysema 48, 54, 303. Recently, 
it has been shown that Mmp12 and neutrophil elastase also mediate emphysema in βENaC-Tg mice 300, 304. 
Second, McDonough et al. showed that small airway obstruction precedes emphysematous destruction in 
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COPD patients 305. In βENaC-Tg mice, airway surface dehydration leads to mucus obstruction in the first 
days of life and preceding the onset of emphysema 176-178, constituting another similarity to COPD patients. 
In this study, we confirmed severe emphysema in air-exposed βENaC-Tg mice, as quantified by the mean 
linear intercept (Lm) 177. However, we did not find a further increase in Lm in the βENaC-Tg mice following 
CS exposure. Given the severity of the constitutive emphysema in adult βENaC-Tg mice, it can be 
questioned whether it is at all possible to establish further enlargement of the Lm upon CS exposure. In 
contrast, quantifying the destructive index (DI), a measure for alveolar destruction, clearly showed that 4 
weeks of CS exposure already induced significant destruction of alveolar tissue in βENaC-Tg mice, while 
there was not yet an effect in WT mice. We also performed lung function measurements and observed a 
decreased resistance and increased compliance and TLC, indicating that the lung function is dominated by 
the severe spontaneous emphysema in βENaC-Tg mice 177. Interestingly, following CS exposure, the 
increased compliance measured in βENaC-Tg mice was accompanied by a decreased tissue damping and 
tissue elasticity. Together with the morphometric analysis of the DI, these data demonstrate that airway 
surface dehydration aggravated CS-induced emphysema, even after short term exposure, suggesting that 
this mechanism may contribute to emphysema formation in smokers with COPD.  
This study suggests that therapeutic targeting of airway surface dehydration may be beneficial in patients 
with COPD, although extrapolation of our experimental findings in mice after (sub)acute cigarette smoke-
exposure to the complex chronic disease COPD in humans should be performed with caution. It has been 
shown in vitro that the CFTR potentiator ivacaftor can partially rescue the CS-induced CFTR deficiency, 
thereby restoring the airway surface dehydration and mucociliary clearance in non-CF epithelial cells 166. 
Moreover, the phosphodiesterase inhibitor roflumilast has beneficial effects on the CS-induced 
dehydration of the airway surface of epithelial cell lines through elevation of intracellular cAMP levels and 
activation of CFTR 165. These proof-of-concept studies may facilitate future clinical trials that will be 
required to determine therapeutic effects improving CFTR function and airway surface hydration on mucus 
obstruction, airway inflammation and emphysema in patients with COPD.  
Of note, our results also suggest that CS exposure of βENaC-Tg mice can be used as a time-saving model 
for COPD-like pathology. Within a short time frame of 4 to 8 weeks, these mice already develop a strong 
pulmonary inflammation, with the formation of lymphoid follicles, and destruction of alveolar tissue, 
whereas these pathologies in WT mice can only be observed following 6 months of CS exposure. In 
addition, βENaC-Tg mice also possess more characteristics of chronic bronchitis, including goblet cell 
metaplasia and intraluminal mucus content, than WT mice.  
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In summary, acquired CFTR malfunction and mucin hypersecretion, both leading to mucus 
hyperconcentration, have been demonstrated in smokers with and without COPD, implicating that airway 
surface dehydration is present in these patients 157, 161. In our study, we have shown that the presence of 
airway surface dehydration in βENaC-Tg mice significantly aggravates the CS-induced pathological 
hallmarks of COPD, including mucin expression, pulmonary inflammation, formation of lymphoid follicles 
and destruction of alveolar walls. We speculate that the impaired mucociliary clearance caused by airway 
surface dehydration results in a retention and concentration of CS in the airways, thus leading to 
exaggerated host responses, such as mucus hypersecretion and enhanced inflammation. Proteases, 
originating from macrophages and neutrophils, can then lead to destruction of alveolar tissue and 
emphysema. The results of our study identify airway surface dehydration as a novel risk factor for CS-
induced pathology.  
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PART II  
 
CHAPTER 8: EPIDEMIOLOGY AND IMPACT OF CHRONIC BRONCHITIS IN COPD 
 
 
 
 
 
 
 
 
 
 
 
 
The chronic bronchitis phenotype in COPD is a validated phenotype with important impact on clinical 
outcomes. However, there are inconsistent reports on the importance of chronic bronchitis on 
exacerbation rate and mortality risk in patients with COPD. Therefore, we aimed to investigate the 
epidemiology of chronic bronchitis in COPD in the Rotterdam Study.   
 
 
 
 
 
 
 
 
Lies Lahousse, Leen J.M. Seys, Guy F. Joos, RS-PI, Bruno H. Stricker, Guy G. Brusselle. Epidemiology and 
impact of Chronic Bronchitis in COPD. Manuscript in preparation 
 90  
ABSTRACT 
BACKGROUND: Research on the association between chronic bronchitis and Chronic Obstructive 
Pulmonary Disease (COPD)-exacerbations has led to discordant results. Furthermore, the impact of chronic 
bronchitis on mortality in COPD subjects is unclear.  
METHODS: This study is embedded within the Rotterdam Study, a population-based cohort study among 
subjects aged 45 years and older with long-term follow-up. Chronic bronchitis was defined as having a 
productive cough for at least three months a year for two consecutive years. Cross-sectional and 
longitudinal analyses were performed with logistic regression and Cox proportional hazard models 
respectively. 
RESULTS: Of 972 COPD subjects included in the study, 752 COPD subjects had no chronic phlegm 
production (CB-) and 220 subjects had chronic phlegm production of whom 172 (78%) met the definition 
of chronic bronchitis (CB+). CB+ subjects were older, more frequently current smokers and had a higher 
amount of pack years of cigarette smoking than CB- subjects. Adjusted for age, sex and pack years, COPD 
subjects with CB had an increased risk of frequent exacerbations (OR 4.0 95%CI 2.7-5.9). During follow-up, 
CB+ subjects had significantly larger decline in lung function (-38 ml per year, 95%CI -61.7;-14.6). Survival 
was worse in especially female COPD subjects with CB. Regarding cause-specific mortality, CB+ COPD 
subjects had a significantly increased risk of respiratory mortality (HR 2.16, 95%CI 1.12-4.17, p=0.022 
adjusted for age, sex and pack years). 
CONCLUSIONS: COPD subjects with chronic bronchitis have an increased risk of exacerbations and 
(respiratory) mortality compared to COPD subjects without chronic phlegm production. 
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INTRODUCTION 
Progressive, not completely reversible airflow limitation is the main characteristic of chronic obstructive 
pulmonary disease (COPD). Patients with COPD typically suffer from chronic cough, expectoration of 
phlegm, dyspnoea and a variety of extra-pulmonary symptoms. Clinical presentation, response to therapy 
and disease progression are very heterogeneous among patients with COPD 2. Identifying and studying 
subgroups of patients with similar traits within the COPD syndrome can aid in guiding more individualised 
therapy and assessment of prognosis 306. Several COPD phenotypes have been proposed, but only a few 
have been validated 14. One of these COPD phenotypes is the chronic bronchitis (CB) phenotype which is 
generally defined as patients with COPD which experience chronic cough and sputum production for at 
least three months per year for two consecutive years 147.  
Epidemiological studies linking the CB phenotype in COPD to outcomes, have generated inconsistent 
results, especially regarding exacerbations and mortality. Both outcomes are crucial since they have a 
substantial impact on the burden of disease 2. Although COPD is a chronic disease, acute exacerbations 
and the rate at which they occur, determine the progression of the disease 188. Because COPD 
exacerbations have been associated with worse quality of life 25, 307, accelerated deterioration of lung 
function 24, 187, an increased risk for hospital admission 308 and an increase in mortality 309, they have an 
important impact on the health care-related costs 14. Two large-scale, patient-based observational studies 
have reported on exacerbation rates in COPD patients with CB, with opposing results. The Evaluation 
of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)-study did not find an 
association between chronic bronchitis and COPD exacerbations, whereas the COPDGene study detected 
a strong association 32, 185, 189. Other patient-based studies seem to contribute to these discordant results 
29, 30, 196, 310. In contrast, observations from population-based studies are scarce 183, 187 
The effect of the presence of CB in COPD patients on mortality risk is unclear as well. Although several 
papers observed an increased mortality risk in COPD patients with CB, it is not clear whether this subgroup 
of COPD patients is more prone to all-cause mortality or specifically to COPD-related respiratory mortality 
182, 191, 192. Furthermore, several studies found different effects of the presence of CB on mortality in men 
and women 182.  
Since previous studies on the impact of chronic bronchitis on the course of COPD have provided discordant 
results, we aimed to investigate the exacerbation rate and mortality risk of COPD patients with or without 
chronic bronchitis in a prospective population-based cohort study with long-term follow-up, the 
Rotterdam Study 283.  
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METHODS 
Study design 
The present study is embedded within the Rotterdam Study (RS), a population based cohort study 
comprising almost 15.000 participants aged ≥45 aiming at assessing the occurrence of, and risk factors for 
chronic diseases in the elderly 283. The study started in 1989 and all participants are invited every 3 to 4 
years to the research centre for follow-up examinations, including spirometry. All participants with 
prevalent COPD and completed questionnaires on chronic bronchitis during the examination rounds 
performed from 2001 up to 2008, were included. Follow-up time was defined as the time period between 
the subject’s visit to the examination round, and death or end of study period (e.g. January 1st, 2013 for 
the validation of (cause-specific) death), whichever came first. The medical ethics committee of the 
Erasmus Medical Centre, Rotterdam, and the review board of The Netherlands Ministry of Health, Welfare 
and Sports, approved the study. Participants gave written informed consent. 
Assessment of COPD 
The diagnosis of COPD was based on an obstructive spirometry examination according to the modified 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (proportion of the forced vital 
capacity exhaled in the first second (FEV1/FVC) < 0.7) or in absence of an interpretable spirometry at the 
research center, based on the diagnosis by a respiratory physician or general practitioner combining 
clinical history, physical examination and spirometry 311. Spirometry was performed between 2001 and 
2008 using a SpiroPro® portable spirometer (Erich Jaeger GmbH, Hoechberg, Germany) and from 2009 
onwards using a Master Screen® PFT Pro (CareFusion, San Diego, CA) by trained paramedical personnel 
according to the ATS/ERS guidelines 312. The incident COPD date was defined as the date of the first 
obstructive lung function or the date of COPD diagnosis in the medical reports or the date of the first 
prescription of COPD medication, whichever came first.  
Assessment of chronic bronchitis 
Chronic bronchitis was assessed by questionnaire and defined as having a productive cough for at least 
three months a year during the last two years. More specifically, all subjects were questioned (1) ‘Did you 
cough nearly daily for three consecutive months during the last two years?’ and (2) ‘Did you cough up 
phlegm nearly daily for three consecutive months during the last two years?’. Subjects answering no on 
both occasions or no to the second question, were defined as having no chronic phlegm production (CB-). 
Subjects answering yes twice were defined as having chronic bronchitis (CB+). 
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Assessment of exacerbations 
All COPD subjects were prospectively followed for the onset of exacerbations from their examination visit 
until death or end of study period (e.g. January 1st, 2011 for the validation of exacerbations). Moderate 
COPD exacerbations were defined as acute episodes of worsening symptoms needing a course of steroids 
and/or antibiotics. Complete information on all filled prescriptions on a day-to-day basis was obtained in 
automated format from the pharmacies.  
Severe COPD exacerbations were defined as exacerbations requiring a hospitalization due to COPD. All 
hospital admissions were continuously registered in The Dutch Medical Registry (LMR). The exacerbation 
rate was defined as the ratio of the total number of exacerbations over the total follow-up time. COPD 
subjects with frequent exacerbations were determined as subjects who had at least two (rounded) 
moderate or severe exacerbations on average per year during follow-up. 
Assessment of quality of life and mortality 
Quality of life was measured by questionnaire and summarized as the weighted average of scores given to 
questions about mobility, ability and activity, self-care, pain and anxiety. Information on vital status was 
obtained from general practitioners and from municipal records. Causes of death during follow-up were 
coded according to the International Classification Of Diseases (ICD)-10 313. The following categories were 
applied: pulmonary mortality (ICD-10: J15-J44), cardiac mortality (ICD-10: I21-I73, R96), death from 
bronchial carcinoma (ICD-10: C34), death from other malignancies (ICD-10: C15-C96 except C34) and other 
causes of death (ICD-10: all other used codes). 
Statistical analyses 
Differences between subjects with and without chronic bronchitis were studied using Mann-Whitney U 
test for continuous variables and Chi-Square test for categorical variables. Logistic regression models were 
used to calculate the risk of frequent exacerbations. Cox hazard regression models were used to calculate 
the time to (cause-specific) death. All models were adjusted for age, sex and pack-years of cigarette 
smoking. Statistical analyses were performed using SPSS, version 23.0 for Windows (IBM, North Castle, 
NY). 
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RESULTS 
 
Patient population 
Of 972 COPD subjects included in the cohort study, 752 subjects with COPD had no chronic phlegm 
production (CB-) and 220 subjects had chronic phlegm production of whom 172 (78%) met the strict 
criteria of chronic bronchitis (CB+) (Figure 1).  CB+ COPD subjects were older, more frequently current 
smokers and had a higher amount of pack years of cigarette smoking (Table 1). Furthermore,  COPD 
subjects with CB had a worse lung function at baseline than COPD subjects without CB (Table 1). In 
addition, quality of life was significantly worse in COPD subjects suffering from chronic bronchitis (Table 
1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study flow chart 
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 COPD, CB- 
(n=752) 
COPD, CB+ 
(n=172) 
p-value 
Age (years) 70.5 (15.2) 74.1 (13.6) 0.004 
Males 380 (50.5%) 96 (55.8%) 0.122 
Smoking status  
     Never smoker 
     Former smoker 
     Current smoker 
134 (17.8%) 
407 (54.1%) 
211 (28.1%) 
17 (9.9%) 
89 (51.7%) 
66 (38.4%) 
0.005 
Pack-years cigarette smoking 23.0 (41.2) 30.6 (35.1) <0.001 
Height (m) 1.69 (0.14) 1.68 (0.12) 0.529 
Weight (kg) 76.7 (18.8) 74.8 (17.3) 0.082 
BMI (kg/m²) 26.6 (5.3) 26.0 (5.5) 0.093 
FEV1 (l) 
 
 (% predicted) 
3.1 (1.6) 2.9 (1.4) 0.034 
FEV1 (% pred) 
 
82.0 (26.7) 70.5 (27.8) <0.001 
FVC (l) 2.0 (1.1) 1.8 (0.9) <0.001 
FVC (% pred) 101.0 (29.5) 91.9 (33.0) 0.008 
FEV1/FVC (%) 65.4 (7.0) 61.0 (10.0) <0.001 
Quality of life (%) 80.0 (21.9) 71.9 (31.3) <0.001 
         
Table 1: Baseline characteristics of COPD subjects without chronic bronchitis and with chronic 
bronchitis.Categorical variables are expressed as numbers (percentage). Values of continuous variables are 
expressed as median (interquartile range). Pack years were missing in 46 subjects, height/weight/BMI in 43 subjects, 
interpretable baseline lung function measurement was missing in 330 subjects, lung function decline over time in 
653 subjects and quality of life in 12 subjects. 
Abbreviations: BMI = body mass index; CB= chronic bronchitis; COPD= Chronic Obstructive Pulmonary Disease; FEV1= 
forced expiratory volume in one second; FVC= forced vital capacity 
Figure 
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Impact of chronic bronchitis on lung function and exacerbation rate 
281 COPD subjects had an interpretable lung function measurement between 2002-2008 and a second 
between 2009-2014. During this follow-up, COPD subjects with CB had a -38.2 ml per year larger decline 
in lung function than COPD subjects without CB (95%CI -61.7;-14.6) adjusted for age, sex and pack years 
of cigarette smoking (Table 2). The adjusted decline in lung function was -42.8 ml per year for male COPD 
subjects with CB and -36.1 ml per year for female COPD subjects with CB compared to male and female 
COPD subjects without CB respectively (Table 2). 
 
  
Model 1 (n=270) Model 2 (n=259) 
β 95% CI p-value β 95% CI p-value 
COPD with chronic 
bronchitis 
-35.2 -57.9;-12.5 0.002 -38.2 -61.7;-14.6 0.002 
Male COPD with 
chronic bronchitis 
-42.8 -77.3;-8.2 0.016 -42.8 -78.1;-7.6 0.018 
Female COPD with 
chronic bronchitis 
-29.4 -58.7;-0.05 0.050 -36.1 -67.1;-5.2 0.022 
 
Table 2: Association between chronic bronchitis and lung function decline (ml/yr) 
Model 1: age and sex* adjusted 
Model 2: adjusted for age, sex* and pack years of cigarette smoking. 
Abbreviations: β= unstandardized bèta-coefficient of millilitres lung function decline per year; CI= Confidence 
Interval; COPD= Chronic Obstructive Pulmonary Disease 
*only in the unstratified analyses. 
 
During follow-up until January 1st, 2011, COPD subjects with CB had a three times higher median rate of 
moderate to severe exacerbations per year (0,33 exacerbations per year (IQR 0,85) in the CB-COPD group 
versus 0,99 (IQR 1,78) in the CB+ COPD group; p ≤ 0.001). The percentage of COPD subjects whom 
experienced at least one severe exacerbation during follow-up was also higher for COPD subjects with CB 
compared to COPD subjects without CB (20.3% versus 7.0%, p<0.001). Adjusted for age, sex and pack years 
of cigarette smoking, COPD subjects with CB had a fourfold increased risk (OR 4.0 95%CI 2.7-5.9) of 
frequent exacerbations (≥2 moderate or severe exacerbations per year) (Table 3). The odds ratio on 
frequent exacerbations was 3.12 for male COPD subjects with CB and 5.10 for female COPD subjects with 
CB compared to male and female COPD subjects without CB respectively (Table 3). Similar results on lung 
function decline and exacerbation rate were observed when the group of 172 subjects meeting the strict 
definition was extended to the 220 subjects with chronic phlegm production.  
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Model 1 (n=924) Model 2 (n=878) 
OR 95% CI p-value OR 95% CI p-value 
COPD with chronic 
bronchitis 
4.13 2.82-6.04 <0.001 3.96 2.67-5.88 <0.001 
Male COPD with 
chronic bronchitis 
3.21 1.90-5.42 <0.001 3.12 1.82-5.31 <0.001 
Female COPD with 
chronic bronchitis 
5.16 2.94-9.05 <0.001 5.10 2.83-9.20 <0.001 
 
Table 3: Association between chronic bronchitis and the frequent exacerbator phenotype. 
Model 1: age and sex* adjusted 
Model 2: adjusted for age, sex* and pack years of cigarette smoking. 
Abbreviations: CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; OR= Odds Ratio *only in the 
unstratified analyses. 
 
Impact of chronic bronchitis on all-cause and cause-specific mortality 
During 5 856 person years of follow-up, 351 COPD subjects died: 92 (53.5%) among those with CB and 259 
(34.4%) among those without CB. COPD subjects with CB had worse survival than COPD subjects without 
CB as illustrated in Figure 2. Compared to COPD subjects without CB, mortality risk was increased by 33% 
in COPD subjects with CB after adjustment for age, sex and pack years (Table 4, HR 1.33, 95%CI 1.04-1.71, 
p=0.024). Stratified for sex, female COPD subjects with CB had a significantly worse survival, while the 
effect was less pronounced in men and no longer significant after adjustment for pack years of cigarette 
smoking (Table 4). 
 
Figure 2: Kaplan-Meier curve of all-
cause mortality according to COPD 
without chronic bronchitis (CB-, 
n=752) or with chronic bronchitis (CB+, 
n=172). 
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Model 1 (n=924) Model 2 (n=878) 
HR 95% CI p-value HR 95% CI p-value 
COPD with chronic 
bronchitis 
1.45 1.14-1.84 0.002 1.33 1.04-1.71 0.024 
Male COPD with 
chronic bronchitis 
1.32 0.98-1.78 0.072 1.22 0.89-1.65 0.212 
Female COPD with 
chronic bronchitis 
1.69 1.14-2.53 0.010 1.57 1.03-2.40 0.036 
 
Table 4 : Association between chronic bronchitis and the risk of all-cause death in COPD, additionally stratified 
according to sex. 
Model 1: age and sex* adjusted 
Model 2: adjusted for age, sex* and pack years of cigarette smoking. 
Abbreviations: CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; HR= Hazard Ratio, *only in 
the unstratified analyses. 
 
The most frequent causes of death in COPD patients are shown in Figure 3 and listed in more detail in 
Table S2 of the online supplement. Compared to CB- COPD subjects, COPD subjects with CB died more 
frequently due to pulmonary complications of COPD including exacerbations, emphysema or pneumonia 
(Figure 3). COPD subjects with CB had a more than twofold increased risk of pulmonary mortality 
compared to COPD subjects without CB (HR 2.70, 95%CI 1.45-5.04, p=0.002 adjusted for age and sex; HR 
2.16, 95%CI 1.12-4.17, p=0.022 adjusted for age, sex and pack years). Of note, mortality due to lung cancer 
(bronchial carcinoma) was numerically higher but did not significantly differ between COPD subjects with 
and without CB (14.1% versus 12.4%) (Figure 3). 
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Figure 2: Major causes of death according to COPD without (CB-, n=752) or with chronic bronchitis (CB+, n=172). 
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DISCUSSION 
In this large, population-based cohort study, we demonstrate that COPD subjects with concomitant 
chronic bronchitis (CB+) have a worse lung function at baseline and a subsequent larger lung function 
decline during follow-up. In addition, CB+ COPD subjects experience significantly more exacerbations 
during follow-up than COPD subjects without CB. Moreover, CB+ COPD subjects have a fourfold increased 
risk of frequent exacerbations. Furthermore, this study shows that CB+ COPD subjects have a higher 
mortality risk, especially COPD-related pulmonary death. Importantly, the increased risk of frequent 
exacerbations and the increased risk of mortality is more pronounced in women than in men.  
In our study, the prevalence of CB in subjects with COPD is 17.7%. Defining CB by the presence of chronic 
phlegm, with or without the presence of chronic cough, increased the prevalence in our study towards 
22.6%. There is a considerable variability in the prevalence of CB among subjects with COPD reported in 
other studies, ranging from 7.4% 183 up to 74% 30. Several variations of the classical definition have been 
used to determine CB. In the PLATINO Study, the prevalence doubled using a less stringent definition 183. 
Furthermore, a higher prevalence is reported in patient-based studies which generally do not include a 
high percentage of patients with mild COPD, whereas population-based studies, such as the Rotterdam 
Study, incorporate an unselected COPD population, which generally includes a larger proportion of 
subjects with mild COPD. Other factors that influence the prevalence of CB among COPD subjects are 
smoking history and geographical localisation 180, 186. Lu et al. reported that living in a rural area was 
associated with an increased risk for the development of chronic bronchitis 186.  
A remarkable observation is that during the follow-up period, COPD subjects with CB experienced an 
excess lung function decline of 38,2 ml/year compared to COPD subjects without CB. Considering that lung 
function decline was determined in a subgroup of the population that survived until the next examination 
round and that had two interpretable measurements, this difference in lung function decline is 
considerable. The association of CB with a more rapid decline in lung function remained significant with 
the less stringent definition of CB and was slightly more pronounced in male COPD subjects with CB.  In 
line with our findings, the population-based Copenhagen City Heart Study reported an excess decline in 
FEV1 of 22.8 ml/year for men and 12.6 ml/year for women during a 5 year follow-up in COPD subjects with 
CB, whereas the patient-based ECLIPSE Study did not detect a difference in lung function decline in COPD 
patients with or without CB during a three year follow-up, indicating the importance of a relevant follow-
up period 187, 195. In addition, Allinson et al. recently showed in a British cohort study with long-term follow-
up, that the presence of CB was associated with an additional 4.5 ml/year decline in FEV1, irrespective of 
the presence of COPD 314. 
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Conflicting results exist regarding the exacerbation rate in COPD patients with CB. In our study, we 
observed a significantly increased exacerbation rate and a fourfold increased risk of frequent 
exacerbations in CB+ COPD subjects compared to COPD subjects without CB. In line, an increased 
exacerbation rate and an increased risk of frequent exacerbations was also reported for COPD subjects 
with CB in the COPDGene Study and in a small study (n=70) in the UK 25, 185. In contrast, the observations 
from the ECLIPSE study and a patient-based study in Spain did not significantly associate chronic bronchitis 
to COPD exacerbations 32, 189, 196. In the population-based PLATINO study, the number of exacerbations in 
the past year were not significantly different for CB+ compared to CB- subjects, but the percentage of 
subjects with at least one exacerbation in the past year was significantly higher in the COPD group with CB 
compared to the COPD group without CB 183.  
Viral and bacterial infections account for the majority of exacerbations in COPD 315, 316. Observations from 
the Copenhagen City Heart Study indicate that indeed subjects with chronic bronchitis are more vulnerable 
for pulmonary infections 187, 191. This was also reported in the Lung Health Study where subjects with 
chronic bronchitis reported significantly more lower respiratory illness than those without chronic 
bronchitis 317. These reports strengthen the association between CB and COPD exacerbations.  
Potentially due to the increased vulnerability to exacerbations, we observed that COPD subjects with CB 
are especially more prone to pulmonary-related death compared to CB- COPD subjects. Furthermore, in 
this population, we demonstrated that the presence of CB induced an increased all-cause mortality risk of 
33% in COPD subjects. Our results of increased mortality in CB+ COPD subjects are in line with those of 
Pelkonen et al., reporting an even higher increase in both all-cause and respiratory-related mortality 192.  
An important observation in this study is that the associated risk of having CB on frequent exacerbations 
and on mortality, is more pronounced in female than in male subjects with COPD. Analogue results were 
found in the Copenhagen City Heart Study, where women with CB experienced more COPD-related 
hospitalisations than men with CB 187.  In addition, results from the US Six Cities Study also indicated that 
women with CB have an increased risk for COPD-related death, compared to men with CB 318. Gender 
differences have been described in the effect of cigarette smoking on lung function and hospitalisation for 
COPD, with women being more vulnerable for the effects of cigarette smoking 319-321. Since the presence 
of CB is strongly associated with current smoking 322, the higher vulnerability of women for the effects of 
cigarette smoking might add to the differences in the risk ratios we observed in this study. 
The strengths of our study are the general population-based setting, allowing us to investigate associations 
in an unselected COPD population, the long-term follow-up and the prospective data collection. In the 
Rotterdam Study, moderate and severe exacerbations are indeed continuously and automatically 
 102  
registered based on pharmacy filled prescription data and a national hospitalization register, which 
prevents recall bias compared to self-reporting of the exacerbation frequency during the previous year in 
retrospective studies. This also includes a limitation, since we have no data on the frequency of mild 
exacerbations, which are attended by an increase of the regular medication.  
A second limitation of our study is the fact that lung function decline could only be determined in a 
subgroup of the COPD subjects since a substantial proportion of the subjects died before lung function 
could be measured a second time and not all subjects had two interpretable lung function tests. However, 
even in this smaller group, the difference in lung function decline between COPD subjects with and without 
CB was significant.  
In conclusion, we have shown that subjects with both COPD and CB have more decline in lung function, 
experience more exacerbations and have a higher risk for pulmonary-related mortality. Moreover, the 
increased risk of frequent exacerbations and mortality is even more pronounced in female COPD subjects 
with CB. The results indicate that COPD patients with CB need optimal prophylaxis and close monitoring 
to prevent exacerbations. Furthermore, this study shows that there is a need for better therapies which 
target CB since these might reduce the exacerbation rate and mortality risk in patients with COPD. 
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PART II 
 
CHAPTER 9: ROLE OF B CELL-ACTIVATING FACTOR IN CHRONIC OBSTRUCTIVE PULMONARY  
                      DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
In COPD, the number of airways with lymphoid follicles is associated with disease severity. In addition, the 
expression of B cell-Activating Factor (BAFF) in these lymphoid follicles in patients with COPD is also 
correlated with disease severity. In order to investigate the role of BAFF and lymphoid follicles in COPD, 
we localized BAFF expression in lymphoid follicles of patients with COPD and antagonized BAFF in a murine 
model of COPD.  
 
 
 
 
Seys LJ, Verhamme FM, Schinwald A, Hammad H, Cunoosamy DM, Bantsimba-Malanda C, Sabirsh A, 
McCall E, Flavell L, Herbst R, Provoost S, Lambrecht BN, Joos GF, Brusselle GG, Bracke KR. Role of B Cell-
Activating Factor in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192: 706-
718. 323 
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ABSTRACT 
Rationale: B cell–activating factor (BAFF) plays a major role in activation of B cells and in adaptive humoral 
immune responses. In chronic obstructive pulmonary disease (COPD), lymphoid follicles have been 
associated with disease severity, and overexpression of BAFF has been demonstrated within lymphoid 
follicles of patients with severe COPD. 
Objectives: To investigate expression and localization of BAFF in the lungs of patients with COPD and to 
study the role of BAFF in COPD by antagonizing BAFF in a mouse model of chronic cigarette smoke (CS) 
exposure. 
Methods: We quantified and localized BAFF expression in lungs of never-smokers, smokers without COPD, 
and patients with COPD and in lungs of air- or CS-exposed mice by reverse-transcriptase polymerase chain 
reaction, ELISA, immunohistochemistry, and confocal imaging. Next, to investigate the role of BAFF in 
COPD, we antagonized BAFF by prophylactic or therapeutic administration of a soluble fusion protein of 
the BAFF-receptor, BAFFR-Fc, in mice exposed to air or CS for 24 weeks and evaluated several hallmarks 
of COPD and polarization of lung macrophages. 
Measurements and Main Results: BAFF expression was significantly increased in lungs of patients with 
COPD and CS-exposed mice. BAFF staining in lymphoid follicles was observed around B cells, CD4+ cells, 
dendritic cells, follicular dendritic cells, and fibroblastic reticular cells. Prophylactic and therapeutic 
administration of BAFFR-Fc in mice reduced pulmonary B-cell numbers and prevented CS-induced 
formation of lymphoid follicles and increases in immunoglobulin levels. Interestingly, prophylactic BAFFR-
Fc administration significantly attenuated pulmonary inflammation and destruction of alveolar walls. 
Moreover, antagonizing BAFF altered the phenotype of alveolar and interstitial macrophages. 
Conclusions: BAFF is significantly increased in lungs of patients with COPD and is present around both 
immune and stromal cells within lymphoid follicles. Antagonizing BAFF in CS-exposed mice attenuates 
pulmonary inflammation and alveolar destruction. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease, characterized by pulmonary 
inflammation, emphysema and obstructive bronchiolitis 4. In Western countries the main cause of COPD 
is cigarette smoking. However, even after smoking cessation, the disease persists and the underlying 
mechanisms need to be elucidated 4.  
Pulmonary inflammation in COPD is characterized by an innate immune response, alongside an important 
increase in adaptive immune cells 4. The innate immune response is thought to be primarily driven by 
recruited neutrophils as well as the most abundant resident cells in the lung, the alveolar and interstitial 
macrophages. Elevated numbers of CD4+ and CD8+ T lymphocytes and B lymphocytes have been observed 
in both large and peripheral airways of patients with COPD 51, 103, 240, 324. In addition, the presence of 
lymphoid follicles is significantly increased in patients with severe COPD 44. B cells are the major cell 
population in these follicles 44 and B cell proliferation within the germinal centers of the follicles has an 
oligoclonal, antigen-specific character 242. Importantly, the antigens responsible for the oligoclonal 
proliferation are not yet identified and could either have a microbial nature or could derive from smooth 
muscle, airway epithelium, pulmonary endothelium or degradation of extracellular matrix 242, 270, 325-327. As 
a result, the question remains whether these follicles are beneficial or harmful. In addition, the role of B 
lymphocytes in COPD remains unclear 206.  
B lymphocytes rely on B cell activating factor (BAFF) for maturation, differentiation and survival. This 
cytokine is a type II transmembrane homotrimer protein of the tumor necrosis factor (TNF) family and is 
expressed by innate immune cells, T cells, activated B cells, stromal cells and airway epithelium. Processed 
soluble BAFF is necessary for B cell homeostasis, but BAFF is also expressed as a membrane-bound protein. 
Three receptors have been described for BAFF, namely BAFF receptor (BAFFR), transmembrane activator 
and cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA). All three receptors are 
located on subsets of lymphocytes 218, 328.  
A significantly higher level of BAFF expression was measured in lymphoid follicles and macrophages of 
patients with COPD compared to control smokers and non-smokers 263. However, the role of BAFF in the 
pathogenesis of COPD is not yet clear. Therefore, we stained BAFF in lungs and lymphoid follicles of 
patients with COPD and co-stained for dendritic cells (DC), B cells, T cells, follicular DC and fibroblastic 
reticular cells. Next, we antagonized BAFF in chronic cigarette smoke-exposed mice and investigated the 
effect on B cells, the occurrence of lymphoid follicles and finally the impact on pulmonary inflammation 
and emphysema. Furthermore, since macrophages contribute to inflammation in the lung, we investigated 
whether BAFFR-Fc administration altered the lung inflammatory state through changes in the polarization 
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status of alveolar and interstitial macrophages. Some of the results of these studies have been previously 
reported in the form of an abstract 329. 
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METHODS 
More details of methods and materials can be found in the online supplement. 
Human study populations 
Written informed consent was obtained from all subjects according to protocols approved by the medical 
ethical committee of the Ghent University Hospital. All tissue originated from lung resection specimens of 
patients diagnosed with solitary pulmonary tumors at Ghent University. Tissue was harvested from the 
resection specimen at maximum distance of the pulmonary lesions by a pathologist. Only tissue without 
signs of pneumonia or tumor invasion was collected. Study populations of 70 and 69 subjects were used 
respectively for RT-PCR analysis on total lung tissue and protein detection in lung homogenates (Table 1 
and 2).  
 
 
 
Table 1: Characteristics of Study Subjects for Lung mRNA Analysis by Quantitative Real-Time Polymerase Chain 
Reactions 
Definition of abbreviations:  COPD = Chronic Obstructive Pulmonary Disease; ICS = inhaled corticosteroids; mRNA = 
messenger RNA; NA = not applicable  
Data are presented as median (IQR) 
# P<0.001, Fisher’s exact test  
† P<0.001 versus never-smokers, Mann-Whitney U test 
ç P<0.05 vs smokers, Mann-Whitney U test  
§ P<0.001 vs smokers, Mann-Whitney U test 
 
 
 
 
 
 
    Never-smokers Smokers COPD II 
Number  16 24 30 
Age (years) 64 (51-71) 65 (55-71) 65 (59-69) 
Gender (M/F) 3/13# 19/5# 29/1# 
Current-smoker/Ex-smoker NA 12/12# 17/13# 
Pack-years NA 33 (15-50)† 45 (40-60)†ç 
FEV1 (% predicted) 110 (92-118) 96 (92-113) 69 (64-74)†§ 
FEV1/FVC (%) 78 (75-83) 76 (73-78) 56 (53-60)†§ 
ICS (yes/no) 0/16# 1/23# 13/17# 
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 Never-smokers Smokers COPD II 
Number 19 18 32 
Age (years) 65 (51-71) 61 (52-68) 66 (59-73) 
Gender (m/f) 5/14# 13/5# 29/3# 
Current-smoker/Ex-smoker NA 17/1# 21/11# 
Pack-years 0 34 (22-46)† 44 (35-60)†ç  
FEV1 (% predicted) 110 (97-118) 95 (91-112) 73 (65-77) †§ 
FEV1/FVC (%) 80 (75-83) 76 (73-80) 56 (51-63) †§ 
ICS (yes/no) 0/19# 1/17# 15/17# 
 
Table 2: Characteristics of Study Subjects for Protein Analysis in Lung Homogenate by ELISA 
Definition of abbreviations:  COPD = Chronic Obstructive Pulmonary Disease; ICS = inhaled corticosteroids; mRNA = 
messenger RNA; NA = not applicable  
Data are presented as median (IQR) 
# P<0.001, Fisher’s exact test  
† P<0.001 versus never-smokers, Mann-Whitney U test 
ç P<0.05 vs smokers, Mann-Whitney U test  
§ P<0.001 vs smokers, Mann-Whitney U test 
 
Mice 
Male C57Bl/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME) at 6-8 weeks of age. 
The mice were kept under standard conditions with a 12h light-dark cycle and a standard diet (Pavan, 
Brussels, Belgium). Chlorinated tap water was provided at libitum. The local Ethics Committee for animal 
studies of the Faculty of Medicine and Health Sciences (Ghent University) approved all in vivo 
manipulations. 
Cigarette smoke exposure 
Mice were exposed to mainstream cigarette smoke (CS) as described previously 278. Four times a day, five 
days a week, mice were exposed whole body to the smoke of five cigarettes (Reference Cigarette 3R4F 
without filter, University of Kentucky, Lexington, KY). A smoke-free interval of 30 minutes was respected 
in between smoke exposures. The smoke/air ratio was 1/6. The control groups were exposed to room air. 
Antagonizing BAFF – study protocol 
Eight groups of 10 mice were exposed to air or CS for 24 weeks. Six groups of mice were treated twice 
weekly intraperitoneally (ip) with 200µl of either phosphate-buffered saline (PBS), mouse IgG1 isotype 
(clone IA7) (1 µg/µl) (MedImmune, Gaithersburg, MD, USA ) or BAFFR-Fc (1 µg/µl) (AstraZeneca, Alderley 
Park, UK) during the 24 weeks (i.e.prophylactic setup). In a therapeutic setup, two other groups received 
twice weekly ip treatment with either mouse IgG1 isotype or BAFFR-Fc from halfway through the CS 
exposure period, i.e. starting at week 13 of the CS exposure period. (Suppl. Fig. E1). The injections were 
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given 1 hour before air or CS exposure. The antagonizing agent, BAFFR-Fc, is a fusion protein that exists of 
the extracellular domain of mouse BAFFR, fused at the C-terminus to a linker peptide and the Fc-portion 
of human IgG1. 
We did not detect a meaningful difference between the PBS-treated and the isotype-treated control 
groups nor between the prophylactic and therapeutic isotype-treated groups. Therefore, for reasons of 
clarity, the PBS-treated groups and the therapeutic isotype-treated group will not be displayed.  
Quantification and detection of BAFF 
BAFF mRNA expression was measured in mice and human lung tissue using TaqMan Gene Expression 
Assays (Applied Biosystems, Foster City, CA) 330. Immunofluorescence staining was performed on frozen 
sections of human lung tissue of patients with COPD. These sections were stained with anti-BAFF (Abcam), 
anti-BAFFR (Abcam), anti-CD19, biotinylated anti-CD11c, biotinylated anti-CD68, anti-CD4, anti-CD8, anti-
Ki-M4 and anti-ERTR-7. Immunohistochemical staining was performed with anti-BAFF antibody (Abcam) 
on lung tissue of mice. The protein levels of BAFF in BAL fluid supernatant of mice and in homogenate of 
human lung tissue were determined with an ELISA kit (R&D systems).  
Quantification of lymphoid follicles and aggregates 
Paraffin-embedded sections of the left lung of mice were stained immunohistochemically with anti-CD3 
(DAKO) and anti-B220 (BD biosciences), as described previously 257. Dense accumulations of more than 50 
cells were counted as lymphoid follicles. Diffuse infiltrations of less than 50 cells were counted as lymphoid 
aggregates.  
Quantification of inflammation 
Flow cytometry (FACSCalibur, BD biosciences) was used to quantifiy the inflammatory cells in BAL fluid and 
lung tissue 253, 292, 293. The flow cytometry data of the BAL samples were supplemented with differential cell 
counts via cytospin. In BAL fluid and lung homogenate, the protein levels of cytokines and chemokines 
were determined with a cytometric bead array (BD biosciences, San Diego, CA) 279. Immunoglobulins were 
measured in BAL fluid and serum via commercially available ELISA kits (R&D systems). Reverse 
transcriptase-polymerase chain reaction (RT-PCR) with the Biomark System (Fluidigm, San Francisco, CA) 
was performed to establish the mRNA expression levels of 92 target genes.  
Quantitative image analysis of macrophage phenotypic markers 
Immunohistochemical staining with anti-F4/80, anti-iNOS and anti-SOCS3 antibody from Abcam, anti-
Arginase-1 antibody (Atlas Antibodies) and anti-CD163 antibody (Leica) was performed using an IntelliPath 
FLX automated staining machine. Computerized image analysis using Visiopharm Integrator System 
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software (version 4.6.3, Visiopharm, Horsholm, Denmark) was used. Results were expressed as area 
fractions.  
Quantification of emphysema 
Emphysema was measured by two complementary methods. By calculating the mean linear intercept 
(Lm), the enlargement of the alveolar airspaces was established 280. Destruction of the alveolar walls was 
quantified by determining the destructive index 246, 281.  
Statistical analysis 
The statistical analyses were calculated with Sigma Stat software (SPSS 21.0; Chicago, IL) using non-
parametric tests (Kruskall-Wallis, Mann-Whitney-U). All reported values are expressed as mean ± SEM and 
p-values < 0.05 were considered significant.  
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RESULTS 
Expression of BAFF in patients with COPD 
The mRNA levels of BAFF were quantified in lung tissue of 70 subjects and were significantly upregulated 
in patients with COPD and smokers without COPD compared to never smokers (Fig. 1A). In agreement with 
the mRNA expression, quantification of BAFF protein levels in lung homogenates of 69 subjects, revealed 
significantly higher BAFF protein in patients with COPD and smokers without COPD, compared to never 
smokers (Fig. 1B). No significant differences were observed between smokers with or without COPD, 
neither on the mRNA nor on the protein level (Fig. 1A-B). 
 
Figure 1: mRNA and protein 
levels of B cell activating factor. 
BAFF mRNA levels in total lung 
tissue of 16 never-smokers, 24 
smokers without airway 
obstruction and 30 patients with 
COPD GOLD stage II (A). mRNA 
expression levels in human lung 
tissue are relative to 7 reference 
genes (HPRT1, GAPDH, POP4, 
IPO8, PPIA, POLR2A, PSMC4).  
BAFF protein levels in lung 
homogenates of 19 never-
smokers, 18 smokers without 
airway obstruction and 32 
patients with COPD GOLD stage II, 
as measured by ELISA (B).   
BAFF mRNA levels in total lung 
tissue (C) and BAFF protein levels 
in bronchoalveolar lavage fluid 
(D) of mice exposed to 4 and 24 
weeks of air or cigarette smoke 
(CS). mRNA expression levels in 
mice are relative to 3 reference 
genes (Hprt1, Gapdh, Tfrc). 
Immunohistochemical staining of 
BAFF on lung tissue of mice 
exposed to 24 weeks of CS: (E) 
isotype control staining, (F-G) 
BAFF staining in lymphoid 
follicles, airway epithelium, 
endothelium, macrophages and 
alveolar walls.  
*p<0.05,  **p<0.01, ***p<0.001 
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Figure 2 : Confocal staining of B cell activating factor in pulmonary lymphoid follicles of patients with COPD 
Immunofluorescence staining of conventional dendritic cells (CD11c) (A), B cells (CD19) (B), B cell activating factor 
(BAFF) (C) and the merge of the stainings (D).  
Immunofluorescence staining of conventional dendritic cells (CD11c) (E), B cells (CD19) (F), BAFF receptor (BAFFR) 
(G) and the merge of the stainings (H). 
 Immunofluorescence staining of CD4+ cells (I), B cell activating factor (BAFF) (J) and the merge of the stainings 
(K). Immunofluorescence staining of CD8+ cells (L), B cell activating factor (BAFF) (M) and the merge of the 
stainings (N).  
(O) Immnuofluorescence staining of BAFF and follicular dendritic cells (identified using Ki-M4 as marker). (P) 
Immunofluorescence staining of BAFF and fibroblastic reticular cells (identified using ERTR7 as marker). 
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Confocal imaging of lung tissue of patients with COPD was performed to localize BAFF and BAFFR in 
lymphoid follicles. BAFF, B cells and conventional DC were co-stained in lymphoid follicles (Fig 2 A-D). 
Merged images showed that BAFF was present in the area closely surrounding DCs and parts of the B cell 
area. In a second immunofluorescence staining, BAFFR was co-stained with B cells and conventional DCs 
(Fig 2 E-H). These images showed that BAFFR was co-localized with B cells. Co-staining of BAFF with CD4 
or CD8 revealed BAFF staining in the vicinity of CD4+, but not CD8+ cells (Fig. 2I-N). Co-staining of BAFF with 
follicular dendritic cells (identified using Ki-M4 as marker) and fibroblastic reticular cells (identified using 
ER-TR7 as marker) showed that BAFF was present in the vicinity of these stromal cell types in lymphoid 
follicles of patients with COPD (Fig. 2O-P).  
 
Expression of BAFF in mice following cigarette smoke exposure 
Analysis of the pulmonary BAFF mRNA levels after 4 and 24 weeks of air or CS exposure did not reveal 
significant differences (Fig 1C). Four weeks of CS exposure induced a significant increase in BAFF protein 
levels in BAL fluid. This increase in BAFF protein was even more pronounced after 24 weeks of CS exposure 
(Fig 1D). The localization of the BAFF protein in lung tissue of mice was established by 
immunohistochemistry. In mice exposed to 24 weeks of CS, the lymphoid follicles, airway epithelium, 
smooth muscle cells, macrophages and neutrophils were positive for BAFF (Fig 1 E-G).  
 
Antagonizing BAFF reduces B cells in BAL, lung and mediastinal lymph nodes 
CS exposure induced an increase in the numbers of B cells in BAL, lung and mediastinal lymph nodes (MLN). 
To investigate the functional role of BAFF, we administered BAFFR-Fc to C57Bl/6 mice, either 
prophylactically (i.e. from the start of the CS exposure) or therapeutically (i.e. starting after 13 weeks of 
CS exposure) (Suppl. Fig. E1). Both prophylactic and therapeutic administration of BAFFR-Fc significantly 
reduced the number of B cells in all three compartments in air- and CS-exposed mice (Fig 3 A-C). In lung 
and MLN the B cell count was diminished to approximately a tenth of the number of B cells of the isotype-
treated control groups (Fig 3 B-C). In BAL the B cell population was decreased to a greater extent (Fig 3 A). 
Moreover, mRNA expression levels of CD19 and CXCR5, both highly expressed in B cells, were significantly 
reduced in all BAFFR-Fc-administered groups (Suppl Table E1).  
In addition, the mRNA transcript levels of BAFF, APRIL and their receptors BAFFR, TACI and BCMA (which 
are mainly expressed on B cells) were determined. CS exposure did not evoke a significant change in any 
of the transcript levels. On the other hand, BAFFR-Fc administration significantly decreased the transcript 
levels of APRIL, BAFFR, TACI and BCMA, but had no effect on the mRNA expression of BAFF (Fig. 3 D-H).  
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However, quantitative scoring of immunohistochemical staining revealed reduced levels of BAFF protein 
in the airway epithelium of prophylactic BAFFR-Fc-treated mice compared to isotype-treated mice (Suppl 
Fig. E2). Additionally, macrophages were scored semi-quantitatively for BAFF protein, but no differences 
were detected between groups (data not shown).  
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Figure 3: Antagonizing B cell activating factor reduces the number of B cells in bronchoalveolar lavage, lung and 
mediastinal lymph nodes.  
B cell numbers in bronchoalveolar lavage (BAL) (A),  lung (B) and mediastinal lymph nodes (MLN) (C).  
mRNA expression of BAFFR (gene name Tnfrsf13c) (D), TACI (gene name Tnfrsf13b) (E), BCMA (gene name Tnfrsf17) 
(F), BAFF (gene name Tnfsf13b) (G)  and APRIL (gene name Tnfsf13) (H)  in total lung tissue relative to 3 reference 
genes (Hprt1, Gapdh, Tfrc). 
*p<0.05, **p<0.01, ***p<0.001 
A B C 
D E F 
G H 
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Antagonizing BAFF prevents lymphoid follicle formation 
Upon CS exposure, lymphoid follicles, defined as large, dense infiltrations of more than 50 cells, were 
generated in the isotype-treated group, both peribronchial and in the lung parenchyma (Fig 4 A-B). 
Conversely, CS exposure did not induce the formation of lymphoid follicles in groups treated both 
prophylactic and therapeutic with BAFFR-Fc. CS exposure also elicited lymphoid aggregates, defined as 
small-numbered, diffuse lymphoid infiltrations, in the isotype-treated group. BAFFR-Fc administration 
minimized the occurrence of both peribronchial and parenchymal aggregates (Fig 4 C-D). Moreover, the 
CS-induced upregulation of CXCL13, a chemokine important for lymphoid follicle formation, was 
significantly decreased in the prophylactic BAFFR-Fc-treated, CS-exposed group (Suppl. Table E1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistent with the reduction in the number of B cells in BAL, lung and MLN, and the absence of lymphoid 
follicles, antagonizing BAFF resulted in significantly lower levels of immunoglobulins in BAL and serum (Fig: 
5 A-F). In BAL, IgA, IgG and IgM were reduced in the BAFFR-Fc-treated groups compared to the isotype-
Figure 4: Antagonizing B cell activating factor prevents formation of lymphoid follicles and diminishes the 
number of lymphoid aggregates.  
Quantification of peribronchial lymphoid follicles normalized for the number of airways (A) and parenchymal 
follicles normalized for the area of parenchyma (B),.  
Quantification of peribronchial aggregates normalized for the number of airways (C) and parenchymal 
aggregates normalized for the area of parenchyma (D). 
(E) Immunohistochemical staining of a pulmonary lymphoid follicle with anti-cd3 (brown) and anti-B220 
(blue)  **p<0.01, ***p<0.001 
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treated groups (Fig 5 A-C). Furthermore, in serum, IgG and IgM levels were decreased in all BAFFR-Fc-
treated groups, compared to the isotype-treated groups (Fig. 5 D-F). 
 
 
 
 
 
 
Antagonizing BAFF attenuates the immune response in BAL and lung 
In BAL, CS exposure induced an increase in total cell count, macrophages, neutrophils, DC and lymphocytes 
in the isotype-treated group (Fig. 6). Prophylactic BAFFR-Fc administration significantly attenuated the CS-
induced increase in total cells, macrophages, neutrophils and DC (Fig. 6 A-D), and tended to attenuate the 
increase in T lymphocytes (Fig. 6 E-G). Therapeutic BAFFR-Fc administration did not affect the CS-induced 
inflammation in BAL (Fig. 6 A-G).  
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Figure 5: Immunoglobulins in bronchoalveolar lavage and serum.  
Immunoglobulin (Ig) levels in bronchoalveolar lavage (BAL): IgA(A), IgG (B)  and IgM. (C)  Immunoglobulin (Ig) 
levels in serum: IgA(D), IgG (E)  and IgM (F). 
*p<0.05, **p<0.01, ***p<0.001 
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Protein levels of chemokines and cytokines were measured in BAL supernatant. CS exposure induced an 
increase in KC, RANTES, MCP-1, TNF, IL-6, IFNγ and IL-17A in both isotype-treated and BAFFR-Fc-treated 
groups (Suppl. Table E2). However, no significant differences were detected between the CS-exposed 
groups.  
In lung, CS exposure induced a significant increase in the number of DC, CD3+ T cells, CD4+CD69+ T cells, 
CD8+CD69+ Tcells and regulatory T cells (Tregs) in the isotype-treated group. Prophylactic BAFFR-Fc 
administration significantly attenuated the CS-induced increase in DCs, CD4+CD69+ T cells and Tregs, but 
not in CD8+CD69+ T cells (Fig. 7 A-E).  
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Figure 6: Prophylactic administration of BAFFR-Fc attenuates the immune response in bronchoalveolar lavage of 
chronic cigarette smoke-exposed mice.  
Quantification of total bronchoalveolar lavage (BAL) cells (A), BAL macrophages (B), BAL neutrophils (C), BAL 
dendritic cells (D), BALT cells (E), BAL CD4+ T cells (F) and BAL CD8+ T cells (G).  
*p<0.05, **p<0.01, ***p<0.001 
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D E F 
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mRNA expression analysis of 92 target genes on total lung tissue revealed primarily a downregulation of B 
cell-associated genes in BAFFR-Fc-treated groups, as well as a significant reduction in CTLA4 and IL-12a 
mRNA levels (Suppl. Table E1).  
In addition, protein levels of chemokines and cytokines were measured in lung homogenates. CS exposure 
induced an increase in KC, MCP-1, MIG, GM-CSF, TNF, IFNγ, IL-17A, IL-4 and IL-10 in the isotype-treated 
group (Suppl. Table E3). The CS-induced increase in GM-CSF protein levels was significantly attenuated in 
groups treated prophylactically and therapeutically with BAFFR-Fc (Suppl. Table E3).  
 
Antagonizing BAFF alters the macrophage phenotype in the lung 
In lungs of patients with COPD, CD68-positive macrophages were detected in and around lymphoid follicles 
(Fig 8 A-B). In accordance, F4/80-positive macrophages were localized in lymphoid follicles of mice exposed 
to 24 weeks of CS (Fig. 8 C).  
In order to determine the macrophage phenotype, cross-sections of the left lung of mice were stained 
with anti-F4/80, anti-iNOS, anti-SOCS3, anti-CD163 and anti-Arginase-1 antibodies. Alveolar and interstitial 
macrophages stained equally positive for the pan-macrophage marker F4/80. Interestingly, alveolar 
Figure 7: Prophylactic administration of BAFFR-Fc results in a decreased number of dendritic cells and  altered 
T cell response in lungs of cigarette smoke-exposed mice. 
Quantification of lung dendritic cells (A), lung T cells (B), lung CD4+CD69+ T cells (C), lung CD8+CD69+ T cells (D) 
and lung regulatory T cells (E).  
*p<0.05, **p<0.01, ***p<0.001 
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macrophages stained more positive for SOCS3, a marker of M(IFNγ)-like phenotype, compared to 
interstitial macrophages. In contrast, compared to alveolar macrophages, interstitial macrophages stained 
stronger for Arginase-1 and CD163, both markers of a M(IL-4)-like phenotype (Fig. 8 D-M). 
 
In murine lung, CS induced a significant increase in F4/80-positive alveolar and interstitial macrophages, 
as well as a significant increase in the number of macrophages positive for the phenotypic markers iNOS 
and CD163 (Fig. 8 D-M). Antagonizing BAFF did not influence the numbers of F4/80-positive macrophages. 
However, prophylactic administration of BAFFR-Fc significantly enhanced the CS-induced increase of iNOS-
positive alveolar macrophages. In contrast, both prophylactic and therapeutic administration of BAFFR-Fc 
significantly attenuated the CS-induced increase of CD163-positive interstitial macrophages (Fig. 8 D-M). 
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Antagonizing BAFF partially protects mice against alveolar wall destruction  
Emphysema was determined by two complementary methods. The mean linear intercept (Lm) was 
determined in order to quantify alveolar airspace enlargement. Although the Lm was numerically 
increased upon CS exposure, no significant changes were observed between the study groups (Fig 9 A). 
Destruction of alveolar walls was quantified using the destructive index (DI). CS exposure significantly 
increased the alveolar wall destruction in isotype- and BAFFR-Fc-treated groups. However, prophylactic 
BAFFR-Fc administration significantly attenuated the CS-induced destruction of alveolar walls (Fig 9 B).  
 
 
 
 
 
 
 
 
 
Figure 8: Macrophage staining in lymphoid follicles in lung tissue of patients with COPD and murine lung and 
the effect of BAFFR-Fc administration on macrophage phenotype. 
A: Immunohistochemical staining of CD68-positive macrophages in lymphoid follicles in lung tissue of patients 
with COPD. B: Immunofluorecence staining of CD68-positive macrophages in and around lymphoid follicles of 
patients with COPD. C: Immunohistochemical staining of F4/80-positive macrophages in  lymphoid follicles in 
lung tissue of CS-exposed mice. D: Immunohistochemical staining of F4/80-positive macrophages in lung tissue 
of CS-exposed mice. E: Quantification of F4/80-positive area fraction of alveolar (AM) and interstitial (IM) 
macrophages. F: Immunohistochemical staining of iNOS-positive macrophages in lung tissue of CS-exposed mice. 
G: Quantification of iNOS-positive area fraction of alveolar and interstitial macrophages. H: 
Immunohistochemical staining of SOCS3-positive macrophages in lung tissue of CS-exposed mice. I: 
Quantification of SOCS3-positive area fraction of alveolar and interstitial macrophages. J: Immunohistochemical 
staining of Arginase-1-positive macrophages in lung tissue of CS-exposed mice. K: Quantification of Arginase-1-
positive area fraction of alveolar and interstitial macrophages. L: Immunohistochemical staining of CD163-
positive macrophages in lung tissue of CS-exposed mice. M: Quantification of CD163-positive area fraction of 
alveolar and interstitial macrophages. *p<0.05, **p<0.01 
 
 
Figure 9: Prophylactic BAFFR-Fc administration reduces CS-induced alveolar wall destruction.  
A: Mean linear intercept (Lm), B: Destructive index (DI). 
Representative images of the parenchyma of isotype-treated, air-exposed mice (C), isotype-treated cigarette 
smoke-exposed (CS) mice (D), BAFFR-Fc-treated, air-exposed mice (E), prophylactic BAFFR-Fc-treated CS-exposed 
mice (F), and therapeutic BAFFR-Fc-treated, CS-exposed mice (G). *p<0.05, **p<0.01, ***p<0.001 
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DISCUSSION 
In this translational study, we demonstrate elevated BAFF mRNA and protein levels in lung tissue of 
patients with COPD. Furthermore, confocal imaging illustrates that BAFF is present in the vicinity of both 
immune and stromal cells in lymphoid follicles of patients with COPD. In addition, immunohistochemical 
staining of the lung tissue illustrates that macrophages are present in and around lymphoid follicles. 
Experimentally, antagonizing BAFF in chronic CS-exposed mice dramatically reduced the number of B cells 
and immunoglobulin levels and completely prevented the formation of lymphoid follicles. Importantly, 
prophylactic inhibition of BAFF reduced the CS-induced inflammatory response in BAL fluid and lung tissue, 
reduced the expression of macrophage phenotypic markers and attenuated the CS-induced alveolar wall 
destruction. 
B cell activating factor (BAFF) was discovered in 1999 as a key factor in B cell homeostasis. Soon thereafter, 
its role in autoimmunity became clear and recently the role of BAFF in several other diseases, such as 
infection, allergy and hematological and lymphoid cancers, has been described 224. Several reasons warrant 
an investigation into the role of BAFF in COPD. First, B cell numbers are increased in patients with COPD 
240. Second, an increased number of ectopic lymphoid follicles consisting mainly of B cells, has been 
described in patients with severe COPD 44, 242. And finally, the possibility has been raised that an 
autoimmune component contributes to the pathogenesis of COPD 206, 242, 270, 325-327. 
Previously, Polverino et al. reported higher protein levels of BAFF in lungs of patients with COPD compared 
to never smokers 263. We confirmed this finding in our study population both at mRNA and protein level. 
Interestingly, BAFF mRNA and protein levels were already elevated in smokers without airflow limitation. 
It should be noted that the gender distribution of our never-smoker and smoker populations are skewed 
towards respectively a female and male predominance. Immunofluorescence staining and confocal 
imaging illustrate that BAFF is present in pulmonary lymphoid follicles of patients with COPD, more 
specifically in the vicinity of B cells, CD4+ cells, conventional dendritic cells, follicular dendritic cells and 
fibroblastic reticular cells. However, since BAFF appears mainly as a soluble protein 218, we cannot be 
absolutely certain that these cells actually produce BAFF. Nevertheless, this is the first time BAFF has been 
localized in the close surroundings of stromal cells of lymphoid follicles in lungs of patients with COPD, 
indicating that, once a follicle is organized, a micro-environment is created in which B cell maturation and 
survival is promoted.  
In mice, antagonizing BAFF with a soluble BAFFR-Fc complex resulted in a strong reduction in the number 
of B cells. This is in line with the fact that BAFF is a necessary survival factor for all mature B cell subsets 
except memory B cells and a fraction of the B1 B cells 218, 331-333. Since B1 B cells are confined to specific 
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anatomic sites 333, we suggest that the few B cells that are still present in lungs and mediastinal lymph 
nodes after BAFFR-Fc administration, are memory B cells. As a consequence of the reduction in B cell 
numbers, the mRNA expression levels of all 3 BAFF receptors are significantly decreased since these 
receptors are mainly located on B cells. BAFFR-Fc administration also resulted in a downregulation of APRIL 
mRNA expression levels but did not influence the mRNA expression levels of BAFF. In all BAFFR-Fc-treated 
groups, the absence of B cells and lymphoid follicles resulted in significantly reduced levels of 
immunoglobulins, both in BAL fluid and in serum. Although lower immunoglobulin levels suggest an 
increased susceptibility to infections, this has not been detected in the phase III clinical trials of 
belimumab, a human monoclonal antibody against BAFF registered for treatment of systemic lupus 
erythematosus 334, 335. However, the immunoglobulin levels were more severely decreased in our BAFFR-
Fc-treated mice compared to the decrease in immunoglobulins reported in the clinical trials 334.  
Next to the effect on B cells, BAFFR-Fc administration led to an attenuation of the CS-induced inflammatory 
response in BAL fluid and lung tissue. Especially in BAL, the inflammatory cell count was severely reduced 
after prophylactic BAFFR-Fc administration.  
In recent years, it has become clear that the function of BAFF is not limited to B cell homeostasis but 
extends to influencing both adaptive and innate immunity 224, 230, 231. It is suggested that BAFF stimulates 
DCs in order to attract immune cells to sites of inflammation 336. In our experiment, antagonizing BAFF 
resulted in decreased numbers of DCs following CS exposure, both in BAL and lung. It has also been 
described that BAFF stimulates monocyte survival and differentiation into a macrophage phenotype 231. 
Prophylactic administration of BAFFR-Fc in CS exposed mice, decreased the numbers of macrophages in 
BAL, but not in lung, and reduced the levels of GM-CSF in lung homogenates. Macrophages play a central 
role in the pathogenesis of COPD 337. We have demonstrated that macrophages are present in and around 
lymphoid follicles in lungs of patients with COPD, underlining their ubiquitous presence in the lung. In 
order to investigate their function in COPD, several studies have reported on the phenotype of 
macrophages in the disease. However, the reports are ambiguous 96, 338, 339. In the murine lung, we have 
observed that both alveolar and interstitial macrophages express F4/80 to the same extent. In contrast, 
alveolar macrophages express more SOCS3, a marker of a pro-inflammatory (M1) macrophage phenotype, 
whereas interstitial macrophages express substantially more CD163 and Arginase-1, both markers of an 
immunoregulatory (M2) macrophage phenotype. This difference in expression pattern may relate to 
differences in location and function of the two types of tissue-resident macrophages 340. Exposing mice to 
CS resulted in higher numbers of F4/80-, iNOS-, CD163- and Arginase-1-positive macrophages. 
Interestingly, administration of BAFFR-Fc enhanced the CS-induced increase in iNOS-positive alveolar 
 124  
macrophages, while it almost completely prevented the CS-induced increase in CD163- positive interstitial 
macrophages. 
Several studies have explored the effect of BAFF on T cell function. Sutherland et al. observed that BAFF 
favors Th1 responses and suppresses Th2 responses 230. In addition, BAFF promotes Th17 and regulatory 
T cells 229, 341. Although we did not determine the different T helper subsets, we did measure significantly 
fewer CD4+CD69+ T cells and regulatory T cells in the prophylactically BAFFR-Fc administered group 
following CS exposure. However, since BAFF exerts some of its effects on inflammation via a B cell 
dependent mechanism 229, 341, it is difficult to distinguish between the direct effects of BAFF and the effects 
of B cell depletion.  
In our experiment, CS-induced destruction of alveolar walls was significantly attenuated by prophylactic 
BAFFR-Fc administration. This was consistent with lower numbers of macrophages and neutrophils in BAL, 
two cell types that produce proteolytic enzymes. Importantly, the development of emphysema in C57BL/6 
mice is rather mild, suggesting that the early stages of COPD have been evaluated in this experiment. This 
is different from human COPD, where accumulation of lymphoid follicles is observed in more severe stages 
of the disease. 
Recently, it has been shown that B cell deficient mice are completely protected against CS-induced 
emphysema 276. Previously, we demonstrated that neutralization of CXCL13 in chronic CS-exposed mice 
resulted in the absence of lymphoid follicles without a significant reduction of B cell numbers in the lung. 
As demonstrated here, BAFF neutralization not only eliminated tertiary follicles, but also led to a significant 
reduction in B cell numbers in the lung. Interestingly, anti-CXCL13 treatment attenuated the CS-induced 
alveolar wall destruction, similar to what we observed with BAFF neutralization. Together, the data 
indicate that organized B cell lymphoid follicles, rather than the mere presence of B cells in lung tissue, 
contribute to the development of emphysema. As follicles are required for an efficient humoral response 
this suggests that (auto)antibodies, locally produced in the lungs of CS exposed mice, might contribute to 
alveolar wall destruction. Our observation that both BAFF and CXCL13 neutralization resulted in significant 
reductions in immunoglobulins, locally and systemically, may further support this notion. 
In conclusion, we have demonstrated that BAFF mRNA and protein levels are increased in patients with 
COPD. We also illustrated that BAFF is present in lymphoid follicles of patients with COPD, in the vicinity 
of B cells, CD4+ cells, dendritic cells, follicular dendritic cells and fibroblastic reticular cells, suggesting that 
organized lymphoid follicles are niches in which B cell maturation and survival is promoted. By 
antagonizing BAFF with BAFFR-Fc in CS-exposed mice, we have demonstrated that the immune response 
to CS exposure is attenuated in absence of BAFF. Furthermore, the phenotype of pulmonary macrophages 
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is altered after BAFFR-Fc administration. Importantly, antagonizing BAFF partially protects against 
destruction of lung parenchyma. These novel findings may influence future therapeutic strategies for 
COPD. 
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PART II 
 
CHAPTER 10: DISCUSSION AND FUTURE PERSPECTIVES 
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In this translational research work, the mucosal immune response to cigarette smoke is the central theme. 
We have studied the innate defense response by investigating the effect of mucociliary dysfunction on 
cigarette smoke-induced pathology in a murine model of COPD. Next, we studied the effect of chronic 
bronchitis on clinical manifestations of COPD in a large population-based cohort.  
Whereas the mucociliary clearance system is the first line of defense against inhaled noxious stimuli, the 
adaptive immune response steps in later in mucosal immunity. This adaptive response is quite extensive 
with the formation of B cell-rich lymphoid follicles which are predominantly formed peri-bronchially. A 
thought to consider is the possibility that lack of adequate innate immune defense leads to an exaggerated 
adaptive immune response. In this research, we aimed to investigate the role of the lymphoid follicles by 
antagonizing B cell activating factor (BAFF).  
 
10.1  ROLE OF MUCUS DYSFUNCTION IN COPD 
 
10.1.1  AIRWAY SURFACE DEHYDRATION AGGRAVATES CIGARETTE SMOKE-INDUCED HALLMARKS OF COPD 
 
Mucociliary dysfuntion is evident in individuals with chronic bronchitis, a feature that is highly prevalent 
in subjects with COPD 124. Furthermore, unrelated to the presence of chronic bronchitis, mucus obstruction 
of small airways is cardinal in the pathogenesis of COPD 44. In recent years, the concept of mucociliary 
structure, function and physicochemical properties has changed dramatically. It has become clear that 
adequate hydration of the airway surface liquid, regulated by ion channels, is crucial to maintain the 
function of this defense mechanism 123. In patients with COPD, Bodas et al. showed that CFTR (cystic 
fibrosis transmembrane conductance regulator; a Cl- channel) protein expression correlates with lung 
function and inversely correlates with disease severity 342. Zhao et al. confirmed these results and 
additionally showed that the expression of ENaC – the Na+ channel - is associated with disease severity 170. 
Although these studies imply a functional role for airway surface dehydration in cigarette smoke-induced 
pathology, this has not been investigated in vivo.  
To examine whether airway surface dehydration contributes to the development and progression of 
COPD, we exposed βENaC-Tg mice and their wild-type littermates to cigarette smoke. As described by 
Livraghi et al. and Mall et al., we observed airway inflammation, increased numbers of goblet cells, 
elevated mucin expression and distal airspace enlargement in air-exposed βENaC-Tg mice, adding to the 
notion that mucus stasis is sufficient to trigger inflammation 177, 343. The synergistic effect of airway surface 
dehydration and CS exposure, resulted in significantly higher numbers of macrophages, neutrophils and 
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lymphocytes, especially CD8+ T cells, in βENaC-Tg mice compared to their wild-type littermates. Gehrig et 
al. found that neutrophil elastase plays an important role in the development of the airway inflammation, 
mucin expression and emphysema present in βENaC-Tg mice 304.  
Of note, accumulations of lymphocytes were detected in βENaC-Tg mice after 8 weeks of CS exposure and 
have not been detected in wild-type mice after such a relative short exposure period. This suggests that 
the lack of mucociliary clearance (innate defense) might contribute to the initiation of lymphoid follicles. 
This might be through an increased susceptibility to infections or through the aggravated airway 
inflammation which leads to a higher amount of proteases, reactive oxygen intermediates and other 
products of inflammatory cells that break down lung tissue. This enhanced destruction of lung parenchyma 
may promote the  formation of neo- or self-antigens. 
In βENaC-Tg mice, an increased number of goblet cells was reported previously and is confirmed in our 
study 176-178. Although CS exposure did not induce a further increase of the number of goblet cells, we 
consistently measured a significant CS-induced upregulation of Muc5ac in βENaC-Tg mice but not in wild-
type littermates, coinciding with the observation that Muc5ac rapidly responds to injurious substances 288. 
Moderate mucin hypersecretion alone will probably not induce mucociliary dysfunction, since Muc5ac 
overexpressing mice do not exhibit mucus plugging 299. However, severe hypersecretion or mucin 
hypersecretion in combination with ion channel impairment will result in a hyperconcentrated mucus 
layer, because mucins are stored intracellular in dehydrated form and expand enormously by binding H2O 
once secreted 123, 138, 158, 344. Hyperconcentrated mucus increases the osmotic pressure, resulting in mucus 
stasis and ultimately adhesion, which predisposes for bacterial infections 125, 344. 
Alongside mucociliary dysfuntion and airway inflammation, βENaC-Tg mice develop severe emphysema, 
illustrated in our study by a substantial difference in mean linear intercept and in static and dynamic 
compliance between transgenic and wild-type mice. As in patients with COPD, MMP12 and neutrophil 
elastase play key roles in the development of emphysema 300, 304. Mean linear intercept did not increase 
significantly following CS exposure, which might be due to the severity of the constitutive emphysema. 
However, the destructive index, a measure for the degree of alveolar destruction, did significantly increase 
after subacute CS exposure in βENaC-Tg mice whereas no effect was detected in wild-type mice, indicating 
that in the presence of airway surface dehydration, CS exposure induces accelerated development of 
emphysema.  
Exposing βENaC-Tg mice to CS allowed us to study the effect of airway surface dehydration in vivo, 
however, this model does include some limitations. Recently, it has become clear that interactions 
between host and microbiome can steer the inflammatory response 117. It is likely that the presence of 
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airway surface dehydration induces alterations in the composition of the microbiome, which might 
influence the outcome 123, 295. Next, recent papers show that acidification of airway surface liquid 
diminishes bacterial killing 139, 345. Since CS in itself is already quite acidic, it might contribute to the 
acidification created by the loss of HCO3- secretion as a consequence of CFTR dysfunction in cigarette 
smokers 346. In this model, airway surface dehydration is achieved by Na+ hyperabsorption and does not 
alter Cl- secretion by CFTR and hence, presumably not the HCO3- secretion, excluding the possibility to 
research this feature in these mice.  
In conclusion, CS exposure of βENaC-Tg mice results in significantly increased neutrophilic airway 
inflammation, mucin expression and alveolar destruction, indicating that airway surface dehydration 
contributes to the development and progression of COPD.  
 
10.1.2  EPIDEMIOLOGY OF CHRONIC BRONCHITIS IN COPD 
 
Chronic bronchitis, defined as chronic cough and sputum production for at least 3 months per year for 2 
consecutive years, is highly prevalent in patients with COPD and to a lesser extend in the general public 
147, 182. Several different definitions have been used, explaining the variability in reported prevalence in 
part. However, whether the classic definition - as stated above -  is used or the less stringent definition of 
‘chronic phlegm for at least 3 months per year for 2 consecutive years’, the effect of chronic bronchitis on 
clinically important outcomes is similar both in our study and in the PLATINO study 183. 
In the Rotterdam Study, COPD subjects with chronic bronchitis were more frequently current smokers, 
smoked more pack-years, had a worse quality of life and importantly experienced an accelerated lung 
function decline. These results corroborate outcomes obtained in other studies, although there is debate 
concerning the effect on lung function decline 182, 183, 185, 187, 195. Furthermore, in our study, the presence of 
chronic bronchitis is also associated with the number of moderate and severe exacerbations per year.  
Chronic bronchitis is the result of chronic mucociliary dysfunction, which is associated with bacterial 
infections 125, 295. An increased vulnerability for pulmonary infections, has also been demonstrated in 
epidemiological studies 191. In healthy mucociliary clearance, bacteria interact with carbohydrates of 
mucins and are subsequently transported towards the pharynx. The adherence of mucus implies that 
bacteria are not eliminated and thus chronic bacterial infection is favored 295. In addition, acidification of 
airway surface liquid, due to lack of HCO3- secretion or due to the acidic nature of cigarette smoke itself, 
impairs bacterial killing 346. This may explain why subjects with COPD and concomitant chronic bronchitis 
are more at risk for experiencing COPD exacerbations, since the majority of exacerbations are caused by 
infections 315, 316. However, chronic bronchitis is often not a stable feature and the majority of subjects with 
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chronic bronchitis seem to follow a remitting-relapsing course 314. This implies that cross-sectional studies 
or studies with a short follow-up period might not detect associations 347. The Rotterdam Study allowed 
us to measure exacerbation rate during a long follow-up period, resulting in the observation that COPD 
subjects with chronic bronchitis have an increased risk for being a frequent exacerbator.  
In the Rotterdam Study, we detected that especially women with COPD and chronic bronchitis have an 
increased mortality risk. Stratifying for the cause of death revealed that in the presence of chronic 
bronchitis, subjects with COPD died more frequently due to pulmonary related causes compared to COPD 
subjects without chronic bronchitis. This might explain the increased mortality risk in women detected 
here, since it has been observed before that women are more vulnerable for COPD-related death and 
hospitalizations due to pulmonary infections 187, 318. 
In conclusion, in the Rotterdam Study, a large prospective, population-based cohort study, we have shown 
that subjects with COPD and concomitant chronic bronchitis have an increased risk for accelerated lung 
function decline, COPD exacerbations and for being a frequent exacerbator. Furthermore, in the presence 
of chronic bronchitis, subjects with COPD have an increased risk of mortality and importantly, women with 
COPD and chronic bronchitis have a higher mortality risk than men with COPD and chronic bronchitis.  
 
10.1.3  MUCOCILIARY DYSFUNCTION: FUTURE PERSPECTIVES 
 
Currently, there is not a satisfying therapy available to treat chronic bronchitis symptoms. Several attempts 
have been made to increase mucociliary function resulting in, at best, partial improvement of the 
symptoms. A thorough knowledge of the contributing factors can aid in the search for new therapeutic 
options. Therefore, it would be interesting to unravel the contribution of airway surface liquid acidification 
to cigarette smoke-induced chronic bronchitis. In COPD patients with chronic bronchitis, the vulnerability 
to bacterial infections could potentially be explained by the decreased activity of antimicrobials in the 
presence of an acidic pH 348. Reduced pH has been measured in exhaled breath condensate of patients 
with COPD 349. Interestingly, ex-smokers with COPD had lower pH values in exhaled breath condensates 
than current smokers with COPD 350. Of note, recently it was shown that administration of resolvin D1, a 
specialized proresolvin lipid mediator, reduced chronic inflammation and emphysema in cigarette smoke-
exposed mice 351. However, mice are less vulnerable to acidification due to lack of H+/K+ adenosine 
triphosphatase which is present in human airway epithelial cells 139. With proper correction for acidic pH, 
these naturally occurring lipid mediators could be a candidate for a new therapeutic option.  
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Another interesting line of inquiry is the expression and function of Short Palate Lung and Nasal epithelial 
Clone 1 (SPLUNC1) in patients with COPD. SPLUNC1 is thought to be a soluble volume sensor that regulates 
the airway surface liquid hydration by inhibiting ENaC. SPLUNC1’s capacity to negatively regulate ENaC is 
pH-sensitive; pH ≤ 6.5 inactivates SPLUNC1 124. Cleavage of SPLUNC1 results in a peptide, S18, that can 
inactivate ENaC in a pH-independent manner, and is therefore currently considered a molecule of interest 
in cystic fibrosis 352.  
Whether or not chronic bronchitis is a pre-stage of COPD for a subgroup of patients is currently extensively 
discussed. Earlier this year, two papers were published describing the importance of chronic bronchitis in 
subjects without COPD. Allinson et al. analyzed data from the Medical Research Council National Survey 
of Health and Development and found that chronic mucus hypersecretion in smokers between 36 and 43 
years old predisposes for the development of COPD. The longer the mucus hypersecretion was present 
over 20 years, the greater the impact on lung function decline 314. In addition, Woodruff et al. observed 
that smokers with respiratory symptoms but without airflow limitation are more vulnerable for respiratory 
exacerbations and experience more physical limitations than asymptomatic smokers, underlining the 
impact of respiratory symptoms 353. Considering that middle-aged symptomatic (ex-)smokers without 
COPD represent a population which has been excluded from clinical COPD trials, it would be interesting to 
study the impact of chronic bronchitis in subjects without COPD and determine the impact on several 
clinically important outcomes such as risk for developing COPD, risk for hospitalization, medication use, 
risk for cardiovascular disease, mortality… in the Rotterdam Study.  
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10.2  B CELL RICH LYMPHOID FOLLICLES IN COPD 
 
10.2.1  ROLE OF B CELL-ACTIVATING FACTOR IN COPD 
 
Along with disease severity, an increased number of B cells and lymphoid follicles are observed in lungs of 
patients with COPD 44. Although the demonstration of oligoclonality in the follicular B cells suggests a local 
antigen-specific immune response, the role of these lymphoid follicles in COPD is still controversial, 
especially since it is not known which antigens are involved 206, 242. Different options come to mind why 
these lymphoid follicles are generated. In a first scenario, these lymphoid follicles are formed in reaction 
to infections. Lymphoid follicles are predominantly observed in patients with severe and very severe COPD 
and these patients also experience significantly more acute exacerbations than patients with mild-to-
moderate COPD 189. As discussed before, the majority of exacerbations are infectious by nature 188. In 
addition, lymphoid follicles in COPD patients can be a response to the altered microbiome or chronic 
infection in the lung. The lung microbiome of COPD patients is significantly different from that of control 
patients 117. A recent murine study showed that host-microbiome crosstalk favored lymphoid neogenesis 
109. Furthermore, chronic pulmonary infection might predispose for  acute exacerbations. Another option 
is that lymphoid follicles are generated as part of an autoimmune response. Several different auto-
antibodies have been described 206, 271, 354. In addition, an increasing number of studies suggest a crucial 
role for IL-17A,  a cytokine implicated in autoimmunity, in CS-induced pathology 108, 109, 355. A final 
alternative that cannot be excluded as long as the inducing antigens are not identified and confirmed, is 
that the options stated here, might all be valid. Baraldo et al. reported both oligoclonal and polyclonal Ig 
rearrangements 249. Moreover, since oligoclonality has only been investigated in small numbers of 
patients, it is far from certain that all COPD patients generate lymphoid follicles against the same type of 
antigen 242, 249. In patients with (very) severe COPD, the immune system has been overstimulated for 
decades and is perhaps primed to easily form lymphoid follicles. Immune cell-stromal cell interactions 
might be important is this respect. 
In two consecutive experiments, we have attempted to elucidate the functional role of lymphoid follicles 
in COPD by interrupting their formation. In a first experiment, we prevented lymphoid follicle formation 
by administering anti-CXCL13 to CS-exposed mice. Prophylactic administration, i.e. from the start of the 
CS exposure, attenuated CS-induced airway inflammation and alveolar destruction. Although the 
intervention with anti-CXCL13 prevented the formation of organized follicles, B cell aggregates were still 
present 246.  Next, we antagonized BAFF by administration of soluble BAFFR-Fc in chronic cigarette smoke-
exposed mice. This intervention resulted in almost complete loss of B cells in BAL, lung and mediastinal 
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lymph nodes, thus preventing the formation of lymphoid follicles and aggregates. As a consequence, 
immunoglobulin levels in BAL and serum were significantly decreased. Prophylactic administration of 
BAFFR-Fc, significantly attenuated airway and pulmonary inflammation, to a greater extent than anti-
CXCL13 treatment. Furthermore, as did prophylactic anti-CXCL13 treatment, prophylactic administration 
of BAFFR-Fc partially protected CS-exposed mice against alveolar wall destruction. This indicates that 
organized lymphoid follicles, rather than the mere presence of B-cells, contribute to the development of 
emphysema.  
The importance of lymphoid follicles in the development and progression of emphysema is recently 
substantiated by the recent network analysis of lung transcriptomics that identified a B cell signature and 
lymphoid follicle formation in COPD patients with emphysema but not in those with obstructive 
bronchiolitis 250.  In addition, the 3D reconstructions of Mori et al. show that the majority of lymphoid 
follicles are in contact with alveolar epithelium and a vast lymphatic vessel network 243. Moreover, B cell-
deficient mice which lack lymphoid follicles, are completely protected against CS-induced development of 
emphysema 276. All together, these observations suggest that the antigens inducing lymphoid follicle 
formation in COPD are likely sampled from within the alveoli and not only from within the airways. 
Although this does not pin down the identity of the responsible antigens, it narrows down the search and 
might contribute to determine whether these lymphoid follicles are protective or harmful in the 
pathogenesis of COPD. Of note, the lack of protection against the development of emphysema by 
therapeutic administration of anti-CXCL13 or BAFFR-Fc, i.e. administration that starts after 3 months of CS 
exposure, supports the idea that immunoglobulins contribute to the development of emphysema. In mice, 
the presence of lymphoid follicles after only 3 months of CS exposure is uncommon; however, 
immunoglobulins against alveolar antigens may be generated in lung-draining lymph nodes.  
In contrast to prophylactic administration of BAFFR-Fc, therapeutic administration did not have an effect 
on CS-induced inflammation, although B cells and lymphoid follicles were absent and immunoglobulin 
levels were decreased to the same level as in the prophylactic setting. This discrepancy suggests that 
during the first 3 months of CS exposure, B cells and/or immunoglobulins play an active role in CS-induced 
pathology. It has been repeatedly described that B cells modulate inflammatory responses in their capacity 
of cytokine-secreting and antigen-presenting cells 273-277. To a lesser extent than dendritic cells, B cells also 
carry antigen to the lung-draining lymph nodes 356. Additionally, in the first 3 months of CS exposure, BAFF 
could have affected the immune response. BAFF is known to promote monocyte survival, dendritic cell 
activation and skew the T cell response towards a Th1 and Th17 response 229-232. 
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Importantly, in lung tissue of patients with COPD, we confirmed the work of Polverino et al. and Ladjemi 
et al. by demonstrating an upregulation of BAFF mRNA expression and an elevated BAFF protein level in 
lung homogenate 263, 264. We continued to investigate BAFF in patients with COPD by performing a series 
of co-staining experiments on lymphoid follicles. We co-localized BAFF with stromal and immune cell 
types. Importantly, we corroborated recent observations that fibroblastic reticular cells contribute to the 
production of BAFF 227. The high amount of BAFF staining in lymphoid follicles suggest the generation of a 
micro-environment that favors B cell maturation and survival.   
10.2.2  LYMPHOID FOLLICLES IN COPD: FUTURE PERSPECTIVES 
 
Although substantial progress has been made to elucidate the role of lymphoid follicles in patients with 
COPD, the inducing antigens are still unknown. Microbiota are suggested to be critical and in that regard 
it would be interesting to expose germ-free mice chronically to CS. Yadava et al. reported that the 
microbiome promotes the formation of lymphoid follicles in an LPS/elastase model 109. However, CS is a 
far more complex stimulus and the chronicity of the exposure might also influence the host-microbiome 
interactions. By exposing germ-free mice chronically to CS, the contribution of the host-microbiome 
interactions to the pathogenesis of COPD can be studied. In addition, depletion (either selective or 
complete, of microbiota in mice chronically exposed to CS, can also contribute to the role of microbiota in 
the persistence of inflammation and lymphoid follicles. 
Stromal cell – immune cell interactions have stepped into the spotlight in chronic inflammatory diseases 
254. Investigating these interactions might help to identify which cell type acts as lymphoid tissue organizer 
cell and which immune cell acts as lymphoid tissue inducer cell. Furthermore, it is highly possible that 
stromal cell – immune cell interactions change due to chronic infections of the lung, a feature that is highly 
prevalent in patients with COPD. The most common bacteria that cause chronic infections in patients with 
COPD are non-typeable Haemophilus influenzae (NTHi), Moraxella catarrhalis, Streptococcus pneumoniae 
and Pseudomonas aeruginosa 357, 358. The reaction of the host to the infectious bacteria might play a key 
role in the pathogenesis of COPD 117. Therefore, combining co-cultures of stromal cell and immune cells 
with bacterial lysates or live bacteria can help in elucidating the initiating factors of lymphoid follicle 
formation.  
Finally, lymphoid follicles are important sites for local induction of IgA responses. As mentioned in the 
introduction, IgA is a crucial component of the mucociliary clearance system. In patients with COPD, 
increased production of IgA does not translate into increased secretory IgA levels in BAL due to 
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downregulation of the polymeric immunoglobulin receptor 264, 268. Cigarette smoke exposure of pIgR-/- mice 
can help to unravel the importance of this feature in patients with COPD.  
 
10.3  GENERAL CONCLUSION 
 
In conclusion, a functional mucociliary clearance is of utmost importance in host defense. In βENaC-Tg 
mice, airway surface dehydration enhances airway inflammation, mucin expression and alveolar 
destruction. Furthermore, chronic bronchitis, the clinical discourse of dysfunctional mucociliary clearance, 
increases the risk of COPD subjects for an accelerated decline of lung function, exacerbations and 
respiratory mortality.  
We have also shown that BAFF is increased in patients with COPD and is highly expressed in lymphoid 
follicles, indicating the development of a micro-environment that favors B cell maturation and survival. 
Furthermore, antagonizing BAFF with consequential loss of B cells attenuates pulmonary inflammation 
and alveolar wall destruction in chronic CS-exposed mice, suggesting a more central role for BAFF, B cells 
and lymphoid follicles in COPD pathogenesis than considered so far.  
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Figure 23: Schematic overview of the research work presented in this thesis.  
Cigarette smoke induces internalization of cystic fibrosis transmembrane conductance regulator (CFTR), leading 
to loss of Cl- and HCO3- secretion and stimulation of Na+ absorption via the Epithelial Natrium Channel (ENaC). 
The net result is airway surface dehydration and mucus stasis/adherence which aggravates the CS-induced 
inflammatory response and mucus production.  
Innate immune cells produce B cell-activating factor (BAFF) which stimulates B cell survival, maturation and 
differentiation. In addition, within lymphoid follicles both stromal and immune cells produce BAFF, resulting in 
an environment that promotes B cell survival and differentiation. The presence of organized lymphoid follicles 
aggravates airway and pulmonary inflammation and alveolar wall destruction.  
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SUMMARY 
Chronic obstructive pulmonary disease (COPD) is a highly prevalent, disabilitating disease, affecting more 
than 200 million people worldwide. COPD is characterised by an abnormal inflammatory reaction and 
destruction of lung tissue in response to noxious particles and gases, most commonly cigarette smoke. The 
main symptoms are progressive and persistent breathlessness accompagnied by chronic cough and 
sputum.  
In healthy individuals, the mucociliary clearance system captures inhaled noxious substances and 
transports them towards the pharynx. Chronic cigarette smoke exposure compromises the function of this 
system by increasing mucus production and altering the activity of ion channels, both leading to 
dehydration of the airway surface liquid. We have studied the effect of airway surface dehydration on 
cigarette smoke-induced pathology in a murine model of COPD. The presence of airway surface 
dehydration aggravated airway and pulmonary inflammation, increased mucin expression and aggravated 
destruction of alveolar tissue.  
Chronic bronchitis, the clinical manifestation of dysfunctional mucociliary clearance, is common in subjects 
with COPD. We investigated whether the presence of chronic bronchitis in COPD subjects altered the risk 
for acute worsening of COPD and mortality. To study this we used data from a large prospective, 
population-based cohort: the Rotterdam Study. We observed that COPD subjects with chronic bronchitis 
have an increased risk for acute exacerbations of COPD and an increased risk for respiratory mortality. 
Interestingly, especially women with COPD and chronic bronchitis have an increased mortality risk. 
In a third investigation, we investigated the role of B cell-rich lymphoid follicles in patients with COPD, by 
antagonizing B cell-activating factor (BAFF), a necessary factor for B cells to survive, mature and 
differentiate. First, we studied the expression and localisation of BAFF in patients with COPD. We 
determined that both stromal cells and immune cells in lymphoid follicles produce BAFF, thus supporting 
the survival of B cells. Next, we antagonized BAFF in mice that were chronically exposed to cigarette 
smoke. We observed that antagonizing BAFF resulted in complete loss of B cells and lymphoid follicles and 
attenuated pulmonary inflammation and destruction of alveolar tissue. We concluded that B cells and 
BAFF mediate pulmonary inflammation and that organized lymphoid follicles are important in the 
development of emphysema.  
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SAMENVATTING 
Chronisch obstructief longlijden (COPD) is een zeer frequent voorkomende ziekte die wereldwijd meer dan 
200 miljoen mensen treft. COPD wordt gekenmerkt door een abnormale ontstekingsreactie en afbraak 
van longweefsel na langdurige inhalatie van schadelijke gassen en partikels, meestal sigarettenrook. De 
voornaamste symptomen zijn progressieve en continue kortademigheid, samen met chronische hoest en 
slijm productie.  
In gezonde luchtwegen zorgt het mucociliair systeem voor het vangen en verwijderen van schadelijke 
substanties. Chronische blootstelling aan rook compromitteert de functie van dit systeem door de werking 
van de ionenkanalen aan te tasten en de productie van slijm te verhogen, met dehydratatie van de 
vochtlaag die de luchtwegen bedekt, als gevolg. Wij hebben het effect van dehydratatie van het 
luchtwegoppervlak op sigarettenrook-geïnduceerde pathologie onderzocht in een muismodel. Onze 
studie wijst uit dat dehydratatie van het luchtwegoppervlak bijdraagt tot de ontstekingsreactie in de 
luchtwegen, expressie van mucines en beschadiging van longweefsel in reactie op sigarettenrook. 
Dysfunctionele mucociliaire klaring uit zich klinisch als chronische bronchitis en is veelvoorkomend in 
personen met COPD. We hebben nagegaan of de aanwezigheid van chronische bronchitis in personen met 
COPD het risico verhoogt op plotse verergeringen van COPD en mortaliteit. Om dit te bestuderen hebben 
we gebruik gemaakt van gegevens uit de Rotterdam Studie, een grote cohorte studie bij de algemene 
bevolking. De studie toont aan dat mensen met COPD en chronische bronchitis een verhoogde kans 
hebben op acute verergeringen van hun COPD symptomen en een verhoogd risico op sterfte door 
longaandoeningen. Deze studie wijst ook uit dat vooral vrouwen met COPD en chronische bronchitis een 
verhoogd risico op exacerbaties en sterfte hebben. 
In een derde onderzoek hebben we de rol van lymfoïde follikels in patiënten met COPD onderzocht. B 
cellen zijn de voornaamste cellen in deze lymfoide follikels en zijn afhankelijk van B cell-activating factor 
(BAFF) voor hun overleving, maturatie en differentiatie. Eerst hebben we de expressie en lokalisatie van 
BAFF in patiënten met COPD bestudeerd. We stelden vast dat zowel stromale als immuun cellen in 
lymfoïde follikels BAFF produceren en zodoende een gunstig microklimaat genereren dat de overleving 
van B cellen stimuleert. Vervolgens hebben we BAFF geantagoniseerd in muizen die chronisch aan rook 
werden blootgesteld. Het antagoniseren van BAFF leidde tot verlies van B cellen en lymfoïde follikels en 
verminderde de ontstekingsreactie in luchtwegen en de afbraak van longweefsel. We concludeerden dat 
BAFF en B cellen de ontstekingsreactie in de longen mediëren en dat georganiseerde lymfoïde follikels 
bijdragen tot de ontwikkeling van emfyseem.  
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